

## REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.

**PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE (DD-MM-YYYY) 20/Sep/2001	2. REPORT TYPE DISSERTATION	3. DATES COVERED (From - To)		
<b>4. TITLE AND SUBTITLE</b> THE EFFECTS OF OVINE INTEFERON-TREATMENT OF THEILER'S VIRUS-INDUCED DEMYELINATION IN FEMAL SJL/J MICE		5a. CONTRACT NUMBER		
		5b. GRANT NUMBER		
		5c. PROGRAM ELEMENT NUMBER		
<b>6. AUTHOR(S)</b> CAPT TRAEEK KASANDRA T		5d. PROJECT NUMBER		
		5e. TASK NUMBER		
		5f. WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) TEXAS A&M UNIVERSITY			8. PERFORMING ORGANIZATION REPORT NUMBER CI01-255	
<b>9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> THE DEPARTMENT OF THE AIR FORCE AFIT/CIA, BLDG 125 2950 P STREET WPAFB OH 45433			10. SPONSOR/MONITOR'S ACRONYM(S)	
			11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
<b>12. DISTRIBUTION/AVAILABILITY STATEMENT</b> Unlimited distribution In Accordance With AFI 35-205/AFIT Sup 1				
<b>13. SUPPLEMENTARY NOTES</b>				
<b>14. ABSTRACT</b>				
<b>DISTRIBUTION STATEMENT A</b> Approved for Public Release Distribution Unlimited			20011016 185	
<b>15. SUBJECT TERMS</b>				
<b>16. SECURITY CLASSIFICATION OF:</b>		<b>17. LIMITATION OF ABSTRACT</b>	<b>18. NUMBER OF PAGES</b> 234	<b>19a. NAME OF RESPONSIBLE PERSON</b>
a. REPORT	b. ABSTRACT	c. THIS PAGE		19b. TELEPHONE NUMBER (Include area code)

**THE EFFECTS OF OVINE INTERFERON- $\tau$  TREATMENT ON  
THEILER'S VIRUS-INDUCED DEMYELINATION IN  
FEMALE SJL/J MICE**

A Dissertation

by

KASANDRA TANEESHIA TRAWEEK

Submitted to the Office of Graduate Studies of  
Texas A&M University  
in partial fulfillment of the requirements for the degree of

**DOCTOR OF PHILOSOPHY**

August 2001

Major Subject: Veterinary Anatomy

**The views expressed in this article are those of the author  
and do not reflect the official policy or position of the  
United States Air Force, Department of Defense, or U.S.  
Government.**


**THE EFFECTS OF OVINE INTERFERON- $\tau$  TREATMENT ON  
THEILER'S VIRUS-INDUCED DEMYELINATION IN  
FEMALE SJL/J MICE**

A Dissertation  
by  
KASANDRA TANEESHIA TRAWEEK

Submitted to Texas A&M University  
in partial fulfillment of the requirements  
for the degree of

DOCTOR OF PHILOSOPHY


Approved as to style and content by:




C. Jane Welsh  
(Chair of Committee)




Ellen W. Collisson  
(Member)



Ralph Storts  
(Member)



Rajesh C. Miranda  
(Member)

  
E. Tiffany-Castiglioni  
(Head of Department)

August 2001

Major Subject: Veterinary Anatomy

**THE EFFECTS OF OVINE INTERFERON- $\tau$  TREATMENT ON  
THEILER'S VIRUS-INDUCED DEMYELINATION IN  
FEMALE SJL/J MICE**

A Dissertation

by

KASANDRA TANEESHIA TRAWEEK

Submitted to the Office of Graduate Studies of  
Texas A&M University  
in partial fulfillment of the requirements for the degree of

DOCTOR OF PHILOSOPHY

August 2001

Major Subject: Veterinary Anatomy

**The views expressed in this article are those of the author  
and do not reflect the official policy or position of the  
United States Air Force, Department of Defense, or U.S.  
Government.**

**THE EFFECTS OF OVINE INTERFERON- $\tau$  TREATMENT ON  
THEILER'S VIRUS-INDUCED DEMYELINATION IN  
FEMALE SJL/J MICE**

A Dissertation

by

KASANDRA TANEESHIA TRAWEEK

Submitted to Texas A&M University  
in partial fulfillment of the requirements  
for the degree of

DOCTOR OF PHILOSOPHY

Approved as to style and content by:

C. Jane Welsh

C. Jane Welsh  
(Chair of Committee)

Ralph W. Storts

Ralph Storts  
(Member)

Ellen W. Collisson

Ellen W. Collisson  
(Member)

Rajesh C. Miranda

Rajesh C. Miranda  
(Member)

E. Tiffany-Castiglioni

E. Tiffany-Castiglioni  
(Head of Department)

August 2001

Major Subject: Veterinary Anatomy

## ABSTRACT

### The Effects of Ovine Interferon- $\tau$ Treatment on Theiler's Virus- Induced Demyelination in SJL/J Mice. (August 2001)

Kasandra Taneeshia Traweek, B.S., Humboldt State University; M.A.,  
University of the Incarnate Word

Chair of Advisory Committee: Dr. C. Jane Welsh

Theiler's murine encephalomyelitis virus (TMEV) is a picornavirus that is used as an animal model for the study of multiple sclerosis (MS). One of the current therapies for MS involves the administration of a type I interferon, IFN- $\beta$ . The administration of IFN- $\beta$  can result in unfavored, psychological side-effects including clinical depression. A second type I interferon, ovine IFN- $\tau$ , has previously been found to be less cytotoxic than IFN- $\beta$ . This study focuses on the effects of IFN- $\tau$  on SJL/J mice at 0 months, 2 months, and 4 months post-infection with TMEV strain BeAn. Through neurological exams and histological analysis of the CNS, we report that IFN- $\tau$  administration significantly reversed the neurological abnormalities induced by TMEV infection when given at 4 months post-infection. Histologically, treatment at 4 months post-infection resulted in a significant decrease in lesion occurrence in the ventral and dorsal funiculi of the spinal cord. Inflammation and demyelination were both reduced as measured via percent area effected in hematoxylin + eosin stained and myelin oligodendrocyte glycoprotein-specific immunostained spinal cord sections embedded in paraffin. No effect was detected with treatment at 2 months post-infection. In contrast, SJL/J mice pre-treated with IFN- $\tau$  displayed increased disease progression when compared to controls, as well as increased lesion

development. Treatment with IFN- $\tau$  from 4 to 6 months post-infection resulted in an increase in serum IL-10 levels, increase in IL-1, IL-6, IL-10, and IFN- $\gamma$  mRNA in the spinal cord, and a decrease in delayed-type hypersensitivity response to myelin membrane when compared to saline treated, infected controls. No significant change was noted in white blood cell differential between IFN- $\tau$  or saline treated infected animals. In conclusion, it is proposed that IFN- $\tau$  mediates its therapeutic effects by upregulating IL-10 which suppresses delayed-type hypersensitivity responses thereby inhibiting the inflammatory demyelinating process. IFN- $\tau$  may be a useful therapeutic agent in the treatment of multiple sclerosis.

## **DEDICATION**

The work outlined in this dissertation is by no means the efforts of one person. There have been many special people in my life who have believed in and supported me whenever I found it difficult to believe in myself. This work was not possible without the strong foundation the following people have set for me over the years. Thank you for your love and encouragement.

## ACKNOWLEDGEMENTS

I would like to thank Dr. Jane Welsh for her mentorship during my Ph.D. project. She has helped me to focus my ambition and realize my life-long dream of completing my Ph.D.

I would like to thank Dr. Fuller Bazer, Dr. Joanne Fleming, Dr. Greg Johnson, Dr. David Busbee, Dr. Judy Ball, Dr. Ralph Storts, Dr. Rajesh Miranda, Dr. Louise Abbott, Dr. Robert Burghardt, Dr. Ellen Collisson, Dr. Tom Welsh, Dr. Joan Coates, Dr. Mary Meagher, Dr. Suzanne Aldinger, Dr. Deepani Tennakoon, Amy Sieve, Lin Bustamante, Alanzo Rayes, Mamatha Nayak, Reed Johnson, and Eric Weaver for their technical advice during the planning or performing of experiments.

Michelle Garza, Matt Bronsted, Jessica Page, Adam Small, and Joe Mieskia deserve recognition for keeping the laboratory operational and aiding in the performing of some of the experiments listed in this work. The CVM Media Resources staff, CVM Clinical Pathology staff, CVM Image Analysis staff, VTPB histology lab staff, and VAPH histology lab staff aided in the processing and presentation of the histology and blood samples. Thank you for your patience with me and all of your help.

My heartfelt thanks to Dorothy and Bill Stearman who sponsored my research with their generous donation to A&M for MS research. Thank you for your financial support.

Dana Dean deserves a special acknowledgement for all of her scientific and emotional support she has given me during the last year and a half. Her friendship has helped me complete my work and came at a time when I needed it the most. I am honored that she has chosen

to continue my work because I respect her greatly as a researcher and friend. Thank you, Dana.

## TABLE OF CONTENTS

	Page
ABSTRACT.....	iii
DEDICATION.....	v
ACKNOWLEDGEMENTS.....	vi
TABLE OF CONTENTS.....	viii
LIST OF TABLES.....	x
LIST OF FIGURES.....	xi
I. INTRODUCTION.....	1
Background.....	1
Specific Aims.....	29
II. CLINICAL DISEASE PROGRESSION.....	30
Introduction.....	30
Materials and Methods.....	37
Results.....	41
Discussion.....	59
III. HISTOLOGICAL ANALYSIS.....	62
Introduction.....	62
Materials and Methods.....	65
Results.....	72
Discussion.....	112
IV. IMMUNOLOGICAL ANALYSIS.....	115
Introduction.....	115
Materials and Methods.....	122
Results.....	129
Discussion.....	139
V. CONCLUSIONS.....	143
REFERENCES.....	155
APPENDIX.....	190

VITA.....	232
-----------	-----

**LIST OF TABLES**

<b>TABLE</b>		<b>Page</b>
2.1	Experimental groups in IFN- $\tau$ treatment study using..... SJL/J female mice and TMEV	42
4.1	WBC analysis performed on terminal cardiac bleeds..... from SJL/J mice.	130
4.2	Corticosterone RIA on mouse serum samples in relation... to clinical scores at the time of perfusion	136

## LIST OF FIGURES

FIGURE	Page
1.1 TMEV genome.....	14
2.1 Mean weight change IFN- $\tau$ treatment -3 to 0 days..... post-infection	43
2.2 Mean score change IFN- $\tau$ treatment -3 to 0 days..... post-infection	44
2.3 Mean weight change IFN- $\tau$ treatment -3 to 60 days..... post-infection	45
2.4 Mean score change IFN- $\tau$ treatment -3 to 60 days..... post-infection	46
2.5 Mean weight change IFN- $\tau$ treatment 2 to 6 months..... post-infection	49
2.6 Mean score change IFN- $\tau$ treatment 2 to 6 months..... post-infection	50
2.7 Mean weight change IFN- $\tau$ treatment 4 to 6 months..... post-infection	51
2.8 Mean score change IFN- $\tau$ treatment 4 to 6 months..... post-infection	52
2.9 Individual score change before and after IFN- $\tau$ ..... treatment 4 to 6 months post-infection	53
2.10 Individual score change before and after saline..... treatment 4 to 6 months post-infection	54
2.11 Mean weight change IFN- $\tau$ treatment 4 to 6 months..... post-infection #2	55
2.12 Mean score change IFN- $\tau$ treatment 4 to 6 months..... post-infection #2	56
2.13 Mean weight change methylprednisolone 5 to 6 months... post-infection	57
2.14 Mean score change methylprednisolone 5 to 6 months.... post-infection	58

## **LIST OF FIGURES**

FIGURE	Page
2.15 Mean weight change of non-infected mice with IFN- $\tau$ ..... treatment 5 to 7 mo. of age	59
3.1 Correlation graph of histological v. clinical scores.....	75
3.2 Histology rating of gray matter lesions.....	76
3.3 Histology rating of meningeal inflammation.....	77
3.4 Histology rating of dorsal funiculi lesions.....	78
3.5 Histology rating of ventral funiculi lesions.....	79
3.6 Histology rating of lateral funiculi lesions.....	80
3.7 H+E inflammation scores through the cervical, thoracic,.... and lumbar regions of the spinal cord	81
3.8 Demyelination through the cervical, thoracic, and..... lumbar regions of the spinal cord	82
3.9 H+E stained slide of a mouse pretreated from 3 days..... pre- infection to 60 days post-infection with interferon-tau. 40X magnification.	83
3.10 H+E stained slide of a mouse pretreated from 3 days..... pre- infection to 60 days post-infection with interferon-tau. 240X magnification.	84
3.11 H+E stained slide of a mouse treated from 2 to 6 months.... post-infection with interferon-tau. 40X magnification.	85
3.12 H+E stained slide of a mouse treated from 2 to 6 months.... post-infection with interferon-tau. 240X magnification.	86

## LIST OF FIGURES

FIGURE	Page
3.13 H+E stained slide of a mouse treated from 4 to 6 months.... post-infection with interferon-tau. 40X magnification.	87
3.14 H+E stained slide of a mouse treated with interferon-tau.... from 4 to 6 months post-infection. 240X magnification.	88
3.15 H+E stained slide of the mouse with the worst clinical..... score treated from 4 to 6 months post-infection with interferon-tau. 40X magnification.	89
3.16 H+E stained slide of the mouse with the worst clinical..... score treated from 4 to 6 months post-infection with Interferon-tau. 200X magnification.	90
3.17 H+E stained slide of the mouse with the worst clinical..... score treated from 4 to 6 months post-infection with interferon-tau. 240X magnification.	91
3.18 H+E stained slide of a mouse treated with..... methylprednisolone from 5 to 6 months post-infection. 40X magnification.	92
3.19 H+E stained slide of a mouse treated with..... methylprednisolone from 5 to 6 months post-infection. 240X magnification.	93
3.20 H+E stained slide of a mouse infected with virus and given... saline ip from 4-6 months post-infection. 40X magnification.	94
3.21 H+E stained slide of a mouse infected with virus and given.. saline ip from 4-6 months post-infection. 240X magnification.	95
3.22 H+E stained slide of a non-infected mouse..... 40X magnification.	96
3.23 H+E stained slide of a non-infected mouse..... 100X magnification.	97

## LIST OF FIGURES

FIGURE	Page
3.24 Immunostaining for CNS myelin of an infected mouse..... treated with interferon-tau from 4-6 months post-infection. Magnification 40X.	99
3.25 Immunostaining for CNS myelin of an infected mouse..... treated with interferon-tau from 4-6 months post-infection. Magnification 240X.	100
3.26 H+E staining of a serial section of an infected mouse..... treated with interferon-tau from 4-6 months post-infection. Magnification 40X.	101
3.27 H+E staining of a serial section of an infected mouse..... treated with interferon-tau from 4-6 months post-infection. Magnification 240X.	102
3.28 Immunostaining for CNS myelin of an infected mouse with... the worst clinical score treated with interferon-tau from 4-6 months post-infection. Magnification 40X.	103
3.29 H+E staining of a serial section of an infected mouse with.... the worst clinical score treated with interferon-tau from 4-6 months post-infection. Magnification 40X.	104
3.30 Immunostaining for CNS myelin of a non-infected mouse..... Magnification 40X.	105
3.31 Immunostaining for CNS myelin of an infected mouse..... treated with saline from 4-6 months post-infection. Magnification 40X.	106
3.32 H+E staining of a serial section of an infected mouse..... treated with saline from 4-6 months post-infection. Magnification 40X.	107
3.33 EM of demyelination in the ventral funiculi..... Magnification 28,000X.	109

**LIST OF FIGURES**

<b>FIGURE</b>	<b>Page</b>
3.34 EM of demyelination in the ventral funiculi..... Magnification 40,000X.	110
3.35 EM of meningeal inflammation. Magnification 28,000X.....	111
3.36 EM of demyelination and status spongiosus in the ventral... funiculi. Magnification 28,000X.	112
4.1 IFN- $\tau$ ELISA graph of all groups with IFN- $\tau$ treatment.....	132
4.2 IL-10 ELISA graph of all treatment groups.....	133
4.3 DTH graph of 4 to 6 mo. p.i. IFN- $\tau$ treatment and..... saline infected controls	134
4.4 Preliminary correlation graph of corticosterone v..... clinical scores	137
4.5 Spinal cord mck-2b assay.....	138
4.6 RPA analysis graph of cytokines expressed in infected..... IFN- $\tau$ treated mice and saline controls	139
5.1 Mechanisms of Theiler's virus induced demyelination.....	147

## I. INTRODUCTION

### Background

#### *1.1 Multiple sclerosis*

One of the major demyelinating diseases of the central nervous system (CNS) is multiple sclerosis (MS). In addition to demyelination of the white matter, MS symptoms also result from inflammation characterized by the infiltration of lymphocytes and macrophages into the CNS, truncated or transected axons, and deterioration of neurological function (Prineas and Raine, 1976; Prineas and Wright, 1978; Adams et al., 1989, Trapp et al., 1998). To clinically diagnose MS for laboratory research purposes, samples of cerebrospinal fluid are analyzed for: free and bound antibodies to myelin basic protein (MBP), proteolipid protein (PLP), or myelin oligodendrocyte glycoprotein (MOG), as well as other myelin-autoreactive B- and T-cell responses, such as the upregulation of Th1 cytokines (Warren and Catz, 1993; Olsson, 1994; Warren and Catz, 1994).

There are currently over 300,000 cases of MS documented in the US. Women are affected twice as often as men with the typical onset between the ages of 20-40 years. Patients are characterized with relapsing-remitting (RR) or primary-progressive (PP) MS at diagnosis (Lublin et al., 1996). Those affected by RR MS experience serial periods of neurological dysfunction that increase in severity over time followed by brief periods of recovery. PP patients experience a steady gradual decrease in neurological function. Approximately 40% of RR patients eventually develop another form of MS, secondary-progressive, that mimics the PP form.

---

This dissertation follows the style of the Journal of Neuroimmunology.

MS lesions can differ considerably between patients depending on the disease form that is diagnosed. The etiology of MS is unknown, but individual variation in lesions that develop as well as multiple immunogenetic factors have raised the possibility that MS may be the result of several different disease processes (Ebers et al., 1996; Haines, et al., 1996; Sawcer et al., 1996). A recent report by Lucchinetti et al. suggests two different patterns of lesion development, one that is T-cell-mediated or T-cell plus antibody-mediated autoimmune encephalomyelitis and the other involving primary oligodendrocyte damage as the result of a viral or bacterial infection. Of the 83 patients examined, all were found to have both types of MS lesions though multiple active lesions within the same patient were found to involve only one type (Lucchinetti et al., 2000). The presence of two different lesion patterns support a multifactorial etiology.

### *1.2 Major histocompatibility complex genes*

In humans, the major histocompatibility complex (MHC) genes are located on the short arm of chromosome 6 whereas murine MHC genes are located on chromosome 17 of mice. The MHC genes are divided into three different classes, MHC class I, II, and III. MHC class I genes are further subdivided into MHC class Ia and Ib. MHC class Ia genes are highly polymorphic whereas class Ib genes are not. In humans, there are three class Ia loci: A, B and C. The class Ia loci in the mouse H-2 complex are K and D. In human populations, as many as 23  $\alpha$  chain alleles can be found at the A locus, 49  $\alpha$  chain alleles at B, and 8  $\alpha$  chain alleles at C. This polymorphism is a result of variations in the amino acid sequence of the  $\alpha 1$  and  $\alpha 2$  domains of the MHC class I

molecule. The MHC class II genes are also polymorphic. To date, three MHC class II loci, DR, DQ, and DP have been reported with a possibility of 19 DR alleles, 7 DQ alleles, and 7 DP alleles. The MHC class III genes are not directly linked to antigen presentation, but do play a role in immunity through the production of complement serum proteins (Trowsdale, 1995).

Cytotoxic T-cells (CTLs), T-helper 1 (Th1), and T-helper 2 (Th2), cells all play a role in the development of inflammation in the cell-mediated and antibody-mediated immunological responses. CTLs are activated by the expression of CD4<sup>+</sup> cytokines IL-2, IL-4, and IL-6 (Maliszewski et al., 1990). CTLs are able to lyse cells that express foreign antigen in MHC class I molecules causing the production of cellular debris that is phagocytosed by macrophages. Extensive macrophage infiltration and burst can result in inflammation.

Th1 cells will secrete IL-12, IL-2, interferon-gamma (IFN- $\gamma$ ), and tumor necrosis factor-beta (TNF- $\beta$ ) when a CD4<sup>+</sup> T-cell detects a foreign antigen within MHC class II on an antigen presenting cell. IFN- $\gamma$  release activates macrophages which result in increased MHC class II expression, increased phagocytosis and infiltration of macrophages to the site of injury. This is primarily seen with delayed-type hypersensitivity reactions (DTH) (Bottomly, 1988; Altman et al., 1990). IL-12 stimulates the differentiation of primary T-cells (Th0) to Th1 cells as well as CD8<sup>+</sup> T-cells to mature and active CTLs. IL-2 stimulates natural killer cells (NK), that also produce IFN- $\gamma$  and prime macrophages. TNF- $\beta$  promotes B-cell proliferation and immunoglobulin secretion, specifically IgM and IgG2a antibodies.

The interleukins produced by Th2 cells: IL-4, IL-5, IL-6, IL-10 and IL-13 upregulate B-cell proliferation and the production of specific polyclonal immunoglobulins IgG1, IgA, IgM, and IgE (Williams, 1984).

The Th2 interleukins all down regulate the IFN- $\gamma$ /NK cell/macrophage activation pathway and enhance MHC class II expression (Seder and Le Gros, 1995). Th2 cells can inhibit T-cell mediated inflammation and suppress cytokine production in macrophages. In chronic inflammation, the proliferation of Th2 cells is beneficial as they reduce the volume of inflammatory cells that accumulate at the site of injury (Weissmann et al., 1980).

### *1.3 Multiple sclerosis immunology*

Cytokine expression plays a role in the development of demyelinating lesions in MS patients. In order for the MS lesions to occur, myelin self-reacting CD4 $^{+}$  Th1 cells can be activated to release proinflammatory Th1 cytokines IL-2, IFN- $\gamma$  and TNF- $\beta$  (Bottomly, 1988), must travel from the circulatory system into the CNS (Martin and McFarland, 1995; Lucchinetti and Rodriguez, 1997). T-cells collected from MS patients during relapsing episodes are known to produce the Th1 cytokines: IFN- $\gamma$ , TNF- $\alpha$ , and TNF- $\beta$ , (Correale et al., 1995; Voskuhl et al., 1993; Olsson et al., 1990). Conversely, the Th2 response involves the secretion of anti-inflammatory cytokines such as IL-4 and IL-10 that are prevalent in MS patients during remission phases (Correale et al., 1995). Through the secretion of IFN- $\gamma$ , Th1 cells aid in the switch in immunoglobulin production from IgM to IgG2a as well as inhibit Th2 lymphocyte cytokine production. In comparison, Th2 cells facilitate the IgG1 switch to IgE and indirectly suppress Th1 lymphocytes by affecting antigen presenting cells via IL-4, IL-5, and IL-6 (Finkelman, et al., 1990; Mosmann and Coffman, 1989). The possibility that Th1 cytokines may increase the severity of MS lesions is further supported by observation that IFN- $\gamma$

administration to MS patients results in the worsening of symptoms (Panitch et al., 1987).

#### *1.4 Multiple sclerosis: genetic and environmental factors*

The etiology of MS is still unknown though epidemiological studies of the worldwide distribution of MS suggest an infectious agent is involved. The highest prevalence of MS, with 30 per 100,000 cases diagnosed per population, occur in northern Europe into the Union of Soviet Socialist Republics, southern Canada, and northern United States, New Zealand, and southeastern Australia. Scandinavia, central Union of Soviet Socialist Republics, southern Europe, southern United States, and much of Australia are considered intermediate risk areas. Finally, Asia and the tropics appear to be the lowest frequency areas with occurrence rates below 5 per 100,000 in the population. (Goldberg and Kurland, 1962; Kurtzke, 1980; Massey and Schoenberg; 1982). It is important to note that the above occurrence rates appear to be correlated with the location where the patient lived before the age of 20. If the patient moved before that age, the environmental risk level shifts to the new location (Kurtzke, 1993).

It has been proposed that genetics play some role in the development of MS. Though it is improbable that there is one gene responsible for susceptibility to MS, it has been documented that some human leukocyte-associated (HLA) genotypes render people more susceptible to autoimmune disease. In MS, no HLA subset has thus far been found to be elevated in all MS patients assayed, but HLA-A3 and HLA-B7, two of the MHC class I genes, have been associated with the prevalence of MS in northern European whites. MHC class II genes HLA-DR2 and/or HLA-DW2 or HLA-DR4 have also been suspected for

the Northern European whites. An elevated HLA-DR2 expression in MS patients has been the most promising gene related to this disease since it has been seen in the United States, Europe, South Africa, and Mexico (Gorodezky et al., 1962; Fewster and Kies, 1984; Sriram et al., 1985; Van Lambalgen et al., 1986). Patients in Scotland were found to have excess HLA-DQ $\alpha$ 1 and HLA-DQ $\beta$ , instead of HLA-DR2 (Francis et al., 1983; McDonald, 1984; Marcadet et al., 1985). Kolstad et al. discovered that HLA-DQ $\beta$  was expressed in 34 of the 35 MS patients they genotyped, though such a high correlation has yet to be repeated (Kolsted et al., 1989). In short, it appears that MHC genetics may play a role in MS, but it is certainly not the only factor to consider.

### *1.5 Possible viral etiology for MS*

Based on the geographic rates of MS development and risk of disease due to migration, it has been postulated that a viral infection before CNS maturity may play a role in MS (Martin and McFarland, 1995). It is possible that a viral antigen may mimic a host protein thereby initiating an autoimmune reaction that results in chronic inflammatory disease (Rose, 1994; Tsunoda and Fujinami, 1996). One specific viral infection has not been found consistently in all MS patients examined post-mortum, but several viral pathogens have been proposed due to high titers that have been detected in some MS patients when compared to controls. Measles, human coronavirus 229E, Epstein-Barr virus, retroviruses, and human herpes virus-6 have all been extracted from the CNS or cerebrospinal fluid of MS patients (Cook et al., 1996).

### *1.6 MS and pregnancy*

A modification of the maternal immune system is necessary during pregnancy in order to prevent spontaneous abortion. The intermediate metabolites produced when cholesterol is transformed into one of the sex hormones, progesterone, testosterone, and estrogens, are able to interact with the immune system (Lahita et al., 1981; Sambrook et al., 1988). The production of immunosuppressive proteins during pregnancy include increased progesterone (Siiteri et al., 1977), prolactin (Eriksson et al., 1989), estrogen (Lahita, 1992) and interferon-tau (IFN- $\tau$ ), in sheep (Soos et al., 1995). The placenta is able to produce IL-10 (Wegmann et al., 1993; Raghupathy, 1997) and suppress maternal MHC-specific T cells that recognize the fetus as non-self (Tafuri et al., 1995).

Women with RR MS experience approximately a 70 percent decrease in the rate of relapse during the third trimester of pregnancy as compared to their disease progression a year before pregnancy. This protective effect dissipates within the first three months post-partum. Relapsing rates appear to increase during the first year post-partum (Poser and Poser, 1983; Confavreux et al., 1998), but over-all long term increase in disease progression due to pregnancy has not been found (Thompson et al., 1986; Weinshenker et al., 1989; Roulet et al., 1993). There is an apparent shift from a predominant Th1 reaction to a Th2 response during pregnancy, which is reversed after birth of the fetus (Wegmann et al., 1993). Since the Th1 response plays a pathogenic role during MS, the Th2 activation in the mother during the last trimester may account for the remitting period experienced during pregnancy.

### *1.7 Interferon-beta treatment of MS*

Interferon-beta (IFN- $\beta$ ) has a therapeutic effect in MS patients by reducing the severity of MS symptoms and relapse rate (Paty and Li, 1993; Jacobs et al., 1996). However, several undesirable side effects have been noted. Fever, myalgia, headache, fatigue, and chills occur in 75% of treated patients though the duration of these side-effects is patient specific (Lublin et al., 1996). This may be due to the immediate upregulation of inflammatory cytokines and prostaglandins (Arnason and Reder, 1994; Dayal et al., 1995; Brod et al., 1996) resulting in increased spasticity and temporary worsening of symptoms (Lublin et al., 1996).

IFN- $\beta$  has recently been shown to be effective in the treatment of relapsing-remitting MS (IFN- $\beta$  Multiple Sclerosis Study Group, 1993). IFN- $\beta$  also inhibits the progression of relapsing-remitting experimental allergic encephalomyelitis in mice, another animal model for MS (Yu et al., 1996). The exact mechanism of IFN action in these conditions is not completely understood. IFN- $\beta$  has many diverse biological roles ranging from anti-viral to immunomodulatory effects (Belardelli and Gresser, 1996). Since MS is thought to be initiated by a viral infection, the effectiveness of IFN- $\beta$  may be related to its role in viral inhibition. However, the autoimmune aspects of MS may be down regulated through a number of different mechanisms since type I IFNs have been shown to inhibit DTH responses (also important in Theiler's virus-induced demyelination (TVID) and EAE), alter the homing and trapping of lymphocytes, enhance NK and T-cell activity and cytotoxicity, enhance Fc $\gamma$  receptors effects (Belardelli and Gresser, 1996), inhibit T-cell proliferation, and decrease the production of IFN- $\gamma$  (Noronha et al., 1993). Recently,

IFN- $\beta$  has been shown to decrease the migration of T-lymphocytes in vitro by interfering with the production of T-cell matrix metalloproteinases which mediate T-cell migration through matrices. Both NK cells, CD8 $^{+}$  and CD4 $^{+}$  T-cells were also affected by this treatment. The authors demonstrated that IFN- $\beta$  decreased the matrix metalloproteinase levels which in turn prevented the cleavage of fibronectin (Stuve et al., 1996).

### *1.8 Corticosterone treatment of MS*

Corticosterone and cortisol are glucocorticoids that are secreted by the adrenal cortex. Both hormones are products of cholesterol catabolism and they differ by one hydroxyl group. Healthy humans normally produce a 1:5 ratio of corticosterone to cortisol whereas mice only produce corticosterone.

Multiple sclerosis patients are known to have an exaggerated cortisol release when relapsing-remitting MS progresses into secondary progressive MS. This is attributed to proinflammatory cytokines impairing normal glucocorticoid function and the increase in neuronal damage (Bergh et al., 1999). This theory is supported by the fact that neuroendocrine over-activation is seen in MS patients with acute CNS inflammation (Fassbender et al., 1998).

Glucocorticoid therapy can be beneficial in MS treatment, but effectiveness is dependent on the stage of disease progression. Treatment of MS patients with low-dose corticosteroids, 10-20 mg of prednisolone daily, had no significant effect on MS progression with chronic progressive or relapsing-remitting MS (Tourtellotte and Haerer, 1965; Millar et al., 1967). In contrast, rapid clinical improvement is seen in MS patients in acute relapse who have been treated intravenously with methylprednisolone ranging from 250 mg daily to 20

mg/kg daily for 2-7 days (Dowling et al., 1980; Buckley et al., 1982; Abbruzzese et al., 1983; Goas et al., 1983; Newman et al., 1983; Barnes et al., 1985; Durelli et al., 1986; Milligan et al., 1987; Thompson et al., 1989).

The clinical benefits seen in patients with glucocorticoid therapy is attributed to the immunosuppressive effects of corticosterone that are dosage dependent. Supraphysiological corticosteroid dosage can inhibit antibody-dependent cellular cytotoxicity (Nair and Schwartz, 1984), neutrophil complement and IgG receptor binding (Forslid and Hed, 1982), antigen presentation by monocytes (Dumble et al., 1981; Hirschberg et al., 1982; Rhodes et al., 1986), astrocyte binding to measles-infected cells (Maki et al., 1980), monocyte cellular differentiation (Rinehart et al., 1982) and leukocyte production of IL-2 and IFN- $\gamma$  (Arya et al., 1984; Cesario et al., 1986).

Treatment with high corticosterone levels in Lewis rats with chronic EAE also force a down-regulation of IL-2 and IFN- $\gamma$  (Dowdell et al., 1999) suggesting a common decrease in Th1 cytokine expression as a result of the abnormal corticosterone levels.

### *1.9 Animal models for multiple sclerosis*

Several animal models of multiple sclerosis have been developed to study treatment strategies and pathology of MS in a laboratory setting. There are seven such models that are commonly used in this capacity, most of which involve virally-induced demyelination. These seven models include animal interactions with: Theiler's virus, mouse hepatitis virus, Semliki Forest virus, visna virus, canine distemper virus, plus experimental allergic encephalomyelitis, and chemical induction of demyelination. Infections with Theiler's virus, mouse hepatitis virus,

Semliki Forest virus, experimental allergic encephalomyelitis, and chemically-induced demyelination are murine models whereas infections with visna virus and canine distemper virus are sheep and canine models respectively. The main focus of this work involves the in-depth understanding of Theiler's virus infection and experimental allergic encephalomyelitis in the mouse. Those models will be outlined in detail below. The five other animal models will be discussed here briefly.

Mouse hepatitis virus (MHV) is a coronavirus. It is an enveloped virus that contains a positive sense, single-stranded, non-segmented, polyadenylated, RNA genome (Lai and Stohlman, 1978). Not all strains of MHV cause hepatitis in mice. MHV-4, A59, and JHM are three neurotropic strains of MHV that produce a pronounced CNS disease. MHV is not naturally neuroinvasive so the virus is injected into the cerebellum or the olfactory nerve of mice or rats to induce CNS disease. MHV-4 is extremely neurovirulent and induces an encephalitis that is fatal within the first week of infection. Strains A59 and JHM are avirulent and cause the development of inflammatory demyelination in the brain and spinal cord (Taguchi et al., 1979; Barthold and Smith, 1983; Koolen et al., 1983; Barthold, 1986). Replication of the avirulent strains is confined to developing oligodendrocytes which induce demyelination via oligodendrocyte cell lysis (Beushausen and Dales, 1985; Pasick and Dales, 1991).

Semliki Forest virus (SFV) is an alphavirus in the family *Togaviridae* and is also a positive-sense, enveloped, RNA virus. L10, M9 and A7 are the three most common strains of SFV that are studied. L10 is virulent (Atkins and Sheahan, 1982; Atkins et al., 1990; Smyth et al., 1990; Glasgow et al., 1991; Balluz et al., 1993) while M9 and A7 are avirulent in adult mice (Atkins et al., 1985, 1995; Fazakerley et al., 1993). SFV is neuroinvasive and neurotropic and may induce

demyelination when administered intraperitoneally. A systematic viremia develops and SFV is able to cross the brain-blood barrier by infecting cerebral vascular endothelial cells. L10 then infects neurons and oligodendrocytes where a fatal encephalitis develops after two weeks post-infection (Barrett et al., 1980; Atkins and Sheahan, 1982; Atkins et al., 1990; Smyth et al., 1990; Glasgow et al., 1991; Balluz et al., 1993). The A7 and M9 strains remain at the site of CNS entry and induce a long-term CNS demyelination by infecting oligodendrocytes and not neurons (Atkins et al., 1985, 1994; Fazakerley et al., 1993). The demyelination caused by SFV-A7 and SFV-M9 infection is dependent upon a bystander effect mediated by CD8<sup>+</sup> T-cells (Subak-Sharpe et al., 1993).

Visna virus (VV) is a lentivirus of the family *Retroviridae*. It is a lentivirus with an RNA genome that is transformed to DNA which integrates into the host genome (Pyper et al., 1984). In the sheep, visna virus produces a chronic infection when there is a strong host immune reaction present (Georgsson et al., 1987). Replication is restricted to monocytes that are differentiating into macrophages though the virus is able to stay dormant in monocytes until differentiation occurs (Vigne et al., 1994). Inflammatory infiltrates in the CNS of Icelandic sheep infected with visna virus produces lesions in the white matter and cause necrosis of axons and myelin sheaths (Petursson et al., 1976). This type of "early" white matter damage may be seen even years after initial infection. The "late" type of lesion can take up to 11 years post-infection to detect, but results in demyelination in the spinal cord with axon preservation and continuous myelin breakdown similar to the lesions seen in chronic-progressive MS (Georgsson et al., 1982; Georgsson et al., 1987).

Canine distemper virus is a morbillivirus in the *Paramixoviridae* family that is negative, single-stranded, enveloped, and contains RNA (Norrby and Oxman, 1990). CNS demyelination in this model can be induced through intraperitoneal or intranasal infection of dogs and may be non-inflammatory or inflammatory depending upon the degree of immunosuppression at the time of infection. Non-inflammatory, demyelinating plaques are common in the initial stages of viral infection and are attributed to direct viral effect (Cerruti-Sola et al., 1983). Viral infection of astrocytes is common whereas oligodendrocyte infection is rare and restricted meaning that viral RNA is detected in oligodendrocytes but viral proteins are not. The death of the astrocyte leads to non-viable conditions for the oligodendrocytes due to the increase of extracellular waste products (Summers et al., 1987).

There are several chemicals that may be used to induce CNS demyelination in experimental animals. Some of these chemicals include cuprizone, ethidium bromide, hexachlorophene, lysolecithin, tellurium, and triethyltin. Cuprizone and ethidium bromide can cause status spongiosus of the white matter and intramyelinic edema when administered into the CNS. Hexachlorophene and triethyltin induce brain swelling as well as edema between the myelin sheaths. Lysolecithin is more selective since demyelination occurs only at the site of injection. Finally, tellurium is used to induce hindlimb paralysis in experimental animals via lipofuscinosis (Doull, 1996).

#### *1.10 Theiler's murine encephalomyelitis virus (TMEV)*

TMEV infection is a model for the progressive form of MS (Lipton, 1994). TMEV is a positive sense, single-stranded RNA virus in the family *Picornaviridae* (Pevear et al., 1987). TMEV was first characterized as a

murine model for MS in 1975 when it was discovered that TMEV infection may result in a relapsing-remitting demyelination pattern (Lipton, 1975). Vpg is a viral protein necessary for the translation of viral RNA on smooth endoplasmic reticulum. Four capsid proteins, VP1, VP2, VP3, and VP4, are produced which form an icosahedral structure from proteins 1D, 1B, 1C, and 1A respectively. Viral proteins 2B and 2C are needed for viral replication. 3A and 3B are utilized in the initiation of RNA synthesis. 3C is the viral protease that cleaves the genomic polyprotein, and 3D is the viral RNA polymerase which is able to lengthen RNA primers. The L protein has been suspected to play a role in viral pathogenesis due to differences in the L region between TMEV strains. The function of protein 2A and the receptor for TMEV are still unknown (Figure 1.1). TMEV strains have been divided into two subgroups composed of the neurovirulent GDVII and FA substrains and the less virulent TO substrains. The TO substrains include BeAn 8386, DA, WW, TO<sub>4</sub> and Yale (Lipton, 1978, 1980).




Figure 1.1: TMEV genome.

There are differences in susceptibility to Theiler's virus infection among different inbred strains of mice (Lipton and Dal Canto, 1979).

The highly susceptible strains include SJL/J, DBA/1, DBA/2, SWR/J, NZW, RIIIS/J, and PL/J mice. AKR, CBA, and C3H strains are intermediately susceptible and 129Sv, C57BL/6, C57BL/10, C57L and BALB/c strains are resistant (Nicholson et al., 1994).

### *1.11 TMEV-induced demyelination (TVID)*

Theiler's virus-induced demyelination is a very involved process. Not only is demyelination a direct result of viral replication, but the host immune reaction to viral infection plays a significant role in the development of demyelinating lesions. The exact process of demyelination in TMEV infection is still being debated. Several theories include the activity of viral replication, CD8<sup>+</sup> cytotoxic T-cells, CD4<sup>+</sup> T-cells, antibody production to virus or myelin, and IFN- $\gamma$  during the course of infection.

Intracranial (i.c.) inoculation of susceptible mice with neurotropic GDVII results in acute fatal encephalitis during the first week of infection (Dal Canto and Lipton, 1975). Alternatively, permissive hosts infected i.c. with one of the TO substrains of TMEV develop a flaccid paralysis by 2 weeks post-infection (p.i.), by which time viral antigens and genomic RNA are located in the neurons of the gray matter (Dal Canto and Lipton, 1975).

The BeAn strain of TMEV is capable of inducing demyelination in the CNS. The demyelinating phase of TMEV is preceded by a "gray matter" disease (Lipton, 1980). During the first four weeks of infection, virus is found replicating in neurons following intracranial injection of BeAn (Dal Canto and Lipton, 1975). The chronic persistence of TMEV in the white matter of the spinal cord begins 1 month p.i. and continues throughout the duration of infection (Miller and Gerety, 1990, Yamada

et al., 1991). By six weeks post-infection, virus can be detected in astrocytes, macrophages and oligodendrocytes and continues to replicate in these cells until the animal is terminated. Clinical signs of demyelination can be detected as early as 8 weeks post-infection, indicating that the white matter of the spinal cord has begun to be affected.

Persistent viral infection of the CNS is necessary for the development of demyelinating lesions (Bureau et al., 1993; Pritchard et al., 1993). During the course of chronic TMEV infection, Th1 cells specific to TMEV are reported to be the direct cause of a DTH reaction that occurs (Miller and Gerety, 1990). Susceptible strains of mice have a limited T-cell defense and are unable to clear virus efficiently. This lead to the conclusion that viral replication plays a part in the development of demyelinating lesions. One theory is that direct viral lysis of oligodendrocytes can cause demyelination (Rodriguez et al., 1983; Blakemore et al., 1988). Viral infection of these cells can interfere with myelin synthesis and viral lysis can spread infectious virus to astrocytes and macrophages that keep the extracellular space surrounding the oligodendrocytes free of chemical and physical debris (Miller et al., 1997). The release of viable virions may also increase the infection of BeAn in other oligodendrocytes. BeAn has been detected in demyelinating lesions via immunoperoxidase staining and viral particles have been detected in oligodendrocytes by electron microscopy giving merit to the idea that viral replication in oligodendrocytes plays a role in the production of demyelinating lesions (Rodriguez et al., 1983; Brahic et al., 1984; Blakemore et al., 1988; Rossi et al., 1997).

The MHC-class I molecules randomly bind proteins found in the intracellular matrix and express the proteins as peptides on the surface of the cell that the peptides are derived from. MHC-class I molecules are

located on the surface of all nucleated cells including oligodendrocytes. CD8<sup>+</sup> cytotoxic T-cells (CTLs) are able to recognize and kill cells that have been infected with TMEV when viral fragments are presented via MHC-class I molecules. When CTLs lyse viral infected oligodendrocytes, demyelination occurs. CTLs may contribute to extracellular viral spreading by lysing viral-infected cells that contain infectious virus (Murray et al., 1998; Rivera-Quinones et al., 1998). The role of CD8<sup>+</sup> cells in TVID is controversial, though. Treatment of susceptible mice with anti-CD8<sup>+</sup> antibodies does not alter the course of TMEV-induced demyelination (Borrow et al., 1992), and viral infection can result in demyelination even in  $\beta_2$ -microglobulin-deficient resistant mice lacking functional CD8<sup>+</sup> T-cells (Pullen and Kim, 1991; Fiette et al., 1993). It has been proposed that a poor CD8<sup>+</sup> T-cell response may actually account for the viral persistence in SJL/J mice since low levels of virus-specific CTLs in these mice have been noted (Lindsley et al., 1991; Lin et al., 1998).

MHC-class II molecules are located on the surface of antigen presenting cells (APCs). Dendritic cells are the most efficient APCs though astrocytes and macrophages may also function in this capacity. Peptides that are contained within MHC-class II molecules are presented to CD4<sup>+</sup> T-cells. Th1 and Th2 are both subtypes of CD4<sup>+</sup> cells though they release different cytokines. IFN- $\gamma$  is produced by Th1 cells and induces MHC-class II expression on astrocytes (Borrow and Nash, 1992) and cerebrovascular endothelial cells of TMEV susceptible but not TMEV resistant mice (Welsh et al., 1993). The upregulation of MHC-class II results in increased viral or autoantigen presentation which, in turn, increases the production of antibodies to these antigens (Miller et al., 1997). The MHC-class II T-cell lines derived from demyelinating lesions in the spinal cords of SJL/J mice react with the VP1, VP2 and VP3 viral

capsid proteins (Yauch and Kim, 1994; Cameron et al., 2001) and T-cells recognizing VP1 produce the highest levels of IFN- $\gamma$ . MHC-class II or CD4 $^{+}$  T-cell inactivation/depletion via antibody treatment is able to suppress demyelination caused by TMEV (Rodriguez et al., 1986; Welsh et al., 1987; Yauch et al., 1998) further implicating the role of CD4 $^{+}$  T-cells in TVID. In addition, interfering with the activation of the Th1 cells with cyclosporine treatment reduces the incidence of demyelination with TMEV infection (Rodriguez and Lindsley, 1992).

Inactivation of IL-12, the Th1 cytokine needed for the clonal expansion and priming of T-cells for high IFN- $\gamma$  production (Manetti et al., 1994), result in an increase in clinical presentation when antibody to IL-12 is given at the time of infection with Theiler's virus. TNF- $\alpha$  and IFN- $\gamma$  production decrease and IL-10 and IL-4 are increased (Inoue et al., 1998). This correlates with the need for Th1 cytokines during initial viral infection.

In concert with the antibody production, IFN- $\gamma$  secretion results in Th1 cell proliferation and the suppression of Th2 lymphocytes. Th1 cells are responsible for the DTH reaction to myelin which contributes to demyelination in Theiler's virus infection (Miller et al., 1997; Borrow et al., 1998). Increasing the virus-specific DTH reaction in susceptible mice correlates with the development of increased disease severity (Clatch et al., 1985), which supports a role for Th1-mediated CNS inflammation. Spleen cells from infected mice are able to demyelinate *in vitro* (Dal Canto et al., 2000) and autoimmune responses to epitopes of myelin membrane have been detected which suggests T-cells are produced against myelin as a result of infection (Miller et al., 1997).

Another consequence of MHC-class II restricted DTH CD4 $^{+}$  T-cell activation is the recruitment of macrophages which release proteases, reactive oxidative radicals, and TNF- $\alpha$  which contribute to bystander

demyelination (Vanguri and Shin, 1988). Therefore, bystander demyelination is not a direct effect of CD4<sup>+</sup> T-cells, but rather the activation of macrophages. Macrophages secrete proteases as waste into the extracellular environment. When macrophages are activated to remove myelin debris via endocytosis in an area of demyelination, eventually, the macrophage will become gorged with debris. The proteases that are produced while the macrophage undergoes cytoplasmic digestion of the debris are able to degrade myelin which subsequently damage oligodendrocytes and myelin.

### *1.12 MHC haplotypes and TMEV*

In TVID, inflammation and MHC haplotypes play an important role in susceptibility. Mice with heterozygous or homozygous dominant MHC class I *H2-D* allele *b*, are resistant to TVID (Azoulay-Cayla et al., 2000). Animals with *d*, *k*, and *s* haplotypes are intermediately susceptible to TMEV, yet mice with *p*, *q*, *r* and *f* *H2-D* alleles develop chronic disease when infected with TMEV (Clatch et al., 1985, 1987; Rodriguez and David, 1985; Rodriguez et al., 1986, 1990; Patick et al., 1990; Brahic and Bureau, 1998). The resistant *b* haplotype is dominant (Bureau et al., 1992). Two other genes, *Tmevp2* and *Tmevp3* have been implicated in the persistence of TMEV in susceptible mice through the use of multiple background crosses. The exact function of these genes is still unknown (Bihl et al., 1999).

One of the major differences between the three groups of inbred mice stated above is that susceptible mice produce less IFN- $\gamma$  post-infection and fewer cytotoxic T-cells. These mice are unable to clear the virus efficiently before it infects oligodendrocytes (Chamorro et al., 1986; Lipton et al., 1991, 1998). The oligodendrocytes are lysed by CTLs

resulting in macrophage infiltration and demyelination. Susceptible mice also have a higher DTH response to myelin late in the disease process that contributes to inflammation and demyelination (Borrow et al., 1998).

### *1.13 Theiler's virus and interferons*

IFN- $\alpha/\beta$  receptor knockout mice have demonstrated the importance of type I interferons in TVID. 129Sv mice were utilized in this study. The capacity to respond to endogenous IFN- $\alpha/\beta$  is necessary for survival of 129Sv mice to the chronic phase of TMEV. Heterozygous or homozygous dominant *H-2D<sup>b</sup>* haplotype 129Sv mice are naturally resistant to the DA strain of Theiler's virus whereas 129Sv mice that are homozygous recessive for *H-2D<sup>b</sup>* are susceptible to persistent infection (Azoulay-Cayla et al., 2000).

Infection with the DA Theiler's strain produces a similar disease as BeAn infection in susceptible mice. 129Sv or BALB/c mice that lack the IFN- $\alpha/\beta$  receptors die of severe encephalitis due to DA infection and those that lack IFN- $\gamma$  receptors develop extreme late inflammatory and demyelinating disease. High viral load of DA was observed throughout the CNS tissue (Fiette, et al. 1995; Van den Broek et al., 1995; Njenga et al., 1997). Conversely, SJL/J mice infected with DA and treated with mouse IFN- $\alpha/\beta$  for five weeks experienced remyelination and a decrease in clinical presentation of disease. However, long-term treatment resulted in an exacerbation of disease (Njenga et al., 2000). This work re-enforces the importance of interferon activation in resistance to initial viral infection and the potentially dangerous long-term effects IFN- $\beta$  treatment may pose on MS patients.

### **1.14 DTH and Theiler's virus**

Type IV delayed-type hypersensitivity is a form of cell-mediated immunity that occurs 24-48 hours after challenge with an antigen previously encountered by the host. This is a T-cell mediated response resulting in the infiltration of macrophages and inflammation. In the case of a Theiler's virus infection, the major protein of concern is host myelin basic protein when the focus is autoimmunity. Myelin that was prepared from the brains of adult SJL mice initiates a DTH reaction within 24 hours when injected into the ears of SJL mice chronically infected with TMEV strain BeAn. The intensity of the DTH reaction is assessed via measurement of ear thickness where PBS injections into the opposite ears of the same mice are used as controls (Borrow et al., 1998; Slavin et al., 1998; Wang et al., 1999).

During the course of chronic TMEV infection, Th1 cells specific to TMEV are reported to be the direct cause of a delayed-type hypersensitivity reaction that occurs and contributes to bystander demyelination (Miller and Gerety, 1990; Borrow et al., 1998). DTH responses may also be used to determine the immune reactivity to TMEV using UV-irradiated whole virus particles (Pullen et al., 1994; Lipton et al., 1995; Drescher et al., 1998; Murray et al., 1998; Koh et al., 2000), active TMEV (Karpus et al., 1995; Inoue et al., 1996; Inoue et al., 1997; Inoue et al., 1998; Inoue et al., 1999), or specific viral peptides (Miller et al., 1995; Burt et al., 1999; Pavelko et al., 2000). In all of these experiments, the DTH response was used as an assessment of the efficiency of the immune system to recognize virus after either an immunomodulating treatment or a genetic mutation that affects MHC presentation.

Disease susceptibility in TVID correlates with the temporal development of chronic high levels of TMEV-specific, MHC-class II-restricted DTH responses, but not with virus-specific serum antibody responses or with viral titers in the CNS (Gerety et al., 1991; Gerety et al., 1994). DTH responses to PLP, MOG, (Miller et al., 1997) and whole myelin (Borrow et al., 1998) have been reported during the late demyelinating phase of TMEV in SJL/J mice. The phenomenon of epitope spreading occurs during TVID, whereby mice develop segmental T-cell responses to different myelin epitopes during the course of the disease (Miller et al., 1997). Furthermore, these autoreactive T-cells appear to contribute to the demyelinating process since spleen cells from infected mice are able to demyelinate *in vitro* cultures following stimulation with PLP (Dal Canto et al., 2000). Thus, DTH T-cells reacting to both virus and myelin appear to play a role in inflammatory demyelination in this model.

### *1.15 Experimental allergic encephalomyelitis (EAE)*

EAE focuses on the autoimmune component of MS and is induced by the injection of myelin basic protein (Meyer et al., 1996), whole spinal cord homogenate (Brown et al., 1981) or proteolipid protein plus adjuvant into laboratory animals including mice (Trotter et al., 1987; Fritz and McFarlin, 1989; Ke and Kapp, 1996). EAE can also develop through adoptive transfer of CD4<sup>+</sup> T-cells to naïve mice which establishes it as an autoimmune model for MS (Pettinelli and McFarlin, 1981; McCarron and McFarlin, 1988; Satoh et al., 1988; Fallis et al., 1989; Kuchroo et al., 1992).

The development of clinical symptoms begins 6-8 days after adoptive transfer occurs and is characterized as changes in gait, hind

limb paralysis, and incontinence. These symptoms last for about two weeks after which the animal may recover slightly. Other relapses will continue to occur and will become progressively worse over time (Dal Canto et al., 1995).

EAE mimics MS in that it is an autoimmune inflammatory disease of the CNS that is T-cell-mediated (Zamvil and Steinman, 1990). The upregulation of IL-2, IFN- $\gamma$ , and TNF- $\beta$  (Van der Veen and Stohlman, 1993; Cua et al., 1995; Olsson, 1995) and the down regulation of TGF- $\beta$ , IL-10, and IL-4 (Okuda et al., 1995; Issazadeh et al., 1996; Diab et al., 1997) have been detected in the CNS of animals with EAE resulting in the conclusion that development of disease is the result of Th1 cell cytokine secretion and the balance between Th1/Th2 cell activation (Van der Veen and Stohlman, 1993; Cua et al., 1995; Olsson, 1995). Chronic-relapsing EAE results in inflammatory cell activation in the CNS and is seen in the meninges, perivascular spaces, and eventually the parenchyma. Axonal destruction is less extensive in EAE than in Theiler's virus, though macrophages remain in the CNS tissue for many weeks in both models. In chronic-relapsing EAE, the amount of inflammation seen in the CNS is not constant. During the remitting stages of disease, inflammation is reduced as it is in RR MS (Dal Canto et al., 1995).

#### *1.16 Sex differences in TMEV and EAE*

Susceptibility to Theiler's virus and EAE vary in different sexes of inbred strains of mice. Male and female SJL/J mice are both equally susceptible to TMEV infection with BeAn 8386 (Kappel et al., 1990) though male SJL/J mice are less susceptible to the TMEV DA strain than female SJL/J mice (Hill et al., 1998). EAE is induced to a greater

degree in female as opposed to male SJL/J mice (Voskuhl et al., 1996). For the extent of this work, female SJL/J mice were used exclusively so that comparisons could be made to previous reports of IFN- $\tau$  treated, female SJL/J mice with chronic EAE (Soos et al., 1995; Majtaba et al., 1997; Soos et al., 1997; Majtaba et al., 1998).

### *1.17 Cytokine expression in the CNS during chronic EAE or TMEV*

The expression of Th1 and Th2 cytokines in the CNS during EAE or TMEV infection is important to note since it is believed the change in cytokine expression is partially responsible for the induction of demyelination seen in both animal models. During the exacerbation phase of EAE in SJL/J mice, 14 days post-inoculation, Th1 cytokines IL-2 and IFN- $\gamma$  are up-regulated in the brain, spinal cord, and cerebrospinal fluid (Renno et al., 1994).

The cytokine data concerning chronic TMEV infection is controversial. Using the DA strain of TMEV, at 40 days p.i. in SJL/J mice, Sato et al. found that the Th1 cytokines IL-1 and IL-2 were not detectable in the spinal cord whereas Th2 cytokines, IL-10, and Th1 cytokines TNF- $\alpha$ , IL-12, and IFN- $\gamma$  were elevated when compared to controls. In the brains of the same animals, IL-10, IL-12, TNF- $\alpha$ , IL-1, IL-2, IL-6, and IFN- $\gamma$  were not detected at 40 days p.i. but, IL-4 production was high in the brain (Sato et al., 1997). It has also been reported that IFN- $\gamma$ , IL-1, IL-2, IL-6, IL-12, TNF- $\alpha$ , TGF- $\beta$ 1, IL-4, IL-5 and IL-10 cytokine RNA was detected at levels above controls at 60 days p.i. in SJL/J mice also infected with DA (Chang et al., 2000). High levels of lymphotoxin- $\beta$ , TNF- $\alpha$ , IL-6, and TGF- $\beta$  were observed in the brains of SJL/J mice infected with DA for 60 days in a separate study (Theil et al.,

2000). Since there appears to be inconsistencies between 40 and 60 days p.i. with the same TMEV strain, it would be interesting to see if there was a difference in cytokine expression in the CNS of mice infected with the BeAn as compared to the DA strain of TMEV.

### *1.18 Interferon-tau in sheep*

IFN- $\tau$  has been characterized as one of the pregnancy recognition signals that is secreted by sheep trophoblasts between days 9 and 24 of pregnancy (Godkin et al., 1984). IFN- $\tau$  has 70% homology with IFN- $\alpha$  (Stewart et al., 1989), and is therefore classified as a type I interferon. Only trophoblast cells and their derivatives are able to transcribe IFN- $\tau$  due to the promoter region -126 to -450 base pairs from the transcriptional start site. This unique promoter region accounts for the majority of the 30% sequence difference between IFN- $\tau$  and the other type I interferons. It enables the expression of IFN- $\tau$  to be dependent upon pregnancy (Cross and Roberts, 1991). IFN- $\tau$  functions as an anti-luteolytic agent by decreasing the endometrial gene expression of oxytocin receptors (Vallet and Lemming, 1991; Spencer et al., 1996). Though a threshold for IFN- $\tau$  effectiveness may be dose dependent since it has been reported that high doses of IFN- $\tau$  may result in apoptosis in sheep hepatocytes *in vivo* (Kim et al., 2000).

### *1.19 Immunomodulator functions of IFN- $\tau$*

Unlike the other type I interferons, IFN- $\tau$  is not induced by viral infection and double stranded RNA (Roberts et al., 1992). Its synthesis is maintained over a period of days as opposed to hours as is the case with IFN- $\alpha$  and IFN- $\beta$  (Godkin et al., 1982). IFN- $\tau$  acts in an anti-inflammatory capacity *in vivo* by inhibiting Th1 lymphocyte proliferation (Newton et al., 1989, Niwano et al., 1989; Skopets et al., 1992; Assal-Meliani et al., 1993), promoting the production of placental Th2 cytokines IL-4 and IL-10 (Chaouat et al., 1995), and activating NK cells *in utero* (Tuo et al., 1993).

### *1.20 The anti-viral effects of IFN- $\tau$*

The anti-viral activity of IFN- $\tau$  is comparable or superior to IFN- $\alpha$  in ovine lentivirus, human papilloma virus, feline immunodeficiency virus, and human immunodeficiency virus infections without the cytotoxicity seen with IFN- $\alpha$  at high concentrations.

Ovine lentivirus titers are reduced by 90% as compared to controls in lambs that receive IFN- $\tau$  during the first month of infection. Inflammation is also reduced in the lungs of treated lambs (Juste et al., 2000). IFN- $\tau$  decreases the intracellular levels of E6 and E7 of human papilloma virus in normal human keratinocytes, which induces apoptosis via increasing p53 concentrations (Johnson et al., 1999). Feline lymphocytes infected with FIV and human lymphocytes infected with HIV-1 do not reduce in viability as a result of IFN- $\tau$  treatment (Pontzer et al., 1997). In a similar study, IFN- $\tau$  had a 35-fold antiviral effect over IFN- $\alpha$  in peripheral blood lymphocytes infected with HIV. In

monocyte-derived macrophages, IFN- $\tau$  is 100 fold more efficient in inhibiting HIV replication than IFN- $\alpha$ . Both IFN- $\alpha$  and IFN- $\beta$  reduced cell viability at 50,000 U/ml whereas IFN- $\tau$  did not (Dereuddre-Bosquet et al., 1996). Finally, IFN- $\tau$  is able to inhibit TMEV replication, up regulate MHC class I and down regulate MHC class II in cerebral vascular endothelial cells (Tennakoon et al., 2001).

### *1.21 Interferon treatment of EAE*

EAE has been used as a model to understand the mechanism of action of the beneficial affects of IFN- $\beta$  seen in MS since this is poorly understood. Recombinant mouse IFN- $\beta$  is able to successfully treat chronic EAE in SJL/J and (SWR x SJL)F<sub>1</sub> mice via reduction of IFN- $\gamma$ , increase in IL-10 and TGF- $\beta$  production, and inhibition of DTH response (Brod and Burns, 1994; Yu et al., 1996; Yasuda et al., 1999).

IFN- $\tau$  has proven to be an effective treatment in EAE by preventing acute induction and superantigen reactivation of EAE via CD4 $^{+}$  T-suppressor cells that inhibit MBP activation of T-cells (Mujtaba et al., 1997). This protection occurs without the toxicity that is seen with high concentrations of IFN- $\alpha$  and IFN- $\beta$  treatment (Soos et al., 1995). Oral as well as i.p. administration of IFN- $\tau$  in EAE give the same amount of protection, but oral administration does not result in the production of non-neutralizing antibodies to IFN- $\tau$  that is seen with i.p. delivery. The current hypothesis is that this protection occurs via Th2 cytokine activation. The Th2 proliferation theory is supported by an increased IL-10 production during IFN- $\tau$  treatment, the inhibition of B-cell and T-cell responses in active and chronic EAE *in vivo* and *in vitro*, and the lack of

inflammatory lymphocytic lesions and activation of microglia in the CNS during IFN- $\tau$  treatment (Soos et al., 1997; Majtaba et al, 1998).

### *1.22 Hypothesis*

Dual roles exist for the T-cells involved in Theiler's virus-induced demyelination. T-cells are required for the decrease in viral load during the early course of infection, but are known to play a part in the demyelination that occurs during chronic infection. Both CD4 $^{+}$  and CD8 $^{+}$  cells are important in viral clearance during acute disease. Mice depleted of CD4 $^{+}$  cells do not survive the initial viral infection (Welsh et al., 1987) and mice depleted of CD8 $^{+}$  T-cells suffer high viral titers and subsequently more severe demyelinating disease (Borrow et al., 1992). However, the severity of demyelination and inflammation in chronic TMEV can be reduced with immunosuppressive therapies such as anti-CD4 antibody treatment (Welsh et al., 1987) and cyclophosphamide administration (Lipton and Dal Canto, 1976).

Based on the aforementioned anti-viral and cytokine-modulating effects of IFN- $\tau$  *in vivo* and during EAE, as well as the immunosuppressive data on TMEV, it is believed there is a possibility that IFN- $\tau$  treatment may reduce the development of and/or degree of demyelinating lesions in the CNS of chronically TMEV-infected mice. Different time points for treatment during the course of infection need to be investigated in order to assess the appropriate time frame where immunosuppression with IFN- $\tau$  would be beneficial. After the development of a persistent TMEV infection in the CNS, IFN- $\tau$  treatment should aid in the upregulation of Th2 cytokines thereby decreasing Th1 proliferation, which may result in a decrease in disease progression. Alternatively, IFN- $\tau$  treatment administered before viral infection is

expected to result in immunosuppression and increase initial viral load thereby enhancing lesion development.

### **Specific Aims**

1. To determine the most effective time course of IFN- $\tau$  treatment in SJL/J mice during different stages of disease resulting from TMEV infection and to compare IFN- $\tau$  treatment with treatment using a known anti-inflammatory, methylprednisolone. Weekly clinical scoring and weights will be used to determine disease progression.
2. To analyze histological changes in the spinal cords of mice treated with IFN- $\tau$  in the areas of demyelination, status spongiosus, and inflammation as opposed to infected non-treated and treated non-infected controls. H+E and slides stained for CNS myelin will be used.
3. To investigate the mechanism of action of IFN- $\tau$  treatment as it relates to immunosuppression. Serum levels of IL-10 and corticosterone will be measured by ELISA and RIA analysis respectively. Circulating antibody levels to IFN- $\tau$  will also be measured via ELISA. DTH to myelin will be measured as an indication of Th1 cell activation. Th1 and Th2 cytokine expression in the spinal cord of 4-6 month IFN- $\tau$  treated group will be documented through the use of RNase protection assay (RPA) analysis.

## II. CLINICAL DISEASE PROGRESSION

### Introduction

#### 2.1 Interferon treatment in multiple sclerosis

Interferon-beta (IFN- $\beta$ ) has a therapeutic effect in MS patients by reducing the severity of MS symptoms and relapse rate (Paty et al., 1993; Jacobs et al., 1996). However, several undesirable side effects have been noted. Fever, myalgia, headache, fatigue, and chills occur in 75% of treated patients though the duration of these side effects is patient specific (Lublin et al., 1996). This may be due to the immediate upregulation of inflammatory cytokines and prostaglandins (Dayal et al., 1995; Brod et al., 1996; Arnason, et al., 1994) resulting in increased spasticity and temporary worsening of symptoms (Lublin et al., 1996).

Occasionally, lymphopenia, neutropenia, leukopenia, and increased liver aminotransferase values are detected in MS patients as a result of IFN- $\beta$  administration (PRISMS study group, 1998). Pre-menopausal women may experience breakthrough bleeding or spotting during IFN- $\beta$  treatment due to a decrease in serum progesterone and estradiol levels (Vial et al., 1994; Kauppila et al., 1982).

Changes in mood, specifically pessimism, depression, and lack of interest in treatment can be increased in MS patients undergoing IFN- $\beta$  treatment, though this may be a side-effect of chronic disease (Mohr et al., 1996; Mohr et al., 1997; Borras et al., 1999). Reaction at the site of injection is dependent upon the method of administration with subcutaneous administration resulting in hardened skin lesions, uninflamed sclerotic dermal plaques, erythematous plaques, ulcers,

and sarcoid-like granulomatous dermatitis (Elgart et al., 1997; Mehta et al., 1998).

## *2.2 Interferons in Theiler's virus infected mice*

Interferon-alpha (IFN- $\alpha$ ) and IFN- $\beta$  are both classified as type I interferons. The capacity to respond to endogenous IFN- $\alpha/\beta$  is necessary for survival of 129Sv mice following infection with TMEV (Azoulay-Cayla et al., 2000). 129Sv knockout mice that lack the IFN- $\alpha/\beta$  receptors die of severe encephalitis due to DA infection and those that lack IFN- $\gamma$  receptors develop extreme late inflammatory and demyelinating disease as well as a high viral load of DA throughout the CNS tissue (Fiette, et al. 1995). BALB/c knockout mice without the IFN- $\alpha/\beta$  receptor also develop severe encephalitis and expire within a two day period when infected with DA (Njenga et al., 1997). This work re-enforces the importance of interferon activation in resistance to initial viral infection.

Administration of type I interferons to TMEV infected mice has beneficial effects during a short term treatment but detrimental effects during a long term treatment. Five week administration of biologically effective doses of IFN- $\alpha/\beta$  increased remyelination significantly. A threefold increase in oligodendrocyte remyelination was reported though the extent of demyelination in the spinal cord was not statistically significant between the five-week treated and control groups. Sixteen-week treatment with IFN- $\alpha/\beta$  increased the absolute area of remyelination in the CNS, but the demyelinating lesions were more extensive and numerous to the extent that total remyelination was negligible. Based on *in situ* hybridization, it was noted that CNS remyelination during the five-week treatment was independent of

replicating virus yet the extent of demyelination in the spinal cord directly correlated to the amount of virus positive cells. On the other hand, there was no correlation found in the sixteen-week treated group between the extent of demyelination and viral load, suggesting the two types of demyelination occur via separate mechanisms (Njenga et al., 2000).

### *2.3 Interferon-tau*

Since it is known that IFN- $\alpha/\beta$  can be both beneficial in short term treatments yet harmful in long term treatments in TMEV, another type I interferon, IFN- $\tau$ , has been investigated in this study. IFN- $\tau$  has 70% homology with IFN- $\alpha$  (Stewart et al., 1989), and is therefore classified as a type I interferon with anti-viral activity comparable or superior to IFN- $\alpha$  in the treatment of ovine lentivirus *in vivo* and *in vitro* (Juste et al., 2000), human papilloma virus *in vitro* (Johnson et al., 1999), and HIV *in vitro* (Dereuddre-Bosquet et al., 1996). In common with the other type I interferons, IFN- $\alpha$  and IFN- $\beta$ , IFN- $\tau$  inhibits T-cell proliferation in response to superantigen stimulation in human peripheral mononuclear cells with staphylococcal enterotoxin B, staphylococcal enterotoxin A, and toxic shock syndrome toxin 1. In contrast to IFN- $\alpha/\beta$ , IFN- $\tau$  does not induce cytotoxicity at concentrations greater than 10<sup>4</sup> units/mL (Soos and Johnson, 1995).

IFN- $\tau$  has been characterized as one of the pregnancy recognition signals that is secreted by sheep trophoblasts between days 9 and 24 of pregnancy (Godkin et al., 1984). It functions as an anti-luteolytic agent by decreasing the endometrial gene expression of oxytocin receptors (Vallet and Lemming, 1991; Spencer et al., 1996).

IFN- $\tau$  also acts in an anti-inflammatory capacity *in vivo* by inhibiting Th1 lymphocyte proliferation (Newton et al., 1989; Niwano et al., 1989; Skopets et al., 1992; Assal-Meliani et al., 1993), promoting the production of placental Th2 cytokines IL-4 and IL-10 (Chaouat et al., 1995), and activating NK cells *in utero* (Tuo et al, 1993).

#### *2.4 Interferon-tau and EAE*

EAE, experimental allergic encephalomyelitis, another model of MS, is induced by the injection of myelin basic protein (Meyer et al., 1996) or proteolipid protein plus adjuvant into laboratory animals including mice (Ke and Kapp, 1996). EAE can also develop through adoptive transfer to naïve mice which establishes it as an autoimmune model for MS (McCarron and McFarlin, 1988; Satoh et al., 1988; Kuchroo et al., 1992).

IFN- $\tau$  has proven to be an effective treatment in EAE by preventing acute induction and superantigen reactivation of EAE via induction of suppressor cells (Soos et al., 1995; Mujtaba et al., 1997). In addition, IFN- $\tau$  administration initiates remission in SJL/J mice with chronic EAE and prevents subsequent relapses (Mujtaba et al., 1998) as well as preventing the acute and chronic forms of EAE when administered orally (Soos et al., 1997). The current hypothesis is that protection occurs via Th2 cytokine activation as noted with increased IL-10 and TGF- $\beta$  production (Soos et al., 1997), the inhibition of B-cell and T-cell responses in active and chronic EAE (Mujtaba et al, 1998), and the lack of inflammatory lymphocytic lesions in the CNS (Soos et al., 1997) during IFN- $\tau$  treatment.

## *2.5 Methylprednisolone*

Another anti-inflammatory agent, methylprednisolone, was utilized in the present study. Methylprednisolone is known to improve recovery of CNS function in human patients with acute damage to the spinal cord (Bracken et al., 1990) and greatly reduces inflammation in rats after partial transection of the spinal cord (Bartholdi and Schwab, 1995). In a double-blind trial where MS patients were examined for 1 year, intravenous infusion of methylprednisolone in saline was found to be as effective in promoting MS remission as dexamethasone (LaMantia et al., 1994). Furthermore, methylprednisolone administration to SJL/J mice following lysolecithin-induced demyelination, initiates remyelination. A reduction in the total number of macrophages found in the spinal cord lesions was also noted suggesting a decrease in the inflammatory response is beneficial to remyelination (Pavelko et al., 1998).

## *2.6 Cytokine expression in TMEV*

Immunosuppressive treatment of TMEV has been favorable when treatments focus on decreasing inflammatory responses during late disease. The use of cyclophosphamide or monoclonal antibodies specific for CD4<sup>+</sup> or CD8<sup>+</sup> T-cells result in a decrease in demyelination when administered during chronic TMEV infection (Rodriguez and Lindsley, 1992). In contrast, immunosuppression with cyclophosphamide that began during early disease, five-weeks post-infection, does not affect demyelination when compared to controls (Roos et al., 1982) possibly due to the need for Th1 cytokines to control early viral titers.

Regulating the type of T-cell response by the use of severe compromised immunodeficient (SCID) mice or the administration of anti-

CD4<sup>+</sup> T-cell and/or anti-CD8<sup>+</sup> T-cell antibodies have been helpful in determining the role of these cells in disease progression. The depletion of CD4<sup>+</sup> T-cells in mice prior to TMEV infection results in high mortality rates 3-5 weeks after infection and lack of antiviral IgG response. Adoptive transfer of CD4<sup>+</sup> T-cells restore survival rates to normal suggesting that CD4<sup>+</sup> T-cells are protective after viral load has decreased (Borrow et al., 1993).

Adoptive transfer of CD8<sup>+</sup> T-cells confers resistance to TMEV-induced demyelinating disease in susceptible recipient mice (Nicholson et al., 1996) supporting theory that CD8<sup>+</sup> CTLs are protective after disease onset. SJL/J and CBA mice depleted of CD8<sup>+</sup> T-cells prior to infection with TMEV suffer from a more severe demyelinating disease than do infected control mice (Borrow et al., 1992) suggesting that CD8<sup>+</sup> T-cells are also important in the reduction of viral load during initial infection. Recently, it was reported by Haynes et al. that CD8<sup>+</sup> cells that are removed from BeAn infected, resistant BALB/cByJ mice are able to specifically down regulate IFN- $\gamma$  and IL-2 production and decrease the DTH Th1 reaction when given to BALB/cByJ animals that have been irradiated and therefore become susceptible to BeAn via regulatory CD8<sup>+</sup> T-cell depletion (Haynes et al., 2000).

The regulation or inactivation of cytokines directly is also used as a type of immunosuppression. Administration of antibody to IFN- $\gamma$ , which is normally a natural anti-viral agent, before TMEV infection of SJL/J mice, results in an increase in disease progression and severity. Mortality rate is not increased due to IFN- $\gamma$  antibody administration (Rodriguez et al., 1995). In contrast, an overwhelming fatal CNS TMEV infection is seen with cyclophosphamide immunosuppressed (Lipton et al., 1976; Rodriguez et al., 1991), T-cell-depleted athymic nude (Rosenthal et al., 1986) or neonatal (Rodriguez et al., 1983) mice.

Suppression of TMEV-induced demyelinating disease onset is seen with pentoxifylline administration due to the depletion of Th1 cytokines TNF- $\alpha$  and IFN- $\gamma$  and the upregulation of Th2 cytokines IL-4 and IL-10 when SJL/J mice infected with BeAn are treated -2 to 12 days post-infection (Fushimi et al., 1998). Though this data is contradictory to the IFN- $\gamma$  data reported above, there is a possibility this discrepancy is due to the fact that the Fushimi group infected mice at 6 weeks of age whereas normally SJL/J mice are infected with TMEV between 3-5 weeks of age when the CNS is not fully myelinated.

The regulation of the immune response is vital to the outcome of TMEV infection. As stated above, depletion of the CD4 $^{+}$  T-cells that produce Th1 cytokines early or before TMEV infection results in an increase in viral load and mortality in susceptible mice. CD8 $^{+}$  T-cell depletion prior to infection also results in increased viral load. In contrast, during chronic disease, suppression of both CD4 $^{+}$  and CD8 $^{+}$  T-cells appear to lead to decreased inflammatory demyelinating disease. We propose that the immunomodulating effects of interferon-tau may play a significant role in remyelination during chronic TMEV infection whereas early administration may not beneficial due to the down regulation of Th1 cytokine production.

## **Materials and Methods**

### ***2.7 Mice***

3-week-old female SJL/J mice (Harlan, Houston, TX) were obtained and infected when 4-5 weeks old.

### ***2.8 Virus***

The BeAn 8386 strain of TMEV was a gift from Dr. Howard L. Lipton (Northwestern University, Evanston, IL). Virus was grown in BHK-21 cells, and the culture supernatant containing infectious virus was aliquoted and stored at -70°C before use. The viral titer was determined by plaque assay on BHK-21 cells (Rueckert & Pallansch, 1981).

### ***2.9 Interferon-tau***

The IFN- $\tau$  was a gift from Dr. Fuller W. Bazer (Texas A&M Health Science Center, College Station, TX). IFN- $\tau$  was isolated as previously described (Ott et al., 1991), diluted in 20mM Tris buffer pH 7.5 with 150mM NaCl, aliquoted and stored at -70°C before use. Protein concentration was determined by the Lowry assay (Lowry et al., 1951).

### ***2.10 Infection of mice and assessment of clinical signs of demyelination***

Mice were anesthetized with Metofane™ (Schering-Plough Animal Health, Union, NJ) and injected intracranially (i.c.) into the right cerebral hemisphere with  $5 \times 10^4$  plaque forming units (PFU) of BeAn in a 20  $\mu$ L volume.

After infection (day 0) all animals were examined weekly for the development of clinical signs indicative of demyelinating disease (Borrow et al., 1998). Clinical signs were scored on a scale from 0 to 6, 0 indicating a healthy animal and 1-6 representing gradual increasing severity of signs as follows: 1, piloerection and/or hunched posture; 2, piloerection and hunched posture plus unsteady gait; 3, very unsteady gait, weak grasp response when placed on wire grid, and occasional slight limb monoparesis; 4, severe hind limb weakness, incontinence, and weight loss; 5, paraparesis of hind limbs, severe weight loss, incontinence, dropped head; 6, moribund/dead.

#### *2.11 IFN- $\tau$ treatment of mice prior to Theiler's virus infection up to the development of moderate demyelinating disease*

Ten mice were injected with  $10^5$  units of IFN- $\tau$  intraperitoneally daily from -3 to 0 days post-infection and 10 mice were treated with the same concentration of IFN-tau -3 to 60 days post-infection. Ten virus-infected control mice for each treatment received 100uL of 0.9% saline i.p. during the same intervals. All perfusions occurred at 6 months post-infection.

### *2.12 IFN- $\tau$ treatment of mice with moderate demyelinating disease*

Ten mice were injected with  $10^5$  units of IFN- $\tau$  i.p. daily from 2 months to 6 months post-infection. Ten virus infected control mice received 100uL of 0.9% saline i.p. at the same intervals. All perfusions occurred at 6 months post-infection.

### *2.13 IFN- $\tau$ treatment of mice with severe demyelinating disease*

A replication of the same experiment was performed to test the therapeutic potential of IFN- $\tau$  in mice suffering from severe demyelinating disease. In each experiment, 10 mice were injected with  $10^5$  units of IFN- $\tau$  (Soos et al., 1995) i.p. daily from 4 months to 6 months post-infection. Ten virus-infected control mice received 100uL of 0.9% saline i.p. at the same intervals. All perfusions occurred at 6 months post-infection.

### *2.14 Methylprednisolone treatment of mice*

Ten mice were injected i.p. with pulse injections of 1mg methylprednisolone (40mg/kg) (Pharmacia & Upjohn, Kalamazoo, MI) every three days from 5 months to 6 months p.i. to inhibit inflammatory responses (Pavelko et al., 1998). Ten virus infected control mice received 100uL of 0.9% saline i.p. at the same intervals. All perfusions occurred at 6 months post-infection.

### *2.15 IFN- $\tau$ treatment of non-infected control mice*

Ten mice were treated from 5 to 7 months of age daily with  $10^5$  units of interferon-tau by i.p. injection. Ten non-infected control mice were injected with 100uL of 0.9% saline i.p. at the same time. The mice were perfused at 7 months of age.

### *2.16 Neurological assessment*

Neurological exams of the -3 to 60 day post-infection mice were performed at days 0, 90, and 170 post-infection. The mice were evaluated by Dr. Joan Coates (Department of Small Animal Medicine and Surgery, Texas A&M College of Veterinary Medicine) using a previously published protocol for rat neurological and behavioral analysis (Whishaw, et al., 1983) that had been modified by Dr. Coates for mice (see appendix for score sheet). Dr. Coates evaluated all of the mice without prior knowledge of the treatment groups.

### *2.17 Statistical analysis*

A repeated measures analysis of covariance (ANCOVA) was performed on the weights and clinical scores of the subjects over time. When appropriate, pre-treatment weights or clinical scores served as a covariate.

## Results

### *2.18 IFN- $\tau$ treatment of mice prior to Theiler's virus infection up to the development of moderate demyelinating disease*

All treatment groups are summarized in table 2.1. Treatment of the infected SJL/J mice with IFN- $\tau$  three days before infection to the day of infection resulted in a significant weight loss,  $p<0.003$ , beginning at 18 weeks p.i. (figure 2.1) and an increase in clinical disease onset,  $p<0.001$ , from 7 weeks p.i. which continued throughout infection (figure 2.2). Treatment with IFN- $\tau$  three days before infection to sixty days post-infection showed the same pattern of disease development with significant weight loss,  $p<0.0002$ , at 18 weeks p.i. (figure 2.3) and worsening of clinical symptoms,  $p<0.0001$ , (figure 2.4) at 7 weeks p.i. as a result of IFN- $\tau$  treatment. According to the neurological assessment, both the pretreated groups developed a significant increase in neurological impairment with stereotyped behaviors including a significant decline in locomotor behavior  $p<0.004$ , a decline in gait ataxia which approached significance  $p<0.06$ , increased resting tremor occurrence which approached significance  $p<0.06$ , and increase aggravated cage behavior which also approached statistical significance  $p<0.06$  when compared to saline treated, virus infected control animals.

**Table 2.1. Experimental groups in IFN- $\tau$  treatment study using SJL/J female mice and TMEV.**

<u>Infected</u>	<u>Treatment</u>	<u>Time Course Treated</u>	<u>n</u>
+	IFN-tau	-3 to 0 days pi	10
+	Saline	-3 to 0 days pi	10
+	IFN-tau	-3 to 60 days pi	10
+	Saline	-3 to 60 days pi	10
+	IFN-tau	2 to 6 mo. pi	10
+	Saline	2 to 6 mo. pi	10
+	IFN-tau	4 to 6 mo. pi	20
+	Saline	4 to 6 mo. pi	20
-	IFN-tau	5-7 mo.	10
-	Saline	5-7 mo.	10
+	Methylprednisolone	5-6 mo. pi	10
+	Saline	5-6 mo. pi	10
-	None	N/A	6




Figure 2.1: Mean weight change IFN- $\tau$  treatment -3 to 0 days post-infection. Change from baseline of 10 BeAn infected female SJL/J mice treated with IFN- $\tau$  -3 to 0 days post-infection and 10 BeAn infected saline controls.




Figure 2.2: Mean score change IFN- $\tau$  treatment -3 to 0 days post-infection. Mean clinical scores from baseline of 10 BeAn infected female SJL/J mice treated with IFN- $\tau$  -3 to 0 days post-infection and 10 BeAn infected saline controls.




Figure 2.3: Mean weight change IFN- $\tau$  treatment -3 to 60 days post-infection. Mean weight change from baseline of 10 BeAn infected female SJL/J mice treated with IFN- $\tau$  -3 to 60 days post-infection and 10 BeAn infected saline controls.




Figure 2.4: Mean score change IFN- $\tau$  treatment -3 to 60 days post-infection. Mean clinical scores of 10 BeAn infected female SJL/J mice treated with IFN- $\tau$  -3 to 60 days post-infection and 10 BeAn infected saline controls.

### *2.19 IFN- $\tau$ treatment of mice with moderate demyelinating disease*

Interferon-tau treatment from two-months post-infection to six-months post-infection did not change the course of disease progression as compared to the saline controls in regards to weight gain,  $p<0.2312$ , (figure 2.5). However, at 11-weeks post-treatment, a divergence is seen where the IFN- $\tau$  treated mice begin to gain weight (figure 2.5). This separation has not been shown to be significant but is worth further evaluation. Clinically, these mice did improve slightly after 8-weeks of treatment and continued to do so until the end of the study,  $p<0.07$ , (figure 2.6).

### *2.20 IFN- $\tau$ treatment of mice with severe demyelinating disease*

During the chronic phase of disease caused by TMEV, a significant improvement in weight gain was noted beginning week 5 of treatment with a slight divergence at week 6 (figure 2.7),  $p<0.0001$ , which was consistently repeated (figure 2.11),  $p<0.0079$ , and clinical scores decreased (figure 2.8) with significant differences between groups occurring at 4-weeks post-treatment,  $p<0.0001$ , (figure 2.12),  $p<0.0053$ . These effects were observed when IFN- $\tau$  was administered during the four to six months post-infection time frame. Figures 2.9 and 2.10 indicate the changes in clinical score immediately prior to IFN- $\tau$  treatment and then after two months of treatment. With the exception of one mouse, all of the mice improved clinically (figure 2.9). The one outlier was noted in this group which had severe clinical symptoms at the beginning of the treatment (figure 2.9). There appears to be a

threshold based on the severity of disease before treatment where IFN- $\tau$  administration is not beneficial to the animal. Disease progression continued in the saline treated, virus infected control animals (figure 2.10).

### *2.21 Methylprednisolone treatment of mice*

The animals treated with methylprednisolone every third day displayed some overall weight gain that was marginally significant after day 5 of treatment,  $p<0.0697$ , (figure 2.13) and decreased in clinical scores,  $p<0.0756$ , (figure 2.14) as compared to virus infected, saline controls, but the animals continued to show marked signs of continuing demyelinating disease progression.

### *2.22 IFN- $\tau$ treatment of non-infected control mice*

Non-infected mice suffered marginally significant weight loss which began after three weeks of daily treatment and continued throughout the treatment period due to IFN- $\tau$  administration,  $p=0.065$ , whereas the non-infected, saline control mice had no weight loss (figure 2.15).




Figure 2.5: Mean weight change IFN- $\tau$  treatment 2 to 6 months post-infection. Mean weight change from baseline of 10 BeAn infected female SJL/J mice treated with IFN- $\tau$  2 to 6 months post-infection and 10 BeAn infected saline controls.




Figure 2.6: Mean score change IFN- $\tau$  treatment 2 to 6 months post-infection. Mean clinical scores of 10 BeAn infected female SJL/J mice treated with IFN- $\tau$  2 to 6 months post-infection and 10 BeAn infected saline controls.




Figure 2.7: Mean weight change IFN- $\tau$  treatment 4 to 6 months post-infection. Mean weight change from baseline of 10 BeAn infected female SJL/J mice treated with IFN- $\tau$  4 to 6 months post-infection and 10 BeAn infected saline controls.




Figure 2.8: Mean score change IFN- $\tau$  treatment 4 to 6 months post-infection. Mean clinical scores of 10 BeAn infected female SJL/J mice treated with IFN- $\tau$  4 to 6 months post-infection and 10 BeAn infected saline controls.




Figure 2.9: Individual score change before and after IFN- $\tau$  treatment 4 to 6 months post-infection.




Figure 2.10: Individual score change before and after saline treatment 4 to 6 months post-infection.




Figure 2.11: Mean weight change IFN- $\tau$  treatment 4 to 6 months post-infection #2. Mean weight change from baseline of all 10 BeAn infected female SJL/J mice treated with IFN- $\tau$  4 to 6 months post-infection and 10 BeAn infected saline controls for the same period.




Figure 2.12: Mean score change IFN- $\tau$  treatment 4 to 6 months post-infection #2. Mean clinical scores of 10 BeAn infected female SJL/J mice treated with IFN- $\tau$  4 to 6 months post-infection and 10 BeAn infected saline controls.




Figure 2.13: Mean weight change methylprednisolone 5 to 6 months post-infection. Change from baseline of 10 BeAn infected female SJL/J mice treated with methylprednisolone from 5 to 6 months post-infection every 3 days and 10 BeAn infected saline controls.




Figure 2.14: Mean score change methylprednisolone 5 to 6 months post-infection. Clinical scores of 10 BeAn infected female SJL/J mice treated with methylprednisolone from 5 to 6 months post-infection every 3 days and 10 BeAn infected saline controls.




Figure 2.15: Mean weight change of non-infected mice with IFN- $\tau$  treatment 5 to 7 months of age. Change from baseline of 10 non-infected female SJL/J mice treated with IFN- $\tau$  5 to 7 months of age and 10 non-infected saline controls of the same age.

## Discussion

IFN- $\tau$  has been shown to prevent the development of the acute form of EAE in NZW mice and the development of chronic-relapsing EAE in SJL/j mice (Soos et al., 1995). In addition to protecting against both acute and chronic forms of EAE, parental or oral administration of IFN- $\tau$  has been shown to alleviate chronic-relapsing EAE in SJL/j mice (Soos et al., 1997). The effectiveness of IFN- $\tau$  in the treatment of active EAE and its ability to exert an effect when administered orally without the induction of neutralizing antibodies makes IFN- $\tau$  a more attractive therapeutic agent for the treatment of MS.

Since MS is thought to be initiated by a viral infection, the effectiveness of type I interferons may be related to their role in viral inhibition. In addition, the autoimmune aspects of MS may be down regulated through a number of different mechanisms since type I IFNs have been shown to inhibit DTH responses (also important in TVID and EAE), alter the homing and trapping of lymphocytes, enhance NK and T-cell activity and cytotoxicity, enhance Fc $\gamma$  receptors effects (Belardelli and Gresser, 1996), inhibit T-cell proliferation, and decrease the production of IFN- $\gamma$  (Noronha et al., 1993).

The administration of type I interferons, IFN- $\alpha/\beta$ , in SJL/J mice infected with the DA strain of Theiler's virus results in increased demyelination when give 4.5-months p.i for sixteen weeks (Njenga et al., 2000). IFN- $\alpha/\beta$  given short term results in the promotion of remyelination. The authors noted that the mice lost weight during weeks 6-7 of treatment, developed reduced DTH responses to TMEV and had decreased numbers of T-cells and B-cells infiltrating the CNS. The treated mice developed antibodies to IFN- $\alpha/\beta$  which did not appear to

affect the efficacy of the treatment. Furthermore, IFN- $\alpha/\beta$  treatment did not affect viral replication as measured by *in situ* hybridization quantification of RNA-positive cells. Therefore, the therapeutic effect was not mediated by the antiviral effects of IFN- $\alpha/\beta$ , but rather by the immunomodulatory functions.

The current study indicates that IFN- $\tau$ , also a type I interferon, is an effective therapeutic agent for the treatment of mice with the late stages of TVID, but administration during early disease progression can exacerbate clinical presentation. Mice that were given IFN- $\tau$  before viral infection were significantly worse than control mice, possibly as a result of the suppression of the Th1 cytokine response during initial infection (Borrow et al., 1993). There was only a slight significant difference noted between the 2-6 month p.i. treated mice and the infected controls at the end of treatment. It is possible continued exposure to IFN- $\tau$  may be of additional benefit to these mice, but additional experiments are required to address this issue.

The 4-6 month post-infection treated mice were the most affected by IFN- $\tau$ . They gained weight and improved clinically, similar to the mice that were CD4 $^{+}$  T-cell deficient late in disease progression (Nicholson et al., 1996). Mice were treated with IFN- $\tau$  at four months post infection in an attempt to mimic the situation in MS where the mean time for diagnosis is two years at which time lesions are well established.

When non-infected mice were dosed with IFN- $\tau$ , a marginally significant weight loss was detected three weeks after administration when compared to saline controls. This confirms that the statistically significant weight gain seen in the 4-6 month p.i. treated group was a real effect of treatment. It is interesting to note, however that IFN- $\tau$  may

have limitations in aiding in disease recovery and that the degree of clinical severity at the time of treatment may also be an important factor. One mouse that was clinically scored above 4.0 before treatment did not survive the length of the study. This implies that clinical presentation before treatment may be as important as timing of dosage.

### III. HISTOLOGICAL ANALYSIS

#### Introduction

##### *3.1 Multiple sclerosis*

The etiology of MS is unknown, but individual variation in lesions that develop, as well as multiple immunogenetic factors, have raised the possibility that MS may be the result of several different disease processes (Ebers et al., 1996; Haines, et al., 1996; Sawcer et al., 1996). In addition, MS lesions can differ considerably between patients depending on the disease form that is diagnosed. A recent report by Lucchinetti et al. (2000) suggests two different patterns of lesion development, one that is T-cell-mediated or T-cell plus antibody-mediated autoimmune encephalomyelitis and the other involving primary oligodendrocyte damage as the result of a viral or bacterial infection. Of the 83 patients examined, all were found to have both types of MS lesions though multiple active lesions within the same patient were found to involve only one type. The presence of two types of different lesion patterns support a multifactorial etiology for MS.

Cytokine expression also plays a role in the development of demyelinating lesions in MS patients. In order for the MS lesions to occur, it is proposed that myelin self-reacting CD4<sup>+</sup> T helper 1 (Th1) cells that can be activated to release proinflammatory Th1 cytokines IL-2, IFN- $\gamma$  and TNF- $\beta$  (Bottomly, 1988), must travel from the circulatory system into the CNS (Martin and McFarland, 1995; Lucchinetti and Rodriguez, 1997). T-cells collected from MS patients during relapsing episodes are known to produce the Th1 cytokines: IFN- $\gamma$ , TNF- $\alpha$ , and TNF- $\beta$ , (Correale et al., 1995; Voskuhl et al., 1993; Olsson et al., 1990).

Conversely, the Th2 response involves the secretion of anti-inflammatory cytokines such as IL-4 and IL-10 that are prevalent in MS patients during remission phases (Correale et al., 1995). By the secretion of IFN- $\gamma$ , Th1 cells aid in the switch in immunoglobulin production from IgM to IgG2a as well as inhibit Th2 lymphocyte production. In comparison, Th2 cells facilitate the IgG1 switch to IgE and indirectly suppress Th1 lymphocytes by affecting antigen presenting cells via IL-4, IL-5, and IL-6 (Finkelman, et al., 1990; Mosmann and Coffman, 1989). The possibility that Th1 cytokines may increase the severity of MS lesions is further supported by observation that IFN- $\gamma$  administration to MS patients results in the worsening of symptoms (Panitch et al., 1987).

### *3.2 EAE and TMEV lesion comparison*

EAE mimics MS in that it is an autoimmune inflammatory disease of the CNS that is T cell-mediated (Zamvil and Steinman, 1990). The upregulation of IL-2, IFN- $\gamma$ , and TNF- $\beta$  (Van der Veen and Stohlman, 1993; Cua et al., 1995; Olsson, 1995) and the down regulation of TGF- $\beta$ , IL-10, and IL-4 (Okuda et al., 1995; Issazadeh et al., 1996; Diab et al., 1997) have been detected in the CNS of animals with EAE resulting in the conclusion that development of disease is the result of Th1 cell cytokine secretion and the balance between Th1/Th2 cell activation (Van der Veen and Stohlman, 1993; Cua et al., 1995; Olsson, 1995). Theiler's virus-induced demyelination (TVID) is also a T-cell dependent demyelination model. This is supported by the failure of adult thymectomized, irradiated, bone marrow-reconstituted susceptible SJL/J mice to develop clinical or microscopic evidence of TVID after i.c. infection with BeAn (Gerety et al., 1994).

The pathological lesions seen in chronic EAE in SJL/J mice are similar to that reported in SJL/J mice infected with BeAn after twelve-weeks post-infection with BeAn. Inflammatory demyelinating lesions are seen in the anterior and lateral funiculi of both EAE and TMEV mice. Inflammatory T-cells accumulate in the subarachnoid space and extend into the spinal cord by traveling through perivascular spaces. Axonal destruction also occurs and is extensive. Meningeal inflammation is prevalent and large amounts of myelin debris can be found in the macrophages of both disease models.

In contrast, SJL/J mice with EAE develop more of a reactive gliosis than mice with TMEV, even though macrophage infiltrates and demyelination are present. The lesion presentation in EAE mirrors TMEV in that the anterior funiculi, lateral funiculi, perivascular spaces, and meninges are the greatest affected. In chronic TMEV infections, new lesions continue to appear throughout disease whereas in chronic relapsing EAE there are times where demyelination is decreased (Dal Canto et al., 1995).

IFN- $\tau$  has proven to be an effective treatment in EAE by preventing acute induction and superantigen reactivation of EAE via suppressor cells (Soos et al., 1995; Majtaba et al., 1997). The current hypothesis is that this protection occurs via Th2 cytokine activation as noted with increased IL-10 production (Soos et al., 1997), the inhibition of B-cell and T-cell responses in active and chronic EAE (Majtaba et al., 1998), and the lack of inflammatory lymphocytic lesions in the CNS (Soos et al., 1997) during IFN- $\tau$  treatment.

This study focuses on a histological examination of the spinal cords of TMEV-infected mice that were treated with IFN- $\tau$  at multiple time points and control animals that were injected with saline during the same treatment periods. Specifically, hematoxylin and eosin

staining, electron microscopy, and immunostaining for CNS myelin was used to analyze the degree of status spongiosus, demyelination, and inflammation within the spinal cord.

## **Materials and Methods**

### *3.3 Mice*

Three-week old female SJL/j mice (Harlan, Houston, TX) were obtained and infected when 4-5 weeks old.

### *3.4 Virus*

The BeAn 8386 strain of TMEV was a gift from Dr. Howard L. Lipton (Northwestern University, Evanston, IL). Virus was grown in BHK-21 cells, and the culture supernatant containing infectious virus was aliquoted and stored at -70°C before use. The viral titer was determined by plaque assay on BHK-21 cells (Rueckert & Pallansch, 1981).

### *3.5 Interferon-tau*

The IFN- $\tau$  was a gift from Dr. Fuller W. Bazer (Texas A&M Health Science Center, College Station, TX). IFN- $\tau$  was isolated as previously described (Ott et al., 1991), diluted in 20mM Tris buffer pH 7.5 with 150mM NaCl, aliquoted and stored at -70°C before use. Protein concentration was determined by the Lowry assay (Lowry et al., 1951).

### *3.6 Infection of mice*

Mice were anesthetized with Metofane™ (Schering-Plough Animal Health, Union, NJ) and injected intracranially (i.c.) into the right cerebral hemisphere with  $5 \times 10^4$  plaque forming units (PFU) of BeAn in a 20 uL volume.

### *3.7 IFN- $\tau$ treatment of mice prior to Theiler's virus infection up to the development of moderate demyelinating disease*

Ten mice were injected with  $10^5$  units of IFN- $\tau$  intraperitoneally daily from 0 to 3 days pre-infection and 10 mice were treated with the same concentration of IFN-tau –3 to 60 days post-infection. Ten infected control mice for each treatment received 100uL of 0.9% saline i.p. during the same intervals. All perfusions occurred at 6 months post-infection.

### *3.8 IFN- $\tau$ treatment of mice with moderate demyelinating disease*

Ten mice were injected with  $10^5$  units of IFN- $\tau$  i.p. daily from 2 months to 6 months post-infection. Ten infected control mice received 100uL of 0.9% saline i.p. at the same intervals. All perfusions occurred at 6 months post-infection.

### *3.9 IFN- $\tau$ treatment of mice with severe demyelinating disease*

Two experiments were performed to test the therapeutic potential of IFN- $\tau$  in mice suffering from severe demyelinating disease. In each experiment, 10 mice were injected with  $10^5$  units of IFN- $\tau$  (Soos et al., 1995) i.p. daily from 4 months to 6 months post-infection. Ten infected control mice received 100uL of 0.9% saline i.p. at the same intervals. All perfusions occurred at 6 months post-infection.

### *3.10 Methylprednisolone treatment of mice*

Ten mice were injected i.p. with pulse injections of 1mg methylprednisolone (40mg/kg) (Pharmacia & Upjohn, Kalamazoo, MI) every three days from 5 months to 6 months p.i. to inhibit inflammatory responses (Pavelko et al., 1998). Ten infected control mice received 100uL of 0.9% saline i.p. at the same intervals. All perfusions occurred at 6 months p.i.

### *3.11 IFN- $\tau$ treatment of non-infected control mice*

Ten mice were treated from 5 to 7 months of age daily with  $10^5$  units of interferon-tau by i.p. injection. Ten non-infected control mice were injected with 100uL of 0.9% saline i.p. at the same time. The mice were perfused at 7 months of age.

### *3.12 Preparation of tissue for microscopic examination*

Mice were anesthetized with Rompun (5mg/kg) (Bayer Corp., Shawnee Mission, Kansas) and Ketamine (100mg/kg) (Fort Dodge Animal Health, Fort Dodge, Iowa) and perfused via the left ventricle with 10% formalin. The fixed spinal columns containing the spinal cord were isolated and demineralized in 12.5% EDTA in NaOH, pH 7.0, for one week. A total of five to seven cross sections of column containing cord were then taken from representative levels (cervical, thoracic, and lumbar), embedded in paraffin, sectioned at 4 microns, and stained with hematoxylin and eosin (H+E) for microscopic examination. Two areas of liver from each animal treated with IFN- $\tau$  4-6 months p.i. were also prepared for examination.

### *3.13 Evaluation of microscopic lesions*

Histological examinations of the spinal cords and livers were made without prior knowledge of experimental protocol or disease classification by two investigators independently. The liver sections were examined for the presence of lesions. The spinal cord sections scoring was determined according to the degree of demyelination, inflammation, and status spongiosus in the meninges, white matter (ventral funiculi, lateral funiculi, dorsal funiculi), and gray matter: 0 – negative, no lesion; 0.5 – very mild – marginally identifiable lesion (0-5% area affected); 1 – mild – definitive lesion, focal and limited in scope (5-25% area affected); 2 – moderate – definitive lesion, multifocal and moderately extensive in scope (25-50% affected); 3- prominent – definitive lesion, multifocal and prominently extensive in scope (50-75%

affected); 4 – very prominent – definitive lesion, multifocal and very prominently extensive in scope (100% affected). Every slide was given an overall score for each area and region of the spinal cord. The pooled control and treated group scores as well as the mean scores were determined. The liver sections were examined and scored plus or minus for the presence or absence of lesions.

### *3.14 Electron microscopy*

For electron microscopy analysis, mice were anesthetized with Rompun (5mg/kg) (Bayer Corp., Shawnee Mission, Kansas) and Ketamine (100mg/kg) (Fort Dodge Animal Health, Fort Dodge, Iowa) and perfused via the left ventricle with 4% paraformaldehyde/gluteraldehyde. Sodium cacodylate-trihydrate 0.2M (EM Sciences, Ft. Washington, PA) was used as a buffer after paraformaldehyde/gluteraldehyde fixation. Spinal cord sections were embedded in Epon/Araldite, sectioned at 80nm and placed on copper grids. Sections were stained with uranyl acetate and lead citrate for 12 minutes each. Sections were then viewed and photographs made using a Zeiss 10C electron microscope.

### *3.15 Preparation of tissue for immunostaining*

Mice were anesthetized with Rompun (5mg/kg) (Bayer Corp., Shawnee Mission, Kansas) and Ketamine (100mg/kg) (Fort Dodge Animal Health, Fort Dodge, Iowa) and perfused via the left ventricle with 10% formalin. The fixed spinal columns containing the spinal cord were isolated and demineralized in a 1:1 solution, 50% formic acid: 20% sodium citrate, for 5 hours. The samples were then rinsed with tap water for 12 hours. A total of five to seven cross sections of column containing cord were

then taken from representative levels (cervical, thoracic, and lumbar), embedded in paraffin, and sectioned at 4 microns.

### *3.16 Immunostaining for myelin oligodendrocyte glycoprotein*

Formalin fixed spinal cord sections were mounted on poly-L-lysine coated slides. Sections were deparaffinized through xylene and graded alcohols. The slides were quenched in methanol and 0.3% hydrogen peroxide for 30 min. Antigen retrieval was performed in 10mM sodium citrate pH 6.0 in a 80°C water bath for 30min. The sections were brought to room temperature and washed with double distilled H<sub>2</sub>O (ddH<sub>2</sub>O) and PBS. Non-specific binding was blocked using 10% normal rabbit serum (Sigma, St. Louis, MO) and the slides were then incubated for 12-14 hours at 4°C coated with myelin/oligodendrocyte Ab-1 IgM (Clone CE1) (NeoMarkers, Inc., Fremont, CA) as the primary antibody. For controls, mouse IgM (Sigma, St. Louis, MO), and PBS/2% BSA were used.

The slides were washed with PBS and PBS/2% BSA/1% triton to cut down on background and then the secondary antibody, rabbit anti-mouse horseradish peroxidase conjugated IgG (Sigma, St. Louis, MO) diluted in 5% normal rabbit serum was left to incubate for 1 hour at room temperature. After washing with PBS and Tris-HCl 0.05M pH 6.8, One 5g 3,3'Diaminobenzidine tetrahydrochloride (DAB) tablet, (ICN, Aurora, OH) diluted in 3% hydrogen peroxide and Tris-HCl 0.05M pH 6.8 was added for signal detection. The samples were then washed with ddH<sub>2</sub>O and counter stained with Mayer's hematoxylin solution (Sigma, St. Louis, MO) for microscopic examination. See appendix for complete protocol.

### *3.17 Evaluation of immunostained slides*

Immunostained slides of the spinal cord tissue of the following treatment groups were rated: experimental mice treated with IFN- $\tau$  4-6 months post-infection and two control groups consisting of BeAn infected mice injected with saline and aged matched healthy mice. Sixteen to twenty slides were prepared and stained per animal in 4 micron sections with 20 microns between each slide cut. Scoring was determined according to the degree of demyelination detected via immunostaining for MOG, in the meninges, white matter (ventral funiculi, lateral funiculi, dorsal funiculi), and gray matter: 0 – negative, no lesion; 0.5 – very mild – marginally identifiable lesion (0-5% area affected); 1 – mild – definitive lesion, focal and limited in scope (5-25% area affected); 2 – moderate – definitive lesion, multifocal and moderately extensive in scope (25-50% affected); 3- prominent – definitive lesion, multifocal and prominently extensive in scope (50-75% affected); 4 – very prominent – definitive lesion, multifocal and very prominently extensive in scope (100% affected). Every slide was given an overall score for each region of the spinal cord. The pooled control and treated group scores as well as the mean scores were determined.

### *3.18 Statistical analysis*

Standard deviations as calculated via ANCOVA from the mean and standard error were used to calculate error bars and determine statistical significance in all the histological analyses.

## Results

### *3.19 Correlation between histology and clinical score rating*

Mean histological and clinical scores for mice from all treatment groups ( $n=120$  mice) were plotted and the  $R^2$  value was determined using Microsoft Excel. A  $R^2$  value of 0.9039 established the connection between clinical scores and histological lesion presentation (figure 3.1). This validates the subjective clinical scoring system.

### *3.20 Evaluation of microscopic lesions in H+E stained slides*

The overall affect of interferon-tau treatment at 4-6 months p.i. was evaluated by rating lesion presentation throughout cervical, thoracic, and lumbar regions of the spinal cords of treated and non-treated infected mice. The location of the lesions was determined and classified as either meningeal, gray matter, or white matter to include the dorsal, ventral, and lateral funiculi. Using histologic score values, figure 3.2 depicts that slight inflammation and status spongiosus that was observed in the gray matter of the treated mice and not in the infected controls,  $p<0.05$ . As seen in figure 3.3, meningeal inflammation decreased in interferon-tau treated mice when compared to infected controls,  $p<0.05$ . Demyelination and inflammation was significantly decreased in the dorsal funiculi of interferon-tau treated mice,  $p<0.05$  (figure 3.4). Similar affects were also seen in the ventral funiculi accompanied with a decrease in status spongiosus,  $p<0.05$  (figure 3.5). No significant differences were seen with interferon-tau treatment in the lateral funiculi,  $p>0.01$  (figure 3.6). A decrease in inflammation and demyelination was observed throughout the cervical, thoracic, and

lumbar regions of the spinal cords of the 4-6 month treated mice, p<0.05 (figures 3.7 and 3.8).

Figures 3.9 and 3.10 display the amount of extensive demyelination and status spongiosus observed in mice treated from 3 days pre-infection to 60 days post-infection with interferon-tau. Status spongiosus and inflammation in the meninges and white matter are evident in the mice treated from 2-6 months with interferon-tau (figures 3.11 and 3.12).

Figures 3.13-3.17 are from mice treated from 4-6 months with interferon-tau. Some inflammation and demyelination are present, though lesion presentation is minimal when compared to virus-infected controls (figures 3.20 and 3.21) where perivascular cuffing is seen in addition to meningeal inflammation, status spongiosus and demyelination in the white matter. Mice treated with methylprednisolone, a known anti-inflammatory, 5-6 months post-infection had a decrease in inflammation though status spongiosus and demyelination are still present (figures 3.18 and 3.19). Non-infected, non-treated controls are shown in figures 3.22 and 3.23. No liver lesions were detected.




Figure 3.1: Correlation graph of histological v. clinical scores.  
Correlation graph between the mean histological rating of H+E stained spinal cord slides per animal and clinical scores of animals infected with BeAn and treated with IFN- $\tau$  or saline.




Figure 3.2: Histology rating of gray matter lesions. Mean histological scores of H+E stained spinal cord sections illustrating gray matter lesions of mice infected with BeAn and treated with IFN- $\tau$  4-6 months p.i. or saline virus-infected controls.




Figure 3.3: Histology rating of meningeal inflammation. Mean histological scores of H+E stained spinal cord sections illustrating meningeal lesions of mice infected with BeAn and treated with IFN- $\tau$  4-6 months p.i. or saline virus-infected controls.




Figure 3.4: Histology rating of dorsal funiculi lesions. Mean histological scores of H+E stained spinal cord sections illustrating dorsal funiculi lesions of mice infected with BeAn and treated with IFN- $\tau$  4-6 months p.i. or saline virus-infected controls.




Figure 3.5: Histology rating of ventral funiculi lesions. Mean histological scores of H+E stained spinal cord sections illustrating ventral funiculi lesions of mice infected with BeAn and treated with IFN- $\tau$  4-6 months p.i. or saline virus-infected controls.




Figure 3.6: Histology rating of lateral funiculi lesions. Mean histological scores of H+E stained spinal cord sections illustrating lateral funiculi lesions of mice infected with BeAn and treated with IFN- $\tau$  4-6 months p.i. or saline virus-infected controls.




Figure 3.7: H+E inflammation scores through the cervical, thoracic, and lumbar regions of the spinal cord. Mean histological rating of inflammation in spinal cord sections of mice treated with IFN- $\tau$  4-6 months p.i. or saline virus-infected controls. Fifty tissue sections were rated per treatment group per level of the spinal cord.




Figure 3.8: Demyelination through the cervical, thoracic, and lumbar regions of the spinal cord. Mean histological rating of demyelination in spinal cord sections of mice treated with IFN- $\tau$  4-6 months p.i. or virus-infected saline controls. Slides stained for CNS myelin were used and 50 tissue sections were rated per treatment group per level of the spinal cord.




Figure 3.9: H+E stained slide of a mouse pretreated from 3 days pre-infection to 60 days post-infection with interferon-tau. 40X magnification. Note status spongiosus and demyelination present in the ventral and lateral funiculi as well as inflammation in the meninges.




Figure 3.10: H+E stained slide of a mouse pretreated from 3 days pre-infection to 60 days post-infection with interferon-tau. 240X magnification. Note status spongiosus and demyelination present in the ventral and lateral funiculi as well as inflammation in the meninges.




Figure 3.11: H+E stained slide of a mouse treated from 2 to 6 months post-infection with interferon-tau. 40X magnification. Note status spongiosus and demyelination present in the ventral and lateral funiculi as well as inflammation in the meninges.




Figure 3.12: H+E stained slide of a mouse treated from 2 to 6 months post-infection with interferon-tau. 240X magnification. Note status spongiosus and demyelination present in the ventral and lateral funiculi as well as inflammation in the meninges.



Figure 3.13: H+E stained slide of a mouse treated from 4 to 6 months post-infection with interferon-tau. 40X magnification. Note lack of status spongiosus and demyelination present in the ventral and lateral funiculi as well as no inflammation in the meninges.




Figure 3.14: H+E stained slide of a mouse treated with interferon-tau from 4 to 6 months post-infection. 240X magnification. Note lack of status spongiosus and demyelination present in the ventral funiculi as well as no inflammation in the meninges.




Figure 3.15: H+E stained slide of the mouse with the worst clinical score treated from 4 to 6 months post-infection with interferon-tau. 40X magnification. Note slight status spongiosus and demyelination present in the ventral and lateral funiculi as well as inflammation in the meninges.




Figure 3.16: H+E stained slide of the mouse with the worst clinical score treated from 4 to 6 months post-infection with interferon-tau. 200X magnification. Note slight status spongiosus and demyelination present in the ventral funiculi as well as inflammation in the meninges.




Figure 3.17: H+E stained slide of the mouse with the worst clinical score treated from 4 to 6 months post-infection with interferon-tau. 240X magnification. Note slight status spongiosus and demyelination present in the ventral funiculi as well as inflammation in the meninges.




Figure 3.18: H+E stained slide of a mouse treated with methylprednisolone from 5 to 6 months post-infection. 40X magnification. Note extensive status spongiosus and demyelination present in the ventral and lateral funiculi as well as inflammation in the white matter and meninges.




Figure 3.19: H+E stained slide of a mouse treated with methylprednisolone from 5 to 6 months post-infection. 240X magnification. Note extensive status spongiosus and demyelination present in the ventral funiculi as well as inflammation in the white matter and meninges.




Figure 3.20: H+E stained slide of a mouse infected with virus and given saline ip from 4-6 months post-infection. 40X magnification. Note status spongiosus and demyelination present in the ventral and lateral funiculi as well as inflammation in the meninges and perivascular cuffing.




Figure 3.21: H+E stained slide of a mouse infected with virus and given saline ip from 4-6 months post-infection. 240X magnification. Note status spongiosus and demyelination present in the lateral funiculus as well as inflammation in the meninges and perivascular cuffing.




Figure 3.22: H+E stained slide of a non-infected mouse. 40X magnification. Note uninterrupted staining through out the section.




Figure 3.23: H+E stained slide of a non-infected mouse. 100X magnification. Note uninterrupted staining through out the section.

### *3.21 Evaluation of immunostained slides*

Infected mice with or without interferon-tau treatment from 4-6 months post-infection and non-infected, control mice were sacrificed. The spinal cords were sectioned as mentioned previously. All three groups had paraffin embedded spinal cord sections immunostained for CNS myelin throughout the cords. Lumbar sections are shown in the following figures. Figures 3.24 and 3.25 show the myelin-specific staining of a mouse treated from 4-6 months p.i. with interferon-tau. Figures 3.26 and 3.27 are the H+E stained serial sections of the same mouse. Notice the uniformity of both staining procedures throughout the sections. Figure 3.28 is the immunostaining of a spinal cord section from the mouse with the most severe clinical score from the 4-6 month interferon-tau treated group. In this section, the majority of the white matter retains myelin stain. An H+E stained section from the same mouse follows in figure 3.29. An immunostained section from a non-infected control mouse follows in figure 3.30. Notice the marked reduction in myelin staining in figure 3.31 taken from a viral infected mouse that was not treated with interferon-tau. The non-specific staining of the meninges in figure 3.31 is interrupted as insignificant. The H+E section of the same non-treated, virus-infected mouse also displays extensive demyelination (figure 3.32).



Figure 3.24: Immunostaining for CNS myelin of an infected mouse treated with interferon-tau from 4-6 months post-infection. Magnification 40X. Notice the darker staining of the white matter.




Figure 3.25: Immunostaining for CNS myelin of an infected mouse treated with interferon-tau from 4-6 months post-infection.

Magnification 240X. Notice the darker staining of the myelin in the white matter.



Figure 3.26: H+E staining of a serial section of an infected mouse treated with interferon-tau from 4-6 months post-infection. Magnification 40X. Notice the lighter staining of the white matter where the myelin is located.



Figure 3.27: H+E staining of a serial section of an infected mouse treated with interferon-tau from 4-6 months post-infection. Magnification 240X. Notice the lighter staining of the white matter where the myelin is located.




Figure 3.28: Immunostaining for CNS myelin of an infected mouse with the worst clinical score treated with interferon-tau from 4-6 months post-infection. Magnification 40X. Notice the darker staining of the white matter.



Figure 3.29: H+E staining of a serial section of an infected mouse with the worst clinical score treated with interferon-tau from 4 to 6 months post-infection. Magnification 40X. Notice the lighter staining of the white matter.



Figure 3.30: Immunostaining for CNS myelin of a non-infected mouse. Magnification 40X. Notice the darker staining of the white matter.




Figure 3.31: Immunostaining for CNS myelin of an infected mouse treated with saline from 4-6 months post-infection. Magnification 40X. Notice the lack of darker staining of the white matter.




Figure 3.32: H+E staining of a serial section of an infected mouse treated with saline from 4-6 months post-infection. Magnification 40X. Notice the lack of darker staining of the white matter.

### 3.22 Electron microscopy

Mice infected for 6 months were sacrificed and their spinal cords were prepared for evaluation via electron microscopy as previously described in order to characterize demyelinating, inflammatory, and status spongiosus lesions in TMEV. Evidence of beginning demyelination is illustrated in figure 3.33 where the lamellae of the myelin sheath can be seen separating around an axon in the lower right quadrant. In figure 3.34, there is marked disorganization of an axon in the spinal cord of a mouse that has been infected with TMEV. There is also splitting of the myelin sheath that could possibly be eliminated as artifact. Status spongiosis and demyelination is shown in figure 3.35 where there are large spaces seen between myelinated axons. Lastly, figure 3.36 illustrates the accumulation of lymphocytes in the meninges of a TMEV infected mouse at 6 months post-infection.

## Discussion

The post-mortum histological analysis of lesions in the central nervous system of 83 patients with MS has led to the suggestion that two different patterns of lesion development exist (Lucchinetti et al., 2000). The two patterns consist of T-cell-mediated or T-cell plus antibody-mediated autoimmune encephalomyelitis or primary oligodendrocyte damage caused by a viral or bacterial infection either of which results in demyelination (Lucchinetti et al., 2000). To further support the theory that T-cell-mediated and T-cell plus antibody-mediated autoimmune encephalomyelitis as a cause for lesion development, it has been reported that MS patients have T-cells in the CNS that produce the Th1 proinflammatory cytokines during relapsing episodes (Correale et al.,

1995; Voskuhl et al., 1993; Olsson et al., 1990) and anti-inflammatory Th2 cytokines during remission phases (Correale et al., 1995).

EAE and Theiler's viral infection, two animal models for multiple sclerosis, have similar pathologies (Dal Canto et al., 1995). Knowing that IFN- $\tau$  has proven to be an effective treatment in EAE by preventing acute induction and superantigen reactivation of EAE via suppressor cells (Soos et al., 1995; Majtaba et al., 1997), it was of interest to investigate the effect of IFN- $\tau$  on lesion development in the CNS.

It is interesting to note that the data generated during the present study supports the findings of interferon-tau treatment of EAE mice. As expected, a decrease in inflammation, status spongiosus, and demyelination was observed in the H+E and immunostained slides of the spinal cords of SJL/J mice when interferon-tau was administered from 4-6 months post-infection which is during the chronic phase of the TMEV infection. The remyelination seen in the MOG slides has also been seen in EAE where inflammation appears to enhance migration of oligodendrocytes though remyelinated myelin never regains its normal thickness after a demyelinating lesion (Ludwin, 1997; Tourbah et al., 1997). The decrease in lesion presentation was attributed to the down regulation of proinflammatory Th1 cytokines via interferon-tau administration in EAE. The current hypothesis is that IFN- $\tau$  protection in EAE occurs via Th2 cytokine activation as noted with increased IL-10 production (Soos et al., 1997), the inhibition of B-cell and T-cell responses in active and chronic EAE (Majtaba et al., 1998), and the lack of inflammatory lymphocytic lesions in the CNS (Soos et al., 1997) during IFN- $\tau$  treatment.




Figure 3.33: EM of demyelination in the ventral funiculi. Magnification 28,000X. Electron microscopy picture of a TMEV demyelinating lesion from the ventral funiculi of a mouse spinal cord 6 months post-infection. Note the separation of the lamellae of the myelin sheath surrounding the axon in the lower right quadrant and the increased interstitial space conducive of status spongiosus in the upper right quadrant of the photograph. A = axon, MS = myelin sheath




Figure 3.34: EM of demyelination in the ventral funiculi. Magnification 40,000X. Electron microscopy picture of a TMEV demyelinating lesion from the ventral funiculus of a mouse spinal cord 6 months post-infection. Note the myelin unwrapping around the axon and the organelle damage in the neuron cell body. A = axon, M = myelin




Figure 3.35: EM of demyelination and status spongiosus in the ventral funiculi. Magnification 28,000X. Electron microscopy picture of a TMEV demyelinating lesion illustrating status spongiosus in the ventral funiculus of a mouse spinal cord 6 months post-infection. The splitting of the myelin sheath around the central axon is suggestive of early demyelination, but could not be totally eliminated as being the result of artifact. SS = status spongiosus



Figure 3.36: EM of meningeal inflammation. Magnification 28,000X. Electron microscopy picture of a Theiler's virus inflammatory lesion from the meninges of a mouse spinal cord 6 months post-infection. Note the lymphocytes present in the left half of the picture.

Interferon-tau treatment was not beneficial in TMEV when administered before viral infection, as seen in the H+E staining of the spinal cords of mice pretreated with interferon-tau before viral infection. Th1 proinflammatory cytokines including interferon-gamma are needed for the immune system to mount an anti-viral response and decrease viral titers (Rodriguez et al., 1995). It follows then that the administration of an immunomodulator like interferon-tau that is able to decrease Th1 cytokine production would result in an increase in lesion presentation due to viral infection when given before the virus.

The stage of disease progression during which interferon-tau treatment occurs is very important to the effectiveness of treatment as seen with the 2-6 month treatment group where no significant difference was observed between treated and infected controls. It is believed this is due to the change of cytokine expression during different stages in TMEV. Like MS, there appears to be a difference in cytokine expression during the chronic demyelinating phase of TMEV and the initial anti-viral phase of TMEV. It is important that interferon-tau is given during the chronic demyelinating phase to suppress the production of autoimmune damage to the CNS by Th1 cytokine expression for the most significant improvement to occur. It is possible that tolerance to interferon-tau may develop if administration continued past 2 months even during the chronic phase of TMEV. Further investigation into the effectiveness of long-term treatment is necessary.

Another interesting factor should be discussed concerning the immunostained slides of the 4-6 month IFN- $\tau$  treated mice. MOG staining was present in the gray matter of IFN- $\tau$  4-6 month infected treated and non-treated, infected mice that was not present in the

healthy controls. Two main possibilities have been proposed to explain this phenomenon; 1) the MOG antibody used is staining pieces of myelin that have been processed by antigen presenting cells and is now being expressed on the outside of those cells in the gray matter or 2) administering Theiler's virus before the CNS was fully myelinated, interrupted normal migration of oligodendrocytes to the white matter of the spinal cord and the satellite cells were stained. Double staining with MHC antibodies is planned for the future to answer some of these questions.

It has previously been reported that IFN- $\tau$  is able to induce hepatocyte apoptosis in sheep when  $5.2 \times 10^6$  antiviral doses are administered subcutaneously twice per day. The livers of these sheep were examined after 1-3 days of IFN- $\tau$  treatment (Kim et al., 2000). No lesions were detected via light microscopy and H+E staining in the livers of the mice in this study that were treated from 4-6 months post-infection with IFN- $\tau$ . This indicates that IFN- $\tau$  is not hepatotoxic at  $10^5$  antiviral units in the TMEV animal model of MS when given i.p. once daily.

## IV. IMMUNOLOGICAL ANALYSIS

### Introduction

#### 4.1 Theiler's virus and EAE

Theiler's murine encephalomyelitis virus (TMEV) and experimental allergic encephalomyelitis (EAE) are two murine models that are used to investigate multiple sclerosis in the laboratory setting. TMEV is primarily a model for the viral etiology of MS, whereas EAE focuses on the autoimmune component.

TMEV is a picornavirus that was first characterized as a murine model for MS in 1975 when it was discovered that TMEV infection causes an inflammatory demyelinating disease (Lipton, 1975). TMEV strains have been divided into two subgroups composed of the neurovirulent GDVII and FA substrains and the less virulent TO substrains. The TO substrains include BeAn 8386, DA, WW, TO<sub>4</sub> and Yale (Lipton, 1980). Intracranial (i.c.) infection of susceptible mice with neurovirulent GDVII results in acute fatal encephalitis during the first week of infection. Alternatively, permissive hosts infected intracranially with one of the TO substrains of TMEV develop a flaccid paralysis by 2 weeks post-infection (p.i.) by which time viral antigens and genomic RNA are located in the neurons of the gray matter. The chronic persistence of TMEV in the white matter of the spinal cord begins one month p.i. and continues throughout the duration of the animal's life (Yamada et al., 1991).

EAE is induced by the injection of myelin basic protein (Meyer et al., 1996) or proteolipid protein plus adjuvant into laboratory animals including mice (Ke and Kapp, 1996). EAE can also develop through

adoptive transfer of autoreactive T-cells to naïve mice which establishes it as an autoimmune model for MS (McCarron and McFarlin, 1988; Satoh et al., 1988; Kuchroo et al., 1992).

EAE mimics MS in that it is an autoimmune inflammatory disease of the CNS that is T-cell-mediated (Zamvil and Steinman, 1990). The upregulation of IL-2, IFN- $\gamma$ , and TNF- $\beta$  (Van der Veen and Stohlman, 1993; Cua et al., 1995; Olsson, 1995) and the down regulation of TGF- $\beta$ , IL-10, and IL-4 (Okuda et al., 1995; Issazadeh et al., 1996; Diab et al., 1997) have been detected in the CNS of animals with EAE resulting in the conclusion that development of disease is the result of Th1 cell cytokine secretion and the balance between Th1/Th2 cell activation (Van der Veen and Stohlman, 1993; Cua et al., 1995; Olsson, 1995).

#### *4.2 DTH and Theiler's virus*

Type IV delayed-type hypersensitivity is a form of cell-mediated immunity that occurs 24-48 hours after challenge with an antigen previously encountered by the host. This is a T-cell mediated response resulting in the infiltration of macrophages and inflammation. In the case of a Theiler's virus infection, the major protein of concern when the focus is autoimmunity is host myelin basic protein. Myelin that was prepared from the brains of adult SJL mice initiates a DTH reaction within 24 hours when injected into the ears of SJL mice chronically infected with TMEV strain BeAn. The intensity of the DTH reaction is assessed via ear thickness where PBS injections into the opposite ears of the same mice are used as controls (Borrow et al., 1998). Viral epitope spreading also results in a DTH reaction in the Theiler's model as TMEV induces new T-cell responses during the course of infection (Miller et al., 1997). Myelin oligodendrocyte glycoprotein (MOG) and myelin

proteolipid protein (PLP) are both suggested autoantigens in MS because they are able to initiate a DTH reaction in mice infected with TMEV (Slavin et al., 1998; Wang et al., 1999).

During the course of chronic TMEV infection, Th1 cells specific to TMEV are reported to be the direct cause of a delayed-type hypersensitivity reaction that occurs and contributes to bystander demyelination (Miller and Gerety, 1990). DTH responses may also be used to determine the immune response to TMEV using UV-irradiated whole virus particles (Pullen et al., 1994; Lipton et al., 1995; Drescher et al., 1998; Murray et al., 1998; Koh et al., 2000), active TMEV (Karpus et al., 1995; Inoue et al., 1996; Inoue et al., 1997; Inoue et al., 1998; Inoue et al., 1999), or specific viral peptides (Miller et al., 1995; Burt et al., 1999; Pavelko et al., 2000). In all of these experiments, the DTH response was used as an assessment of the efficiency of the immune system to recognize virus after either an immunomodulating treatment or a genetic mutation that affects MHC presentation. Therefore, it is widely accepted that DTH responses to myelin, MOG, PLP, and TMEV are involved in the pathogenesis of Theiler's virus-induced demyelinating disease.

#### *4.3 Cytokine expression in the CNS during chronic EAE or TMEV*

It is important to characterize the expression of Th1 and Th2 cytokines in the CNS during EAE or TMEV infection since it is believed the change in cytokine expression is partially responsible for the induction of demyelination seen in both animal models. During the exacerbation phase of EAE in SJL/J mice, 14 days post-inoculation, Th1 cytokines IL-2 and IFN- $\gamma$  are up-regulated in the brain, spinal cord, and cerebral spinal fluid (Renno et al., 1994). In contrast, Th2 cytokines are induced during remissions.

The cytokine data concerning chronic TMEV infection is controversial. Using the DA strain of TMEV, at 40 days p.i. in SJL/J mice, Sato et al. using RNA protection assays found that the Th1 cytokines IL-1 and IL-2 were not detectable in the spinal cord whereas Th2 cytokines, IL-10, and Th1 cytokines TNF- $\alpha$ , IL-12, and IFN- $\gamma$  were elevated when compared to controls. In the brains of the same animals, IL-10, IL-12, TNF- $\alpha$ , IL-1, IL-2, IL-6, and IFN- $\gamma$  were not detected at 40 days p.i. but, IL-4 production was high in the brain (Sato et al., 1997). It has also been reported that IFN- $\gamma$ , IL-1, IL-2, IL-6, IL-12, TNF- $\alpha$ , TGF- $\beta$ 1, IL-4, IL-5 and IL-10 cytokine RNA was detected at levels above controls at 60 days p.i. in SJL/J mice also infected with DA with real-time PCR analysis (Chang et al., 2000). Since there appears to be inconsistencies between 40 and 60 days p.i. with the same TMEV strain, it would be interesting to see if there was a difference in cytokine expression in the CNS of mice infected with the BeAn as compared to the DA strain of TMEV.

#### *4.4 Interferon-tau*

IFN- $\tau$  has been characterized as one of the pregnancy recognition signals that is secreted by sheep trophoblasts between days 9 and 24 of pregnancy (Godkin et al., 1984). It functions as an anti-luteolytic agent by decreasing the endometrial gene expression of oxytocin receptors (Vallet and Lemming, 1991; Spencer et al., 1996). IFN- $\tau$  also acts in an anti-inflammatory capacity *in vivo* by inhibiting Th1 lymphocyte proliferation (Newton et al., 1989, Niwano et al., 1989; Skopets et al., 1992; Assal-Meliani et al., 1993), promoting the production of placental Th2 cytokines IL-4 and IL-10 (Chaouat et al., 1995), and activating NK

cells in utero (Tuo et al., 1993). IFN- $\tau$  has 70% homology with IFN- $\alpha$  (Stewart et al., 1989), and is therefore classified as a type I interferon with anti-viral activity comparable or superior to IFN- $\alpha$  in the treatment of ovine lentivirus *in vivo* and *in vitro* (Juste et al., 2000), human papilloma virus *in vitro* (Johnson et al., 1999), and HIV *in vitro* (Dereuddre-Bosquet et al., 1996).

IFN- $\tau$  has proven to be an effective treatment in EAE by preventing acute induction and superantigen reactivation of EAE via suppressor cells (Soos et al., 1995; Majtaba et al., 1997). The current hypothesis is that this protection occurs via Th2 cytokine activation as noted with increased IL-10 production (Soos et al., 1997), the inhibition of B-cell and T-cell responses in active and chronic EAE (Majtaba et al., 1998), and the lack of inflammatory lymphocytic lesions in the CNS (Soos et al., 1997) during IFN- $\tau$  treatment.

Antibodies to IFN- $\tau$  were detected in SJL/J mice with EAE following i.p. treatment with IFN- $\tau$ . However, these antibodies are non-neutralizing (Soos et al., 1997) and therefore do not interfere with the specific activity of IFN- $\tau$ . Oral administration of IFN- $\tau$  under the same conditions does not lead to the production of anti-IFN- $\tau$  antibodies that are detectable via ELISA using serum from terminal cardiac bleeds (Soos et al., 1997).

As mentioned previously, administration of IFN- $\tau$  is able to increase the production of IL-10 in the serum of SJL/J mice that have EAE. The induction of IL-10 was noted in both oral and i.p. administration if treatment continued for more than 20 days (Soos et al., 1997). IL-10 is also increased in SJL/J mice with chronic EAE during oral IFN- $\alpha/\beta$  therapy when given over a seven week period (Brod et al., 1994).

#### *4.5 Corticosterone and MS treatment*

Corticosterone and cortisol are glucocorticoids that are secreted by the adrenal cortex. Both hormones are products of cholesterol catabolism and they differ by one hydroxyl group. Healthy humans normally produce a 1:5 ratio of corticosterone to cortisol whereas mice only produce corticosterone.

Multiple sclerosis patients are known to have an exaggerated cortisol release when relapsing-remitting MS progresses into secondary progressive MS. This is attributed to proinflammatory cytokines impairing normal glucocorticoid function and the increase in neuronal damage (Bergh et al., 1999). This theory is supported by the fact that neuroendocrine over-activation is seen in MS patients with acute CNS inflammation (Fassbender et al., 1998)

Glucocorticoid therapy can be beneficial in MS treatment, but effectiveness is dependent on the stage of disease progression. Treatment of MS patients with low-dose corticosteroids, 10-20 mg prednisolone daily, had no significant effect on MS progression with chronic progressive or relapsing MS (Tourtellotte and Haerer, 1965; Millar et al., 1967). In contrast, rapid clinical improvement is seen in MS patients in acute relapse who have been treated intravenously with methylprednisolone ranging from 250 mg daily to 20 mg/kg daily for 2-7 days (Dowling et al., 1980; Buckley et al., 1982; Abbruzzese et al., 1983; Goas et al., 1983; Newman et al., 1983; Barnes et al., 1985; Durelli et al., 1986; Milligan et al., 1987; Thompson et al., 1989).

The clinical benefits seen in patients with glucocorticoid therapy is attributed to the corticosterone immunosuppressive effects that are dosage dependent. Supraphysiological corticosteroid dosage can inhibit antibody-dependent cellular cytotoxicity (Nair and Schwartz, 1984),

neutrophil complement and IgG receptor binding (Forslid and Hed, 1982), antigen presentation by monocytes (Dumble et al., 1981; Hirschberg et al., 1982; Rhodes et al., 1986), 1984), astrocyte binding to measles-infected cells (Maki et al., 1980), monocyte cellular differentiation (Rinehart et al., 1982) and leukocyte production of IL-2 and IFN- $\gamma$  (Cesario et al., 1986; Arya et al.).

IFN- $\tau$  may mediate its therapeutic effects in the TVID model by up regulating IL-10 production which would, in turn, decrease damaging DTH responses. IFN- $\tau$  has been reported to increase corticosterone levels in sheep (Ott et al., 1997). High levels of corticosterone would result in immunosuppression which would be beneficial to TMEV-infected mice during the chronic demyelinating phase of the disease. Therefore, corticosterone levels were also measured during TVID.

RNA protection assays on spinal cord tissue, DTH reactions to myelin, serum IL-10 and corticosterone levels, and antibody production to IFN- $\tau$  were measured to determine if IFN- $\tau$  is able suppress the Th1 response to TMEV chronic infection in female SJL/J mice.

## **Materials and Methods**

### **4.6 Mice**

3-week-old female SJL/j mice (Harlan, Houston, TX) were obtained and infected when 4-5 weeks old.

### **4.7 Virus**

The BeAn 8386 strain of TMEV was a gift from Dr. Howard L. Lipton (Northwestern University, Evanston, IL). Virus was grown in BHK-21

cells, and the culture supernatant containing infectious virus was aliquoted and stored at -70°C before use. The viral titer was determined by plaque assay on BHK-21 cells (Rueckert and Pallansch, 1981).

#### *4.8 Interferon-tau*

The IFN- $\tau$  was a gift from Dr. Fuller W. Bazer (Texas A&M Health Science Center, College Station, TX). IFN- $\tau$  was isolated as previously described (Ott et al., 1991), diluted in 20mM Tris buffer pH 7.5 with 150mM NaCl, aliquoted and stored at -70°C before use. Protein concentration was determined by the Lowry assay (Lowry et al., 1951).

#### *4.9 Infection of mice and assessment of clinical signs of demyelination*

Mice were anesthetized with Metofane™ (Schering-Plough Animal Health, Union, NJ) and injected intracranially (i.c.) into the right cerebral hemisphere with  $5 \times 10^4$  plaque forming units (PFU) of BeAn in a 20 uL volume.

After infection (day 0) all animals were examined weekly for the development of clinical signs indicative of demyelinating disease (Borrow et al., 1998). Clinical signs were scored on a scale from 0 to 6, 0 indicating a healthy animal and 1-6 representing gradual increasing severity of signs as follows: 1, piloerection and/or hunched posture; 2, piloerection and hunched posture plus unsteady gait; 3, very unsteady gait, weak grasp response when placed on wire grid, and occasional slight limb monoparesis; 4, severe hind limb weakness, incontinence, and weight loss; 5, paraparesis of hind limbs, severe weight loss, incontinence, dropped head; 6, moribund/dead.

#### *4.10 IFN- $\tau$ treatment of mice prior to Theiler's virus infection up to the development of moderate demyelinating disease*

Ten mice were injected with  $10^5$  units of IFN- $\tau$  intraperitoneally (i.p.) daily from 0 to 3 days pre-infection and 10 mice were treated with the same concentration of IFN-tau -3 to 60 days post-infection. Ten virus infected control mice for each treatment received 100uL of 0.9% saline i.p. during the same intervals. All perfusions occurred at 6 months post-infection (p.i.).

#### *4.11 IFN- $\tau$ treatment of mice with moderate demyelinating disease*

Ten mice were injected with  $10^5$  units of IFN- $\tau$  i.p. daily from 2 months to 6 months post-infection. Ten virus infected control mice received 100uL of 0.9% saline i.p. at the same intervals. All perfusions occurred at 6 months post-infection.

#### *4.12 IFN- $\tau$ treatment of mice with severe demyelinating disease*

Two experiments were performed to test the therapeutic potential of IFN- $\tau$  in mice suffering from severe demyelinating disease. In each experiment, 10 mice were injected with  $10^5$  units of IFN- $\tau$  (Soos et al., 1995) i.p. daily from 4 months to 6 months post-infection. Ten virus infected control mice received 100uL of 0.9% saline i.p. at the same intervals. All perfusions occurred at 6 months post-infection.

#### *4.13 Methylprednisolone treatment of mice*

Ten mice were injected i.p. with pulse injections of 1mg methylprednisolone (40mg/kg) (Pharmacia & Upjohn, Kalamazoo, MI) every three days from 5 months to 6 months p.i. to inhibit inflammatory responses (Pavelko et al., 1998). Ten virus infected control mice received 100uL of 0.9% saline i.p. at the same intervals. All perfusions occurred at 6 months post-infection.

#### *4.14 IFN- $\tau$ treatment of non-infected control mice*

Ten mice were treated from 5 to 7 months of age daily with  $10^5$  units of interferon-tau by i.p. injection. Ten non-infected control mice were injected with 100uL of 0.9% saline i.p. at the same time. The mice were perfused at 7 months of age.

#### *4.15 White blood cell differential analysis of cardiac blood*

Prior to the actual perfusion, approximately 1 ml of whole blood was collected via cardiac puncture and placed into 1.5 ml centrifuge tubes. The chest cavity of each animal was coated with heparin prior to collection. White blood cell differential analysis was performed in duplicate using a Celldyn 3500 automated cell counter (Abbott Laboratories, Abbott Park, IL). Results were reported as number of cells per milliliter of whole blood.

#### 4.16 IFN- $\tau$ ELISA

Serum was collected via tail bleeding before and during IFN- $\tau$  treatment of all post-infection experimental groups. Serum samples were obtained from pretreated groups at 2 months post-infection. The serum was assayed for IFN- $\tau$  antibodies via ELISA as previously described (Johnson et al., 1998). Briefly, 96 well Immulon II flat bottom microtiter plates were treated with 0.2 ug/mL monoclonal antibody to IFN- $\tau$  (gift from Dr. Fuller Bazer, Department of Animal Science, Texas A&M University, College Station, TX) and incubated overnight at 4°C. After four washings with a 1:1 PBS-Tween 20 solution, the plates were washed with distilled water. 100uL of 1% BSA in carbonate coating buffer was added to each well and the plates were incubated as mentioned previously. The wash procedure was repeated. Duplicate serum samples as well as a positive control from a super-immunized mouse was added to the wells in systematic 1:20 dilutions. After a 40 minute incubation in 37°C with 4% CO<sub>2</sub>, plate washing occurred and 50 uL of 1:10,000 dilution of horseradish peroxidase-conjugated rabbit anti-Mouse IgG (H+L) (Sigma, St. Louis, MO) was added to each well. Washing was repeated after a 60 min. incubation at 37°C in 4% CO<sub>2</sub>. 50 uL ABTS in ABTS buffer (Boehringer Mannheim, Germany) was added for colormetric detection. The plates were read at 450nm after 50min incubation at room temperature (Emax precision microplate reader, Molecular Devices, CA).

#### **4.17 IL-10 ELISA**

Serum samples from IFN- $\tau$  treated and control mice were collected before and during IFN- $\tau$  treatment. The serum was analyzed via ELISA for IL-10 with the aid of a kit as per the manufacturer's instructions (R&D Systems Inc., Minneapolis, MN). All samples were analyzed in duplicate.

#### **4.18 Myelin-specific DTH testing**

DTH testing followed the procedure outlined in Borrow et al., 1998. Briefly, 10 chronically infected mice at 6 months pi were tested for DTH against myelin after eight weeks of IFN- $\tau$  treatment. Ten control infected mice at 6 months pi with saline treatment were also analyzed for DTH reactions by injecting the ears of the mice with myelin membrane and measuring the amount of ear thickness with calipers 24 and 48 hours after myelin injection. PBS was injected in the ears of the mice as a control.

#### **4.19 Radioimmunoassay for corticosterone**

Serum samples were analyzed in duplicate using ImmuChem™ Double Antibody Corticosterone RIA kit (ICN Biomedicals Inc., Costa Mesa, CA). Briefly, samples were diluted 1:200 in serial diluent and corticosterone-<sup>125</sup>I was added to all the samples and controls. Corticosterone antibody was added to samples and internal controls from the kit and incubated at room temperature for 2 hours. The precipitant solution was then added, the tubes were vortexed for one minute, and centrifuged at 1000

x g for 15 minutes. The supernatant was removed and all tubes were counted on a gamma counter for corticosterone-specific radioactivity.

#### *4.20 Preparation of tissue for RNase Protection Assay (RPA) analysis*

At six months p.i., mice were anesthetized with Rompun (5mg/kg) (Bayer Corp., Shawnee Mission, Kansas) and Ketamine (100mg/kg) (Fort Dodge Animal Health, Fort Dodge, Iowa). Terminal cardiac bleeds were performed and spinal cord and brain tissue was removed. All tissues were preserved in cryovials, placed in liquid nitrogen for 24 hours, and stored at -80°C until RNA extraction. Tissue was homogenized and RNA extracted using a TRIZOL reagent kit (Life Technologies Inc., Rockville, MD) as described by manufacturer (Gilman, 1993).

#### *4.21 RPA*

The RPA was performed to compare the chemokine and cytokine profiles in the spinal cords of mice treated 4-6 months p.i. with IFN- $\tau$  or saline that were infected with Theiler's virus. Total RNA was amplified from the samples using the Direct Protect TM Lysate Ribonuclease Protection Assay (RPA) (Ambion, Austin, TX) according to the manufacturer's instructions. RPA multiprobe kits were obtained from Pharmingen (San Diego, CA) and used according to the manufacturer's instructions. Radiolabelled anti-sense RNA transcripts for cytokines and chemokines were generated using RiboQuant probe sets for: **MCK-2b** (IL-12p35, IL-12p40, IL-10, IL-1a, IL-1b, IL-1Ra, IGIF, IL-6, IFN- $\gamma$ , MIF, L32, GAPDH)

Briefly, T7 polymerase synthesized transcripts were hybridized to 10mg of total RNA from brain and spinal cords for 16 hrs at 56°C. The non-hybridized RNA was then digested with RNase A/T1. Densitometric scanning (IS-1000 Digital Imaging System) was used to quantify transcript levels. After precipitation, RNA samples were analyzed by 5% denaturing urea polyacrylamide gel electrophoresis. The gels were exposed to a phosphorscreen. RNA loading estimations were conducted with phosphorimaging by comparison of intensity with RNA fragments from two housekeeping genes, L32 and GAPDH (Gilman, 1993).

#### *4.22 Statistical analysis*

A repeated measures analysis of covariance (ANCOVA) were performed on the DTH, IFN- $\tau$  ELISA, and IL-10 ELISA data. When appropriate, standard deviations were used to determine error bars and 95% confidence intervals.

## **Results**

#### *4.23 White blood cell differential analysis of cardiac blood*

IFN- $\beta$  treatment of MS patients has led to lymphopenia, neutropenia, and leukopenia (PRISMS study group, 1998) therefore circulating white blood cell counts were performed on the 4-6 month p.i. IFN- $\tau$  treated mice and their controls. No statistical difference of circulating white blood cell counts was found using ANCOVA analysis between BeAn infected mice treated with interferon-tau 4 to 6 months post-infection,

infected mice treated with saline 4 to 6 months post-infection, and non-infected mice with no treatment of the same age (Table 4.1)  $p>0.05$ . Therefore, IFN- $\tau$  treatment does not appear to cause the same side-effects with regard to changes in white blood cells as IFN- $\beta$  treatment in MS patients.

Table 4.1: WBC analysis performed on terminal cardiac bleeds from SJL/J mice. Groups A and B were both infected with Theiler's virus. Group A received i.p. saline injections from 4-6 mo. p.i. Group B was given IFN- $\tau$  also from 4-6 mo. p.i. Group C was not infected with TMEV and received no treatment. All mice were perfused at 7 months of age. n=5 for each condition. No statistical difference was detected between all three conditions for all cell types ( $p>0.05$ ).

<b>Group</b>	<b>A</b>	<b>B</b>	<b>C</b>
<b>Infected</b>	+	+	-
<b>Treatment</b>	Saline	IFN-tau	None
<b>Neutrophils</b>	$19.819 \pm 13.744$	$14.591 \pm 3.026$	$9.367 \pm 3.857$
<b>Lymphocytes</b>	$68.410 \pm 17.868$	$73.600 \pm 3.652$	$81.286 \pm 6.240$
<b>Monocytes</b>	$8.165 \pm 5.377$	$8.798 \pm 3.696$	$6.106 \pm 7.708$
<b>Eosinophils</b>	$2.804 \pm 0.981$	$2.170 \pm 0.708$	$2.651 \pm 1.088$
<b>Basophils</b>	$0.821 \pm 0.363$	$0.854 \pm 0.263$	$0.589 \pm 0.542$
<b>Total WBC %</b>	$5.807 \pm 2.124$	$5.865 \pm 2.765$	$6.759 \pm 3.156$

#### 4.24 IFN- $\tau$ ELISA

Significant levels of antibodies to interferon-tau were detected in non-infected and infected mice treated with IFN- $\tau$  from 5-7 months of age and 4-6 months post-infection respectively  $p<0.05$ . At the time of

perfusion, however, levels of antibodies to interferon-tau were not statistically different from background levels in the infected mice treated -3 to 0 days post-infection with interferon-tau probably because the serum was collected 6 months after interferon-tau administration  $p>0.05$  (Figure 4.1).

#### *4.25 IL-10 ELISA*

Circulating IL-10 levels were elevated from background in the infected mice treated with methylprednisolone 5 to 6 months post-infection or with interferon-tau 4 to 6 month post-infection  $p<0.05$ . This was attributed to the anti-inflammatory effects of methylprednisolone and interferon-tau which both function to down regulate Th1 cytokines and increase Th2 cytokine production (Figure 4.2).

#### *4.26 Myelin-specific DTH testing*

The delayed-type hypersensitivity to myelin was greatly reduced in infected mice that received interferon-tau 4 to 6 months post-infection as opposed to infected, saline controls  $p<0.05$ . These results correlate with a decrease in the Th1 response of the interferon-tau treated mice (Figure 4.3).




Figure 4.1: IFN- $\tau$  ELISA graph of all groups with IFN- $\tau$  treatment. IFN- $\tau$  ELISA performed on terminal bleeds at 7 months of age for all treatment groups to determine the antibody level to IFN- $\tau$ . The interferon-tau 4 to 6 months and interferon-tau -3 to 0 days were both infected with BeAn. Analysis was performed in duplicate. n=5 for each condition. The both infected and non-infected mice treated with IFN- $\tau$  from 4 to 6 months were significantly different than the control mice ( $p<0.05$ ).




Figure 4.2: IL-10 ELISA graph of all treatment groups. IL-10 ELISA performed on terminal bleeds at 7 months of age for all treatment groups. The interferon-tau 4 to 6 months, interferon-tau -3 to 0 days, control, and methylprednisolone groups were all infected with BeAn. The control mice received saline 4 to 6 months post-infection. The interferon-tau, uninfected group received interferon-tau at 4 to 6 months post-infection. Analysis was performed in duplicate. n=5 for each condition. The mice treated with methylprednisolone and those treated with IFN- $\tau$  from 4 to 6 months p.i. were significantly different than the other treatment groups and control mice ( $p<0.05$ ).




Figure 4.3: DTH graph of 4 to 6 months p.i. IFN- $\tau$  treatment and saline infected controls. Delayed-type hypersensitivity to myelin performed at 6 months post-infection 48 hours before perfusion. Both groups were infected with BeAn. The interferon-tau group received interferon-tau 4 to 6 months post-infection. All data was collected 24 hours after myelin injection and PBS control thickness measurements were subtracted from the myelin measurements. n=10 for both groups ( $p<0.05$ ).

#### *4.27 Radioimmunoassay of corticosterone*

IFN- $\tau$  has been reported to elevate corticosterone levels in sheep (Ott et al., 1997). Therefore, corticosterone was measured in all experimental groups. IFN- $\tau$  treatment did not elevate corticosterone levels in non-infected mice (range 35-90 ng/ml). The RIA for corticosterone is considered preliminary data as the non-infected, 4 to 6 month interferon-tau treated group had an n of 2 (Table 4.2). However, a slight correlation ( $R^2 = 0.7389$ ) was seen between corticosterone levels and the clinical scores of the mice at the time of serum collection (Figure 4.4). This correlation may increase with a higher sample number.

#### *4.28 RPA*

The RPA analysis of the spinal cord tissue extracted from infected mice treated with saline or interferon-tau 4 to 6 months post-infection resulted in a marked difference in cytokine expression between the two groups. Mice treated with interferon- $\tau$  showed an increase in IL-1, IL-6, IL-10 and IFN- $\gamma$  compared to saline treated mice (Figures 4.5 and 4.6).

**Table 4.2: Corticosterone v. clinical scores of all treatment groups.**  
**Corticosterone RIA on mouse serum samples in relation to clinical**  
**scores at the time of perfusion. All samples analyzed in duplicate. No**  
**relation was found between IFN- $\tau$  treatment and corticosterone levels.**

<b>Infected</b>	<b>Treatment</b>	<b>Timing of Treatment</b>	<b>Corticosterone ng/mL</b>	<b>Clinical Scores</b>
+	IFN-tau	-3 to 0 days pi	216.97	3
+	IFN-tau	-3 to 0 days pi	885.32	4.5
+	IFN-tau	-3 to 0 days pi	659.8	4
+	IFN-tau	-3 to 0 days pi	430.11	3.5
+	IFN-tau	-3 to 0 days pi	724.73	4.5
+	Saline	4 to 6 months p.i	68.38	2
+	Saline	4 to 6 months p.i	300.1	3.5
+	Saline	4 to 6 months p.i	460.48	4
+	Saline	4 to 6 months p.i	48.79	3
+	Methylprednisolone	5 to 6 months p.i.	19.61	2.5
+	Methylprednisolone	5 to 6 months p.i.	354.18	3.5
+	Methylprednisolone	5 to 6 months p.i.	1000	5
+	Methylprednisolone	5 to 6 months p.i.	348.48	3.5
+	Methylprednisolone	5 to 6 months p.i.	510.14	3
+	IFN-tau	4 to 6 months p.i	124.93	2
+	IFN-tau	4 to 6 months p.i	445.95	3
+	IFN-tau	4 to 6 months p.i	885.32	3
+	IFN-tau	4 to 6 months p.i	498.4	2.5
-	IFN-tau	4 to 6 months p.i	90.62	0
-	IFN-tau	4 to 6 months p.i	35.26	0
-	None	None	51.84	0
-	None	None	12.66	0
-	None	None	115.03	0
-	None	None	214.22	0




Figure 4.4: Preliminary correlation graph of corticosterone v. clinical scores. Corticosterone levels in serum v. clinical score at the time of perfusion. All samples were performed in duplicate. A slight correlation was found between corticosterone levels in serum and clinical scores of infected mice.




Figure 4.5: Spinal cord RPA mck-2b assay. Spinal cords from infected mice treated either 4 to 6 months with saline or interferon-tau were removed, the RNA extracted, and analyzed for cytokine RNA as outlined in methods. T = IFN- $\tau$  treated mice. S= saline treated mice. Note the increase in IL-6, IFN- $\gamma$ , IL-1 and IL-10 in the mice treated with IFN- $\tau$ .




Figure 4.6: RPA analysis graph of cytokines expressed in infected IFN- $\tau$  treated mice and saline controls. Intensity was measured via phosphoimager. Housekeeping genes were used in comparison to cytokine intensity for all calculations. n=3.

## Discussion

IFN- $\tau$  treatment of Theiler's virus-infected mice during late disease results in reduced inflammation and demyelination. When used to treat chronic BeAn TMEV infections, IFN- $\tau$  does not significantly change the white blood cell differential of female SJL/J mice when compared to non-treated controls. Occasionally, lymphopenia, neutropenia, and leukopenia are detected in MS patients as a result of IFN- $\beta$  administration (PRISMS study group, 1998). This data confirms that IFN- $\tau$  does not effect circulating WBC counts as IFN- $\beta$  does.

Due to the fact that ovine IFN- $\tau$  is a foreign protein in the murine system, it is expected that antibodies would be produced in the murine model. An antibody response to IFN- $\tau$  was detected, but similar findings from Soos et al. in the same strain of female mice found that these antibodies were non-neutralizing, therefore, they do not effect the activity of IFN- $\tau$  *in vivo* (Soos et al., 1997).

Reports that IFN- $\tau$  can inhibit Th1 cytokine production *in vivo* (Newton et al., 1989, Niwano et al., 1989; Skopets et al., 1992; Assal-Meliani et al., 1993) and upregulate the expression of Th2 cytokines (Chaouat et al., 1995) is further supported by the fact that an increase in IL-10 production is found when IFN- $\tau$  is used to treat chronic EAE (Soos et al., 1997) and chronic TMEV infection in SJL/J mice. The increase of IL-10 seen with IFN- $\tau$  administration in EAE is also detected to the same degree when IFN- $\alpha/\beta$  is given orally to treat EAE over a seven week period (Brod et al., 1994) suggesting that IFN- $\tau$  functions in a comparable manner to IFN- $\alpha/\beta$  in the treatment of autoimmune-induced MS like disease.

It is known from previous works that IFN- $\tau$  has anti-viral (Dereuddre-Bosquet et al., 1996; Johnson et al., 1999; Juste et al., 2000) and immunomodulating properties (Newton et al., 1989, Niwano et al., 1989; Skopets et al., 1992; Assal-Meliani et al., 1993; Tuo et al., 1993; Chaouat et al., 1995). A delayed-type hypersensitivity reaction to myelin occurs in TMEV-induced demyelinating disease and is proposed to contribute to bystander demyelination during chronic infection (Miller and Gerety, 1990; Miller 1997; Borrow et al., 1998). The data presented here suggest that IFN- $\tau$  treatment of chronically infected mice is able to decrease the Th1-induced DTH reaction to myelin that occurs during TMEV infections.

IFN- $\tau$  has been reported to increase serum corticosterone levels when administered to sheep (Ott et al., 1997). Increased corticosterone could result in immunosuppression, therefore, corticosterone was measured in the experimental mice. IFN- $\tau$  administration alone did not increase corticosterone levels. Interestingly, high levels of corticosterone were detected in virus infected mice with high clinical scores regardless of treatment group. No statistical correlation was detected between IFN- $\tau$  treatment and high corticosterone levels  $p > 0.05$ . Based on the preliminary data in this report, it is suspected that the level of circulating corticosterone in chronically TMEV-infected mice may correlate the level of clinical disease progression. Though not much is known about corticosterone and TMEV, previous works show that proinflammatory cytokines can impair normal glucocorticoid function in humans and contribute to neuronal damage in MS patients (Fassbender et al., 1998; Bergh et al., 1999). It stands to reason then that an increase in corticosterone would be seen during the chronic phase of TMEV when Th1 cytokine expression is elevated (Chang et al., 2000).

It is curious to note that the highest level of corticosterone reported in this study occurred in the methylprednisolone treated group. It is possible that the dose given was too low to significantly impair the Th1 cytokine damage in the TMVE chronic progressive MS model as seen in MS patients (Tourtellotte and Haerer, 1965; Millar et al., 1967). A larger sample size is needed to determine if there is a true correlation between serum corticosterone levels and TMEV clinical presentation.

The reports on cytokine mRNA in the CNS tissue of mice infected with TMEV are conflicting due to the fact that different investigators use different assays and perform their experiments during different times of infection. Using the DA strain of TMEV, at 40 days p.i. in SJL/J mice, Sato et al. found that the Th1 cytokines IL-1 and IL-2 were not detectable in the spinal cord whereas Th2 cytokines, IL-10, and Th1 cytokines TNF- $\alpha$ , IL-12, and IFN- $\gamma$  were elevated when compared to controls. In the brains of the same animals, IL-10, IL-12, TNF- $\alpha$ , IL-1, IL-2, IL-6, and IFN- $\gamma$  were not detected at 40 days p.i. but, IL-4 production was high in the brain (Sato et al., 1997). It has also been reported that IFN- $\gamma$ , IL-1, IL-2, IL-6, IL-12, TNF- $\alpha$ , TGF- $\beta$ 1, IL-4, IL-5 and IL-10 cytokine RNA was detected at levels above controls at 60 days p.i. in SJL/J mice also infected with DA (Chang et al., 2000). Since there appears to be inconsistencies between 40 and 60 days p.i. with the same TMEV strain, it would be interesting to see if there was a difference in cytokine expression in the CNS of mice infected with the BeAn as compared to the DA strain of TMEV.

The RNA protection assay analysis reported here was performed on spinal cord tissue of mice with the BeAn strain of TMEV at 180 days p.i. (Figure 4.5). An increase was noted in IL-1, IL-6, IL-10, and IFN- $\gamma$  in IFN- $\tau$  4-6 month p.i. treated mice as compared to TMEV-infected

controls. The upregulation of IL-10 was expected due to the IL-10 serum ELISA data discussed previously. The increase in IL-1, IL-6, and IFN- $\gamma$  maybe normal in TMEV BeAn infection but the control, infected mice did not express these cytokines at the same level as the IFN- $\tau$  treated mice. Though clinical presentation improved significantly with IFN- $\tau$  administration, the mice still have significant neurological impairment. This may be due to the fact that TMEV-infected mice develop truncated axons that can not be repaired via remyelination (McGavern et al., 2000). It is also possible that the activation of macrophages through IL-1 and IFN- $\gamma$  and the production of antibodies through IL-6 expression contributes to the demyelination seen in the IFN- $\tau$  4-6 month treated mice. Further cytokine analysis needs to be done on non-infected mice treated with IFN- $\tau$  and larger sample sizes to determine if the upregulation of the Th1 cytokines seen is due to the IFN- $\tau$  treatment or TMEV infection.

In conclusion, the increase in serum and spinal cord IL-10, decrease in DTH response to myelin, decrease in inflammation, and decrease in demyelination in the 4-6 month IFN- $\tau$  treated group imply that IFN- $\tau$  functions as a Th1 immunomodulator when administered during chronic TMEV infection. Viral RNA in the CNS needs to be measured as well as *in situ* hybridization cytokine analysis performed to determine if IFN- $\tau$  administration halts disease progression via anti-viral mechanisms as well as immunosuppressive means. IFN- $\alpha/\beta$  administration in TMEV-infected SJL/J mice did not decrease viral load so an anti-viral mechanism is questionable (Njenga et al., 2000).

## V. Conclusions

Multiple sclerosis is a debilitating disease that effects the central nervous system of over 300,000 people in the United States. It can result in white matter demyelination, chronic inflammatory lesions, axonal damage, and deterioration of neurological function (Prineas and Raine, 1976; Prineas and Wright, 1978; Adams et al., 1989, Trapp et al., 1998).

The post-mortum histological analysis of lesions in the central nervous system of MS patients has led to the suggestion that two different patterns of lesion development exist. The two patterns consist of T-cell-mediated or T-cell plus antibody-mediated autoimmune encephalomyelitis and primary oligodendrocyte damage that is caused by a viral or bacterial infection and results in demyelination (Lucchinetti et al., 2000). To further support the theory that T-cell-mediated and T-cell plus antibody-mediated autoimmune encephalomyelitis as a cause for lesion development, it has been reported that MS patients have T-cells in the CNS that produce the Th1 proinflammatory cytokines during relapsing episodes (Correale et al., 1995; Voskuhl et al., 1993; Olsson et al., 1990) and anti-inflammatory Th2 cytokines during remission phases (Correale et al., 1995).

Since MS is thought to be initiated by a viral infection, the effectiveness of type I interferons may be related to their role in viral inhibition. In addition, the autoimmune aspects of MS may be down regulated through a number of different mechanisms since type I IFNs have been shown to inhibit DTH responses (also important in TVID and EAE), alter the homing and trapping of lymphocytes, enhance NK and T-cell activity and cytotoxicity, enhance Fc $\gamma$  receptors effects (Belardelli

and Gresser, 1996), inhibit T-cell proliferation, and decrease the production of IFN- $\gamma$  (Noronha et al., 1993).

EAE and Theiler's virus, two animal models for multiple sclerosis, have similar pathologies (Dal Canto et al., 1995). IFN- $\tau$  has been shown to prevent the development of the acute form of EAE in NZW mice and to prevent the development of chronic-relapsing EAE in SJL/j mice (Soos et al., 1995). In addition to protecting against both acute and chronic forms of EAE, parental or oral administration of IFN- $\tau$  has been shown to alleviate ongoing, chronic, relapsing EAE in SJL/j mice (Soos et al., 1997). The effectiveness of IFN- $\tau$  in the treatment of active EAE and its ability to exert an effect when administered orally without the induction of neutralizing antibodies makes IFN- $\tau$  a more attractive therapeutic agent for the treatment of MS. Knowing that IFN- $\tau$  has proven to be an effective treatment in EAE by preventing acute induction and superantigen reactivation of EAE via suppressor cells (Soos et al., 1995; Majtaba et al., 1997), it was of interest to investigate the effect of IFN- $\tau$  on lesion development in the CNS in TVID.

IFN- $\alpha$  and IFN- $\beta$  are two of the type I interferons that have been investigated as possible treatments for multiple sclerosis. The administration of type I interferons, IFN- $\alpha/\beta$ , in combination in SJL/J mice infected with the DA strain of Theiler's virus resulted in increased demyelination when given 4.5 months p.i for sixteen weeks (Njenga et al., 2000). IFN- $\alpha/\beta$  given for the short term resulted in the promotion of remyelination. The authors noted that the mice lost weight during weeks 6-7 of treatment, developed reduced DTH responses to TMEV and decreased numbers of T-cells and B-cells infiltrating the CNS. The treated mice developed antibodies to IFN- $\alpha/\beta$  which did not appear to affect the efficacy of the treatment. Furthermore the IFN- $\alpha/\beta$  treatment

did not affect viral replication as measured by *in situ* hybridization quantification of RNA-positive cells. Therefore, the therapeutic effect was not mediated by the antiviral effects of IFN- $\alpha/\beta$ , but rather by the immunomodulatory functions.

IFN- $\tau$  treatment of Theiler's virus-infected mice during late disease results in reduced inflammation and demyelination. When used to treat chronic BeAn TMEV infections, IFN- $\tau$  does not significantly change the white blood cell differential of female SJL/J mice when compared to non-treated controls. Occasionally, lymphopenia, neutropenia, and leukopenia are detected in MS patients as a result of IFN- $\beta$  administration (PRISMS study group, 1998). The data reported in the current study confirms that IFN- $\tau$  does not effect circulating WBC counts in contrast to IFN- $\beta$ .

The data reported here indicates that IFN- $\tau$  is an effective therapeutic agent for the treatment of mice with the late stages of TVID, but administration prior to infection and during the early stages of disease can exacerbate clinical presentation. Mice that were given IFN- $\tau$  before viral infection were significantly worse clinically and lost more weight than control, infected mice, possibly as a result of the suppression of the Th1 cytokine response during initial infection (Borrow et al., 1993). The H+E staining of the spinal cords of mice treated with interferon-tau before viral infection confirmed the clinical presentation data with an increase in demyelination, status spongiosus, and inflammation. Th1 proinflammatory cytokines including interferon-gamma are required for the immune system to mount an effective antiviral response and decrease viral titers (Rodriguez et al., 1995). It follows then that the administration of an immunomodulator like interferon-tau during early TMEV infection would decrease Th1 cytokine

production and result in an increase in lesion presentation due to increased viral load.

Demyelination in Theiler's virus infection occurs through multiple mechanisms including (a) direct viral lysis of oligodendrocytes, (b) autoimmunity, (c) bystander demyelination mediated by antiviral CD4<sup>+</sup> T-cells, and (d) cytotoxic T-cell lysis of infected oligodendrocytes (figure 5.1). It is hypothesized that during early TVID, demyelination is mediated primarily through viral infection, CD8<sup>+</sup> cytotoxicity and CD4<sup>+</sup> T-cell responses to virus. The autoimmune responses to myelin are only evident at late times during the disease process, between 3 and 9 months p.i. (Miller et al., 1997; Borrow et al., 1998). IFN- $\tau$  may be most effective at interfering with the autoimmune aspects of TVID which may explain the reason for its relative ineffectiveness during the 2-6 months treatment period. The first antiviral DTH response in TVID occurs at 34 days p.i. (Miller et al., 1997). Treatment from 2-3 months may interfere with the viral clearance mechanisms, although further experiments are necessary before definite conclusions can be made.

There was only a slight significant difference in the clinical scores and weights of the mice treated with IFN- $\tau$  early in the course of the chronic disease (2-6 month post-infection) compared to the infected controls. All of the 2-6 month infected, treated mice were clinically scored between 2 and 3 before treatment began. It is possible that continued exposure to IFN- $\tau$  may be of additional benefit to these mice although further experimentation is required to address this issue.




Figure 5.1: Mechanisms of Theiler's virus induced demyelination

During the late stage of demyelinating disease (4-6 month post-infection) IFN- $\tau$  treated mice showed marked improvement. At the beginning of treatment, all the clinical scores of the 4-6 month treated mice were between 3 and 4. They gained weight and improved clinically with treatment similar to the other reports of infected mice that were CD4+ T-cell deficient late in disease progression (Welsh et al., 1987; Nicholson et al., 1996). Mice were treated with IFN- $\tau$  at four months post-infection in an attempt to mimic the situation in MS where the mean time for diagnosis is two years at which time lesions are well established.

It is interesting to note that the data presented here supports the findings of interferon-tau treatment of EAE mice. As expected, a decrease in inflammation, status spongiosus, and demyelination was observed in the H+E and immunostained slides of the spinal cords of SJL/J mice when interferon-tau was administered from 4-6 months post-infection. This was attributed to the down regulation of proinflammatory Th1 cytokines via interferon-tau administration. However, MOG staining was present in the gray matter of IFN- $\tau$  4-6 month infected treated and non-treated mice that was not present in the healthy controls. IFN- $\tau$  administration from 4-6 months p.i. did not improve the incidence of lesions in the lateral funiculi as it did in the ventral and dorsal funiculi.

It is possible that IFN- $\tau$  therapy at the late chronic disease stage encourages viral replication via immunosuppression and the change in lesion presentation in the gray matter is due to the imbalance between the virus and immune reactions. It is interesting to note, however, that IFN- $\tau$  may have limitations in aiding in disease recovery. One subject

that was clinically scored above 4.0 before treatment did not survive the length of the study. This implies that clinical presentation before treatment may be as important as timing of dosage.

When non-infected mice were dosed with IFN- $\tau$ , a marginally significant weight loss was detected three weeks after administration when compared to saline controls. This confirms that the statistically significant weight gain seen in the 4-6 month p.i. treated group was a real effect of treatment. No changes in histology were detected in the non-infected, IFN- $\tau$  treated group.

The current hypothesis is that IFN- $\tau$  protection in EAE occurs via Th2 cytokine activation as noted by increased IL-10 production (Soos et al., 1997), the inhibition of B-cell and T-cell responses in active and chronic EAE (Majtaba et al, 1998), and the lack of inflammatory lymphocytic lesions in the CNS (Soos et al., 1997) during IFN- $\tau$  treatment. TVID susceptible SJL mice given an immunosuppressive cytokine, TGF-b2 showed a reduction in the number of virus infected cells and decreased amount of demyelination (Drescher et al., 2000). The mechanism of action was hypothesized to be TGF-b2 reduced infiltration or activation of virus-infected macrophages into the CNS. Female SJL/J mice infected with the DA strain of Theiler's virus and then given IL-4 or IL-10 or both cytokines in combination, showed marked decreases in demyelination and inflammation (Hill et al., 1998). Thus immunosuppressive cytokines are beneficial in the treatment of TVID. It is important that interferon-tau is given during the chronic demyelinating phase of TVID to suppress the production of autoimmune damage to the CNS by Th1 cytokine expression for the most significant improvement to occur. It is possible that tolerance to interferon-tau may develop if administration continued past 2 months even during the

chronic phase of TMEV. Further investigation into the effectiveness of long-term treatment is necessary.

Due to the fact that ovine IFN- $\tau$  is a foreign protein in the murine system, it is expected that antibodies would be produced in the murine model. An antibody response to IFN- $\tau$  was detected (figure 4.1) in TMEV infected mice treated with IFN- $\tau$ . Similar findings from Soos et al. in the same strain of female mice treated with IFN- $\tau$  found that these antibodies were non-neutralizing, therefore, they do not effect the activity of IFN- $\tau$  *in vivo* (Soos et al., 1997). IFN- $\tau$  given orally did not invoke the production of antibodies (Soos et al., 1997) and therefore it would be interesting to determine if oral administration of IFN- $\tau$  to TMEV-infected mice was as effective as i.p. administration.

Reports that IFN- $\tau$  can inhibit Th1 cytokine production *in vivo* (Newton et al., 1989, Niwano et al., 1989; Skopets et al., 1992; Assal-Meliani et al., 1993) and upregulate the expression of Th2 cytokines (Chaouat et al., 1995) is further supported by the fact that an increase in IL-10 production is found when IFN- $\tau$  is used to treat chronic EAE (Soos et al., 1997) and chronic TMEV infection in SJL/J mice. The increase of IL-10 seen with IFN- $\tau$  administration in EAE is also detected to the same degree when IFN- $\alpha/\beta$  is given orally to treat EAE over a seven week period (Brod et al., 1994) suggesting that IFN- $\tau$  functions in a comparative manner to IFN- $\alpha/\beta$  in the treatment of autoimmune-induced MS like disease.

It is known from previous works that IFN- $\tau$  has antiviral (Dereuddre-Bosquet et al., 1996; Johnson et al., 1999; Juste et al., 2000) and immunomodulating properties (Newton et al., 1989, Niwano et al., 1989; Skopets et al., 1992; Assal-Meliani et al., 1993; Tuo et al., 1993; Chaouat et al., 1995). A delayed-type hypersensitivity reaction to

myelin occurs in TMEV-induced demyelinating disease and is proposed to contribute to bystander demyelination during chronic infection (Miller and Gerety, 1990; Miller 1997; Borrow et al., 1998). The data presented here suggest that IFN- $\tau$  treatment of chronically infected mice is able to decrease the Th1-induced DTH reaction to myelin that is thought to contribute to the demyelinating process.

IFN- $\tau$  has been reported to increase serum corticosterone levels when administered to sheep (Ott et al., 1997). Increased corticosterone could result in immunosuppression, therefore, corticosterone was measured in the experimental mice. IFN- $\tau$  administration did not increase corticosterone levels in the mice. Interestingly, high levels of corticosterone were detected in virus infected mice with high clinical scores regardless of treatment group. No statistical correlation was detected between IFN- $\tau$  treatment and high corticosterone levels ( $p > 0.05$ ). Based on the preliminary data in this report, it is suspected that the level of circulating corticosterone in chronically TMEV-infected mice may correlate with the level of clinical disease progression (Table 4.2 & Figure 4.4).

Though not much is known about corticosterone and TMEV, previous works show that proinflammatory cytokines can impair normal glucocorticoid function in humans and contribute to neuronal damage in MS patients (Fassbender et al., 1998; Bergh et al., 1999). It stands to reason then that an increase in corticosterone would be seen during the chronic phase of TMEV when Th1 cytokine expression is elevated (Chang et al., 2000). It is curious to note that the highest level of corticosterone reported in this study occurred in the methylprednisolone treated group and the lesions in that group were fairly prominent. It is possible that the dose given was too low to significantly impair the Th1 cytokine damage in the TMEV chronic progressive MS model as seen in MS

patients (Tourtellotte and Haerer, 1965; Millar et al., 1967). A larger sample size is needed to determine if there is a true correlation between serum corticosterone levels and TMEV clinical presentation.

The reports on cytokine mRNA in the CNS tissue of mice infected with TMEV are conflicting due to the fact that different investigators use different assays and perform their experiments during different times of infection. Using the DA strain of TMEV, at 40 days P.I. in SJL/J mice, Sato et al. found that the Th1 cytokines IL-1 and IL-2 were not detectable in the spinal cord whereas Th2 cytokines, IL-10, and Th1 cytokines TNF- $\alpha$ , IL-12, and IFN- $\gamma$  were elevated when compared to controls. In the brains of the same animals, IL-10, IL-12, TNF- $\alpha$ , IL-1, IL-2, IL-6, and IFN- $\gamma$  were not detected at 40 days p.i. but, IL-4 production was high in the brain (Sato et al., 1997). It has also been reported that IFN- $\gamma$ , IL-1, IL-2, IL-6, IL-12, TNF- $\alpha$ , TGF- $\beta$ 1, IL-4, IL-5 and IL-10 cytokine RNA was detected at levels above controls at 60 days p.i. in SJL/J mice also infected with DA (Chang et al., 2000). High levels of lymphotoxin- $\beta$ , TNF- $\alpha$ , IL-6, and TGF- $\beta$  were observed in the brains of SJL/J mice infected with DA for 60 days in a separate study (Theil et al., 2000). These findings agree with some of the other work done at 60 days p.i. that does not include spinal cord data. Since there appears to be inconsistencies between 40 and 60 days p.i. with the same TMEV strain, it would be interesting to see if there was a difference in cytokine expression in the CNS of mice infected with the BeAn as compared to the DA strain of TMEV.

The RNA protection assay analysis reported here was performed on spinal cord tissue of mice with the BeAn strain of TMEV at 180 days post-infection. An increase was noted in IL-1, IL-6, IL-10, and IFN- $\gamma$  in IFN- $\tau$  4-6 month p.i. treated mice as compared to TMEV-infected

controls. The upregulation of IL-10 was expected due to the IL-10 serum ELISA data discussed previously. The increase in IL-1, IL-6, and IFN- $\gamma$  maybe normal in TMEV BeAn infection but the control, infected mice did not express these cytokines at the same level as the IFN- $\tau$  treated mice. Though clinical presentation improved significantly with IFN- $\tau$  administration, total recovery was not detected with this treatment possibly due to truncated axons that can not be repaired via remyelination though this was not evident by light microscopy (McGavern et al., 2000). It is also possible that the activation of macrophages through IL-1 and IFN- $\gamma$  and the production of antibodies through IL-6 expression contributes to the demyelination seen in the IFN- $\tau$  4-6 month treated mice. Further cytokine analysis is required on non-infected mice treated with IFN- $\tau$  and larger sample sizes to determine if the upregulation of the Th1 cytokines seen is due to the IFN- $\tau$  treatment or TMEV infection.

In conclusion, the increase in serum and spinal cord IL-10, decrease in DTH response to myelin, decrease in inflammation, and decrease in demyelination in the 4-6 month IFN- $\tau$  treated group imply that IFN- $\tau$  functions as a Th1 immunomodulator when administered during chronic TMEV infection. Elevations in IL-10 would result in decreased DTH responses to myelin and subsequently decreased inflammation and demyelination.

The possibility that IFN- $\tau$  may be a therapeutic agent in the fight against MS progression is very exciting, but further work needs to be done with demyelinating animal models to understand the mechanism of IFN- $\tau$ . Viral RNA in the CNS needs to be measured as well as *in situ* hybridization cytokine analysis performed to determine if IFN- $\tau$  administration halts disease progression via antiviral mechanisms as

well as immunosuppressive means. DTH reactions to virus and myelin epitopes in this model are needed as well to answer the antiviral question. IFN- $\alpha/\beta$  administration in TMEV-infected SJL/J mice did not decrease viral load so an antiviral mechanism is questionable (Njenga et al., 2000) though IFN- $\alpha$  and IFN- $\beta$  may function differently when not combined and should be compared to IFN- $\tau$  in TMEV *in vivo*.

Challenge of TMEV-infected mice with a secondary viral agent during IFN- $\tau$  treatment needs to be looked at since the current research suggests IFN- $\tau$  is a Th1 immunosuppressive agent and functions via the same receptor as IFN- $\alpha$  and IFN- $\beta$ . The possibility that IFN- $\tau$  may interfere with the activation of the other type I interferons by receptor competition should also be investigated. Also, oral administration of IFN- $\tau$  would be more favorable for human patients as opposed to injections so oral dosage of IFN- $\tau$  should be included in future research.

As a side note, it was observed during the removal of the spinal cords of infected mice treated 4-6 months with IFN- $\tau$  that the lumbar region was abnormally small and the thoracic area was large in comparison to control TMEV infected mice. The cords of the treated mice appeared to be truncated and contained more dorsal root ganglia originating from the thoracic region than expected. The possibility that IFN- $\tau$  may stimulate axonal regeneration or redirection needs to be studied further with the use of axonal neurotracers and dyes.

## REFERENCES

- Abbruzzese, G., Gandolfo, C., Loeb, C., 1983. "Bolus" methylprednisolone versus ACTH in the treatment of multiple sclerosis. *Italian Journal of Neurological Science* 2, 169-172.
- Adams, CW., Poston, R.N., Buk, S.J., 1989. Pathology, histochemistry and immunocytochemistry of lesions in acute multiple sclerosis. *Journal of Neurological Sciences* 92, 291-306.
- Altman, A., Coggeshall, K.M., Mustelin, T., 1990. Molecular events mediating T cell activation. *Advances in Immunology* 48, 227-360.
- Arnason, B.G.W., Reder, A.T., 1994. Interferons and multiple sclerosis. *Clinical Neuropharmacology* 17, 495-547.
- Arya, S.K., Wong-Staal, F., Gallo, R.C., 1984. Dexamethasone-mediated inhibition of human T cell growth factor and  $\gamma$ -interferon messenger RNA. *Journal of Immunology* 133, 273-276.
- Assal-Melian, A., Charpigny, G., Reinaud, P., Martal, J., Chaouat, G., 1993. Recombinant ovine trophoblast (roTP) inhibits ovine, murine and human lymphocyte proliferation. *Journal of Reproductive Immunology* 25, 149-165.
- Atkins, G.J., Balluz, I.M., Glasgow, G.M., Mabruk, M.J.E.M.F., Natale, V.A.I., Smyth, J.M.B., Sheahan, B.J., 1994. Analysis of the molecular basis of neuropathogenesis of RNA viruses in experimental animals: relevance for human disease? *Neuropathology and Applied Neurobiology* 20, 91-102.
- Atkins, G.J., Mabruk, M.J.E.M.F., Glasgow, G.M., Griffin, A.M., Sheahan, B.J., 1995. Mechanisms of viral teratogenesis. *Reviews in Medical Virology* 5, 75-86.
- Atkins, G.J., Sheahan, B.J., 1982. Semliki Forest Virus neurovirulence

- mutants have altered cytopathogenicity for central nervous system cells. *Infection and Immunity* 36, 333-341.
- Atkins, G.J., Sheahan, B.J., Dimmock, N.J., 1985. Semliki Forest virus infection of mice: a model for genetic and molecular analysis of viral pathogenicity. *Journal of General Virology* 66, 395-408.
- Atkins, G.J., Sheahan, B.J., Mooney, D.A., 1990. Pathogenicity of Semliki Forest virus for the rat central nervous system and primary rat neural cell cultures – possible implications for the pathogenesis of multiple sclerosis. *Neuropathology and Applied Neurobiology* 16, 57-68.
- Azoulay-Cayla, A., Dethlefs, S., Perarnau, B., Larsson-Sciard, E., Lemonnier, F.A., Brahic, M., Bureau, J., 2000. H-2D<sup>b/-</sup> mice are susceptible to persistent infection by Theiler's virus. *Journal of Virology* 74, 5470-5476.
- Balluz, I.M., Glasgow, G.M., Killen, H.M., Mabruk, M.J.E.M.F., Sheahan, B.J., Atkins, G.J., 1993. Virulent and avirulent strains of Semliki Forest virus show similar cell tropism for the murine central nervous system but differ in the severity and rate of induction of cytolytic damage. *Neuropathology and Applied Neurobiology* 19, 233-239.
- Barnes, M.P., Bateman, D.E., Cleland, P.G., Dick, D.J., Walls, T.J., Newman, P.K., Saunders, M., Tilley, P.J.B., 1985. Intravenous methylprednisolone for multiple sclerosis in relapse. *Journal of Neurology Neurosurgery and Psychiatry* 48, 157-159.
- Barrett, P.N., Sheahan, B.J., Atkins, G.J., 1980. Isolation and preliminary characterization of Semliki Forest virus mutants with altered virulence. *Journal of General Virology* 49, 141-147.
- Barthold, S.W., 1986. Host age and genotypic effects on enterotropic

- mouse hepatitis virus infection. *Laboratory Animal Science* 36, 376-382.
- Barthold, S.W., Smith, A.L., 1983. Mouse hepatitis virus S in weanling Swiss mice following intranasal inoculation. *Laboratory Animal Science* 33, 355-360.
- Bartholdi, D., Schwab, M.E., 1995. Methylprednisolone inhibits early inflammatory processes but not ischemic cell death after experimental spinal cord lesion in the rat. *Brain Research* 672, 177-186.
- Belardelli, F., Gresser, I., 1996. The neglected role of type I interferon in the T-cell response: implications for its clinical use. *Immunology Today* 17, 369-372.
- Bergh, F.T., Kümpfel, T., Trenkwalder, C., Rupprecht, R., Holsboer, F., 1999. Dysregulation of the hypothalamo-pituitary-adrenal axis is related to the clinical course of MS. *Neurology* 53, 772-777.
- Beushausen, S., Dales, S., 1985. In vivo and in vitro models of demyelinating disease. XI. Tropism and differentiation regulate the infectious process of coronaviruses in primary explants of the rat CNS. *Virology* 141, 89-101.
- Bihl, F., Brahic, M., Bureau, J.F., 1999. Two loci, *Tmevp2* and *Tmevp3*, located on the telomeric region of chromosome 10, control the persistence of Theiler's virus in the central nervous system of mice. *Genetics* 152, 385-392.
- Blakemore, W.F., Welsh, C.J., Tonks, P., Nash, A.A., 1988. Observations on demyelinating lesions induced by Theiler's virus in CBA mice. *Acta Neuropathology* 76, 581-589.
- Borras, C., Rio, J., Porcel, J., Barrios, M., Tintore, M., Montalban, X., 1999. Emotional state of patients with relapsing-remitting MS treated with interferon beta-1b. *Neurology* 52, 1636-1639.

- Borrow, P. and Nash, A.A., 1992. Susceptibility to Theiler's virus-induced demyelinating disease correlates with astrocyte class II induction and antigen presentation. *Immunology* 76, 133-139.
- Borrow, P., Tonks, P., Welsh, C.J.R., Nash, A.A., 1992. The role of CD8<sup>+</sup> T cells in the acute and chronic phases of Theiler's murine encephalomyelitis virus-induced disease in mice. *Journal of General Virology* 73, 1861-1865.
- Borrow, P., Welsh, C.J.R., Nash, A.A., 1993. Study of the mechanisms by which CD4<sup>+</sup> T cells contribute to protection in Theiler's murine encephalomyelitis. *Immunology* 80, 502-506.
- Borrow, P., Welsh, C.J.R., Tonks, P., Dean, D., Blakemore, W.F., Nash, A.A., 1998. Investigation of the role of delayed-type-hypersensitivity responses to myelin in the pathogenesis of Theiler's virus-induced demyelinating disease. *Immunology* 93, 478-484.
- Bottomly, K., 1988. A functional dichotomy in CD4<sup>+</sup> T lymphocytes. *Immunology Today* 9, 268-274.
- Bracken, M.B., Shepard, M.J., Collins, W.F., Holford, T.R., Young, W., Baskin, D.S., Eisenberg, H.M., Flamm, E., Leo-Summers, L., Maroon, J., Marshall, L.F., Perot, P.L., Piepmeier, J., Sonntag, V.K.H., Wagner, F.C., Wilberger, J.E., Winn, H.R., 1990. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. *New England Journal of Medicine* 322, 1405-1411.
- Brahic, M., Bureau, J.F., 1998. Genetics of susceptibility to Theiler's virus infection. *BioEssays* 20, 627-633.
- Brahic, M., Haase, A.T., Cash, E., 1984. Simultaneous in situ detection of viral RNA and antigens. *Proceedings National Academy of Sciences USA* 81, 5445-5448.

- Brod, S.A., Burns, D.K., 1994. Suppression of relapsing experimental autoimmune encephalomyelitis in the SJL/J mouse by oral administration of type I interferons. *Neurology* 44, 1144-1148.
- Brod, S.A., Marshall, Jr., G.D., Henninger, E.M., Sriram, S., Khan, M., Wolinsky, J.S., 1996. Interferon beta-1b treatment decreases tumor necrosis factor- $\alpha$  and increases interleukin-6 production in multiple sclerosis. *Neurology* 46, 1633-1638.
- Brown, A., McFarlin, D.E., Raine, C.S., 1982. Chronologic neuropathology of relapsing experimental allergic encephalomyelitis in the mouse. *Laboratory Investigation* 46, 171-185.
- Buckley, C., Kennard, C., Swash, M., 1982. Treatment of acute exacerbations of multiple sclerosis with intravenous methylprednisolone. *Journal of Neurology Neurosurgery and Psychiatry* 45, 179-181.
- Bureau, J.F., Montagutelli, X., Bihl, F., Lefebvre, S., Guenet, J.L., Brahic, M., 1993. Mapping loci influencing the persistence of Theiler's virus in the murine central nervous system. *Nature Genetics* 5, 87-91.
- Bureau, J.F., Montagutelli, X., Lefebvre, S., Guenet, J.L., Pla, M., Brahic, M., 1992. The interaction of two groups of murine genes determines the persistence of Theiler's virus in the central nervous system. *Journal of Virology* 66, 4698-4704.
- Burt, R.K., Padilla, J., Dal Canto, M.C., Miller, S.D., 1999. Viral hyperinfection of the central nervous system and high mortality after hematopoietic stem cell transplantation for the treatment of Theiler's murine encephalomyelitis virus-induced demyelinating disease. *Blood* 94, 2915-2922.
- Cameron, K., Zhang, X., Seal, B., Rodriguez, M., Njenga, M.K., 2001.

- Antigens to viral capsid and non-capsid proteins are present in brain tissues and antibodies in sera of Theiler's virus-infected mice. *Journal of Virological Methods* 91, 11-19.
- Cerruti-Sola, S., Kristensen, F., Vandevelde, M., Bichsel, P., Kihm, U., 1983. Lymphocyte responsiveness to lectin and myelin antigens in canine distemper infection in the relation to the development of demyelinating lesions. *Journal of Neuroimmunology* 4, 77-90.
- Cesario, T.C., Slater, L., Poo, W.J., Spindler, B., Walter, B., Gorse, G., Carandang, G., 1986. The effect of hydrocortisone on the production of gamma interferon and other lymphokines by human peripheral blood mononuclear cells. *Journal of Interferon Research* 6, 337-347.
- Chamorro, M., Aubert, C., Brahic, M., 1986. Demyelinating lesions due to Theiler's virus are associated with ongoing central nervous system infection. *Journal of Virology* 57, 992-997.
- Chang, J.R., Zaczynska, E., Katsetos, C.D., Platsoucas, C.D., Oleszak, E.L., 2000. Differential expression of TGF- $\beta$ , IL-2, and other cytokines in the CNS of Theiler's murine encephalomyelitis virus-infected susceptible and resistant strains of mice. *Virology* 278, 346-360.
- Chaouat, G., Assal-Melian, A., Martal, J., Raghupathy, R., Elliot, J., Mosmann, T., Wegmann, T.G., 1995. IL-10 prevents naturally occurring fetal loss in the CBA x DBA/2 mating combination, and local defect in IL-10 production in this abortion-prone combination is corrected by in vivo injection of IFN- $\tau$ . *Journal of Immunology* 154, 4261-4268.
- Clatch, R.J., Melvold, R.W., Miller, S.D., Lipton, H.L., 1985. Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease in mice is influenced by the H-2D region: Correlation with

- TMEV-specific delayed-type hypersensitivity. *Journal of Immunology* 135, 1408-1414.
- Clatch, R.J., Melvold, R.W., Dal Canto, M.C., Miller, S.D., Lipton, H.L., 1987. The Theiler's murine encephalomyelitis virus (TMEV) model for multiple sclerosis shows a strong influence of the murine equivalents of HLA-A, B, and C. *Journal of Neuroimmunology* 15, 121-135.
- Confavreux, C., Hutchinson, M., Hours, M.M., Cortinovis-Tourniaire, P., Moreau, T., 1998. Rate of pregnancy-related relapse in multiple sclerosis. *The New England Journal of Medicine* 339, 285-91.
- Cook, S.D., Rohowsky-Kochan, C., Bansil, S., 1996. Evidence for a viral etiology of multiple sclerosis. In: Cook, S.D. (Ed), *Handbook of Multiple Sclerosis*, Marcel Dekker, Inc., New York and Basel, pp.97-118.
- Correale, J., Gilmore, W., McMaillan, M., Li, S., McCarthy, K., Le, T., Weiner, L.P., 1995. Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. *Journal of Immunology* 154, 2959-2968.
- Cross, J.C., Roberts, R.M., 1991. Constitutive and trophoblast-specific expression of a class of bovine interferon genes. *Proceedings of the National Academy of Sciences USA* 88, 3817-3821.
- Cua, D.J., Hinton, D.R., Stohlman, S.A., 1995. Self-antigen-induced Th2 responses in experimental allergic encephalomyelitis (EAE)-resistant mice. Th1-mediated suppression of autoimmune disease. *Journal of Immunology* 155, 4052-4059.
- Dal Canto, M.C., Calenoff, M.A., Miller, S.D., Vanderlugt, C.L., 2000. Lymphocytes from mice chronically infected with Theiler's murine encephalomyelitis virus produce demyelination of organotypic cultures after stimulation with the major encephalitogenic epitope

- of myelin proteolipid protein. Epitope spreading in TMEV infection has functional activity. *Journal of Neuroimmunology* 104, 79-84.
- Dal Canto, M.C., Lipton, H.L., 1975. Primary demyelination in Theiler's virus infection. An ultrastructural study. *Laboratory Investigation* 33, 626-637.
- Dal Canto, M.C., Melvold, R.W., Kim, B.S., Miller, S.D., 1995. Two models of multiple sclerosis: experimental allergic encephalomyelitis (EAE) and Theiler's murine encephalomyelitis virus (TMEV) infection. A pathological and immunological comparison. *Microscopy Research and Technique* 32, 215-229.
- Dayal, A.S., Jensen, M.A., Lledo, A., Arnason, B.G.W., 1995. Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b. *Neurology* 45, 2173-2177.
- Dereuddre-Bosquet, N., Clayette, P., Martin, M., Mabondzo, A., Fretier, P., Gras, G., Martal, J., Dormont, D., 1996. Anti-HIV potential of a new interferon, interferon- $\tau$  (trophoblastin). *Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology* 11, 241-246.
- Diab, A., Zhu, J., Xiao, B.G., Mustafa, M., Link, H., 1997. High IL-6 and low IL-10 in the central nervous system are associated with protracted relapsing EAE in DA rats. *Journal of Neuropathology and Experimental Neurology* 56, 641-650.
- Doull, J., 1996. Neurotoxins. In: Klassen, C.D., Amdur, M.O., Doull, J., (Eds.), *Casarett and Doull's toxicology. The basic science of poisons*, 5<sup>th</sup> edition, McGraw-Hill Companies, Inc., New York, pp. 478.
- Dowdell, K.C., Gienapp, I.E., Stuckman, S., Wardrop, R.M., Whitacre, C.C., 1999. Neuroendocrine modulation of chronic relapsing experimental autoimmune encephalomyelitis: a critical role for the

- hypothalamic-pituitary-adrenal axis. *Journal of Neuroimmunology* 100, 243-251.
- Dowling, P.C., Bosch, V.V., Cook, S.D., 1980. Possible beneficial effect of high dose intravenous steroid therapy in acute demyelinating diseases and transverse myelitis. *Neurology* 30, 33-36.
- Drescher, K.M., Murray, P.D., Lin, X., Carlino, J.A., Rodriguez, M., 2000. TGF- $\beta$  reduces demyelination, virus antigen expression and macrophage recruitment in a viral model of multiple sclerosis. *Journal of Immunology* 164, 3207-3213.
- Drescher, K.M., Nguyen, L.T., Taneja, V., Coenen, M.J., Leibowitz, J.L., Strauss, G., Hammerling, G.J., David, C.S., Rodriguez, M., 1998. Expression of the human histocompatibility leukocyte antigen DR3 transgene reduces the severity of demyelination in a murine model of multiple sclerosis. *Journal of Clinical Investigation* 101, 1765-1774.
- Dumble, L.J., MacDonald, I.M., Kincaid-Smith, P., Clunie, G.J.A., 1981. Correlation between ADCC resistance to in vitro steroid and renal allograft failure. *Transplantation Proceedings* 13, 1569-1571.
- Durelli, L., Cocito, D., Riccio, A., Barile, C., Bergamasco, B., Baggio, G.F., Perla, F., Delsedime, M., Gusmaroli, G., Bergamini, L., 1986. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. *Neurology* 36, 238-243.
- Ebers, G.C., Kukay, K., Bulman, D.E., 1996. A full genome search in multiple sclerosis. *Nature Genetics* 13, 472-476.
- Elgart, G.W., Sheremata, W., Ahn, Y.S., 1997. Cutaneous reactions to recombinant human interferon beta-1b: the clinical and histologic spectrum. *Journal of the American Academy of Dermatology* 37, 553-558.

- Eriksson, L., Eden, S., Holst, J., Lindstedt, G., von Schoultz, B., 1989. Diurnal variations in thyrotropin, prolactin and cortisol during human pregnancy. *Gynecological and Obstetrical Investigations* 27, 78-83.
- Fallis, R.J., Raine, C.S., McFarlin, D.E., 1989. Chronic relapsing experimental allergic encephalomyelitis in SJL mice following the adoptive transfer of an epitope-specific T cell line. *Journal of Neuroimmunology* 22, 93-105.
- Fassbender, K., Schmidt, R., Mossner, R., 1998. Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: association with cerebral inflammation. *Archives of Neurology* 55, 66-72.
- Fazakerley, J.K., Pathak, S., Scallan, M., Amor, S., Dyson, H., 1993. Replication of the A7[74] strain of Semliki Forest virus is restricted to neurons. *Virology* 195, 627-637.
- Fewster M.E., Kies, B., 1984. HLA antigens in multiple sclerosis in colored south Africans. *Journal of Neurological Sciences* 66, 175-181.
- Fiette, L., Aubert, C., Müller, U., Huang, S., Aguet, M., Brahic, M., Bureau, J., 1995. Theiler's virus infection of 129Sv mice that lack the interferon  $\alpha/\beta$  or interferon  $\gamma$  receptors. *Journal of Experimental Medicine* 181, 2069-2076.
- Fiette, L., Brahic, M., Rossi, C.P., 1993. Theiler's virus infection of beta2-microglobulin-deficient mice. *Journal of Virology* 67, 589-592.
- Finkelman, F.D., Holmes, J., Katona, I.M., Urban, Jr., J.F., Beckmann, M.P., Park, L.S., Schooley, K.A., Coffmann, R.L., Mosmann, T.R., Paul, W.E., 1990. Lymphokine control of in vivo immunoglobulin isotype selection. *Annual Review of Immunology* 8, 303-333.

- Forslid, J., Hed, J., 1982. In vitro effect of hydrocortisone on the attachment and ingestion phases of immunoglobulin G- and complement component 3b-mediated phagocytosis by human neutrophils. *Infection and Immunity* 38, 811-816.
- Francis, D.A., Batchelor, J.R., McDonald, W.I., Hing, S.N., Dodi, I.A., Fielder, A.H.L., Hern, J.E.C., Downie, A.W., 1983. Multiple sclerosis in north-east Scotland. An association with HLA-Dqw1. *Brain* 110, 181-196.
- Fritz, R.B., McFarlin, D.E., 1989. Encephalitogenic epitopes of myelin basic protein. In: Sercarz, E. (Ed), *Chemical Immunology*, Karger, Basel, pp.101-125.
- Fushimi, T., Inoue, A., Koh, C., Yamazaki, M., Ishihara, Y., Kim, B.S., 1998. The effect of pentoxifylline (PTX) on Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease. *Cellular Immunology* 186, 140-146.
- Georgsson, G., Martin, J.R., Klein, J., Palsson, P.A., Nathanson, N., Petursson, G., 1982. Primary demyelination in visna. An ultrastructural study of Icelandic sheep with clinical signs following experimental infection. *Acta Neuropathology* 57, 171-178.
- Georgsson, G., Palsson, P.A., Petursson, G., 1987. Pathogenesis of visna. In: Serlupi Crescenzi, G., (Ed), *A multidisciplinary approach to myelin disease*, Plenum Publishing, New York, pp. 303-318.
- Gerety, S.J., Clatch, R.J., Lipton, H.L., Goswami, R.G., Rundell, M.K., Miller, S.D., 1991. Class II restricted T cell responses in Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease. IV. Identification of an immunodominant T cell determinant on the N-terminal end of the VP2 capsid protein in susceptible SJL/J mice. *Journal of Immunology* 46, 2401-2408.
- Gerety, S.J., Karpus, W.J., Cubbon, A.R., Goswami, R.G., Rundell, M.K.,

- Peterson, J.D., Miller, S.D., 1994. Class II restricted T cell responses in Theiler's murine encephalomyelitis virus-induced demyelinating disease. V. Mapping of a dominant immunopathologic VP2 T cell epitope in susceptible SJL/J mice. *Journal of Immunology* 152, 908-918.
- Gerety, S.J., Rundell, M.K., Dal Canto, M.C., Miller, S.D., 1994. Class II restricted T cell responses in Theiler's murine encephalomyelitis virus-induced demyelinating disease. VI. Potentiation of demyelination with and characterization of an immunopathologic CD4+ T cell line specific for an immunodominant VP2 epitope. *Journal of Immunology* 152, 919-929.
- Gilman, M., 1993. Ribonuclease protection assay. In: Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A., Stuhl, K., (Eds.), *Current Protocols in Molecular Biology*, Vol. 1, John Wiley and Sons, Inc., New York, pp. 471-478.
- Glasgow, G.M., Sheahan, B.J., Atkins, G.J., Wahlberg, J.M., Salminen, A., Liljestrom, P., 1991. Two mutations in the envelope glycoprotein E2 of SFV affecting the maturation and entry patterns of the virus alter pathogenicity for mice. *Virology* 185, 741-748.
- Goas, J.Y., Marion, J.L., Missoum, A., 1983. High dose intravenous methylprednisolone in acute exacerbations of multiple sclerosis. *Journal of Neurology Neurosurgery and Psychiatry* 46, 99.
- Godkin, J.D., Bazer, F.W., Moffatt, J., 1982. Purification and properties of a major, low molecular weight protein released by the trophoblasts of sheep blastocysts at day 13-21. *Journal of Reproduction and Fertility* 65, 141-150.
- Godkin, J.D., Bazer, F.W., Thatcher, W.W., Roberts, R.M., 1984.

- Proteins released by cultured day 15-16 conceptuses prolong luteal maintenance when introduced into the uterine lumen of cyclic ewes. *Journal of Reproduction and Fertility* 71, 57-64.
- Goldberg, I.D., Kurland, L.T., 1962. Mortality in 33 countries from diseases of the nervous system. *World Neurology* 3, 444-465.
- Gorodezky, C., Najera, R., Rangel, B.E., Castro, L.E., Flores, J., Velasquez, G., Granados, J., Sotelo, J., 1986. Immunogenetic profile of multiple sclerosis in Mexicans. *Human Immunology* 16, 364-374.
- Haines, J.L., Ter-Minassian, M., Bazyk, A., 1996. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex. The Multiple Sclerosis Genetics Group. *Nature Genetics* 13, 469-471.
- Haynes, L.M., Vanderlugt, C.L., Dal Canto, M.C., Melvold, R.W., Miller, S.D., 2000. CD8+ T cells from Theiler's virus-resistant BALB/cByJ mice downregulate pathogenic virus-specific CD4+ T cells. *Journal of Neuroimmunology* 106, 43-52.
- Hill, K.E., Pigmans, M., Fujinami, R.S., Rose, J.W., 1998. Gender variations in early Theiler's virus induced demyelinating disease: differential susceptibility and effects of IL-4, IL-10 and combined IL-4 with IL-10. *Journal of Neuroimmunology* 85, 44-51.
- Hirschberg, H., Hirschberg, T., Nousiainen, H., Braathen, L.R., Jaffe, E., 1982. The effects of corticosteroids on the antigen presenting properties of human monocytes and endothelial cells. *Clinical Immunology and Immunopathology* 23, 577-585.
- IFN- $\beta$  Multiple Sclerosis Study Group, 1993. IFN- $\beta$  1-b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multi-center, randomized, double blind, placebo controlled trial. *Neurology*, 43:655.

- Inoue, A., Koh, C., Yamazaki, H., Ichikawa, M., Isobe, M., Ishihara, Y., Yagita, H., Kim, B.S., 1997. Anti-adhesion molecule therapy in Theiler's murine encephalomyelitis virus-induced demyelinating disease. *International Immunology* 9, 1837-1847.
- Inoue, A., Koh, C., Yamazaki, H., Yagita, H., 1999. Effect of anti-B7-1 and anti-B7-2 mAb on Theiler's murine encephalomyelitis virus-induced demyelinating disease. *Journal of Immunology* 163, 6180-6186.
- Inoue, A., Koh, C., Yamazaki, M., Yahikozawa, H., Ichikawa, M., Yagita, H., Kim, B.S., 1998. Suppressive effect on Theiler's murine encephalomyelitis virus-induced demyelinating disease by the administration of anti-IL-12 antibody. *Journal of Immunology* 161, 5586-5593.
- Inoue, A., Koh, C., Yanagisawa, N., Taketomi, T., Ishihara, Y., 1996. Suppression of Theiler's murine encephalomyelitis virus-induced demyelinating disease by administration of gangliosides. *Journal of Neuroimmunology* 64, 45-53.
- Issazadeh, S., Lorentzen, J.C., Mustafa, M.I., Höjeberg, B., Müssener, Å., Olsson, T., 1996. Cytokines in relapsing experimental autoimmune encephalomyelitis in DA rats: persistent mRNA expression of pro-inflammatory cytokines and absent expression of interleukin-10 and transforming growth factor-β. *Journal of Neuroimmunology* 69, 103-115.
- Jacobs, L.D., Cookfair, D.L., Rudick, R.A., 1996. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. *Annals of Neurology* 39, 285-294.
- Johnson, G.A., Austin, K.J., Van Kirk, E.A., Hansen, T.R., 1998.

- Pregnancy and interferon-tau induce conjugation of bovine ubiquitin cross-reactive protein to cytosolic uterine proteins. *Biology of Reproduction* 58, 898-904.
- Johnson, J.A., Hochkeppel, H., Gangemi, J.D., 1999. IFN- $\tau$  exhibits potent suppression of human papillomavirus E6/E7 oncoprotein expression. *Journal of Interferon and Cytokine Research* 19, 1107-1116.
- Juste, R.A., Ott, T.L., Kwang, J., Bazer, F.W., de la Concha-Bermejillo, A., 2000. Effects of recombinant ovine interferon- $\tau$  on ovine lentivirus replication and progression of disease. *Journal of General Virology* 81, 525-532.
- Kappel, C.A., Melvold, R.W., Kim, B.S., 1990. Influence of sex on susceptibility in the Theiler's murine encephalomyelitis virus model for multiple sclerosis. *Journal of Neuroimmunology* 29, 15-19.
- Karpus, W.J., Pope, J.G., Peterson, J.D., Dal Canto, M.C., Miller, S.D., 1995. Inhibition of Theiler's virus-mediated demyelination by peripheral immune tolerance induction. *Journal of Immunology* 155, 947-957.
- Kauppila, A., Cantell, K., Janne, O., Kokko, E., Vihko, R., 1982. Serum sex steroid and peptide hormone concentrations, and endometrial estrogen and progestin receptor levels during administration of human leukocyte interferon. *International Journal of Cancer* 29, 291-294.
- Ke, Y., Kapp, J.A., 1996. Oral antigen inhibits priming of CD8 $^{+}$  CTL, CD4 $^{+}$  T-cells, and antibody responses while activating CD8 $^{+}$  suppressor T-cells. *Journal of Immunology* 156, 916-921.
- Koh, C., Inoue, A., Yamazaki, M., Kim, B.S., 2000. High-dose mediated

- immunoglobulin G administration suppresses Theiler's murine encephalomyelitis virus-induced demyelinating disease. *Journal of Neuroimmunology* 108, 22-28.
- Kolstad, A., Hannestad, K., Vandvik, B., Vartdal, F., 1989. Multiple sclerosis patients have a high frequency of an HLA-DQ $\beta$  epitope defined by a human-human hybridoma antibody. *Tissue Antigens* 33, 546-549.
- Koolen, M.J.M., Osterhaus, A.D.M.E., van Steenis, G., Horzinek, M.C., van der Zeijst, B.A.M., 1983. Temperature-sensitive mutants of mouse hepatitis virus strain A59: isolation, characterization, and neuropathogenic properties. *Virology* 125, 393-402.
- Kuchroo, V.K., Sobel, R.A., Laning, J.C., Martian, C.A., Greenfield, E., Dorf, M.E., Lees, M.B., 1992. Experimental allergic encephalomyelitis by cloned T-cells specific for a synthetic peptide of myelin proteolipid protein: fine specificity and T-cell receptor Vb usage. *Journal of Immunology* 148, 3776-3782.
- Kurtzke, J.F., 1980. Epidemiologic contributions to multiple sclerosis: an overview. *Neurology (NY)* 30(suppl 2), 61-79.
- Kurtzke, J.F., 1993. Epidemiologic evidence for multiple sclerosis as an infection. *Clinical Microbiology Reviews* 6, 382-427.
- Lahita, R.G., 1992. The effects of sex hormones on the immune system in pregnancy. *American Journal of Reproductive Immunology* 28, 136-137.
- Lahita, R.G., Bradlow, H.L., Kunkel, H.G., Fishman, J., 1981. Increased 16 $\alpha$ -hydroxylation of estradiol in systemic lupus erythematosus. *Journal of Clinical Endocrinology and Metabolism* 53, 174-178.
- Lai, M.M.C., Stohlman, S.A., 1978. RNA of mouse hepatitis virus. *Journal of Virology* 26, 236-242.
- LaMantia, L., Eoli, E., Milanese, C., Salmaggi, A., Dufour, A., Torri, V.,

1994. Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses. European Neurology 34, 199-203.
- Lin, X., Pease, L.R., Murray, P.D., Rodriguez, M., 1998. Theiler's virus infection of genetically susceptible mice induces central nervous system-infiltrating CTLs with no apparent viral or major myelin antigenic specificity. Journal of Immunology 160, 5661-5668.
- Lindsey, M.D., Thiemann, R., Rodriguez, M., 1991. Cytotoxic T cells isolated from the central nervous system of mice infected with Theiler's virus. Journal of Virology 65, 6612-6620.
- Lipton, H.L., 1975. Theiler's virus infection in mice: An unusual biphasic disease process leading to demyelination. Infective Immunology 11, 1147-1155.
- Lipton, H.L., 1978. Characterization of the TO strains of Theiler's mouse encephalomyelitis virus. Infection and Immunity 20, 869-872.
- Lipton, H.L., 1980. Persistent Theiler's murine encephalomyelitis virus infection in mice depends on plaque size. Journal of General Virology 46, 169-177.
- Lipton, H.L., 1994. Theiler's murine encephalomyelitis virus: animal models. In: McKendall, R.R., Stroop, W.G. (Eds.) Handbook of Neurovirology, Marcell Dekker, New York, pp.521-528.
- Lipton, H.L., Calenoff, M., Bandyopadhyay, P., Miller, S.D., Dal Canto, M.C., Garety, S., Jensen, K., 1991. The 5' noncoding sequences from a less virulent Theiler's virus dramatically attenuate GDVII neurovirulence. Journal of Virology 65, 4370-4377.
- Lipton, H.L., Dal Canto, M.C., 1976. Theiler's virus-induced demyelination: prevention by immunosuppression. Science 192, 62-64.
- Lipton, H.L., Dal Canto, M.C., 1979. Susceptibility of inbred mice to

- chronic central nervous system infection by Theiler's murine encephalomyelitis virus. *Infection and Immunity* 26, 369-374.
- Lipton, H.L., Melvold, R., Miller, S.D., Dal Canto, M.C., 1995. Mutation of a major histocompatibility class I locus, H-2D, leads to an increased virus burden and disease susceptibility in Theiler's virus-induced demyelinating disease. *Journal of NeuroVirology* 1, 138-144.
- Lipton, H.L., Pritchard, A.E., Calenoff, M.A., 1998. Attenuation of neurovirulence of Theiler's murine encephalomyelitis virus strain GDVII is not sufficient to establish persistence in the central nervous system. *Journal of General Virology* 79, 1001-1004.
- Lowry, O.H., Rosebrough, N.J., Farr, A.L., Randall, R.J., 1951. Protein measurement with the folin phenol reagent. *Journal of Biological Chemistry* 193, 265-275.
- Lublin, F.D., Reingold, S.C., 1996. Defining the clinical course of multiple sclerosis: results of an international survey. *Neurology* 46, 907-911.
- Lublin, F.D., Whitaker, J.N., Eidelberg, B.H., Miller, A.E., Arnason, B.G.W., Burks, J.S., 1996. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. *Neurology* 46, 12-18.
- Lucchinetti, C.F., Brück, W., Parisi, J., Scheithauer, B., Rodriguez, M., Lassmann, H., 2000. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. *Annals of Neurology* 47, 707-717.
- Lucchinetti, C.F., Rodriguez, M., 1997. The controversy surrounding the pathogenesis of the multiple sclerosis lesion. *Mayo Clinic Proceedings* 72, 665-678.
- Ludwin, S.K., 1997. The pathobiology of the oligodendrocyte. *Journal of*

- Neuropathology and Experimental Neurology 56, 111-124.
- Maki, D.V.J., Bankhurst, A.D., Sanchez, M.E., McLaren, L.C., 1980. Modulation of the adherence of human lymphocytes to measles-infected cells by corticosteroids. Cellular Immunology 52, 350-358.
- Maliszewski, C., Gallis, B., Baker, P.E., 1990. The molecular biology of large animal cytokines. Advances in Veterinary Science and Comparative Medicine 35, 181-313.
- Manetti, R., Gersoa, F., Giudizi, M.G., Biagiotti, R., Paronchi, P., Sampognaro, S., Maggi, E., Romagnani, S., Trinchieri, 1994. Interleukin-12 induces stable priming for interferon- $\gamma$  (IFN- $\gamma$ ) production during differentiation of human T helper (Th) cells and transient IFN- $\gamma$  production in established cell clones. Journal of Experimental Medicine 179, 1273-1279.
- Marcadet, A., Massart, C., Semana, G., Fauchet, R., Sabouraud, O., Merienne, M., Dausset, J., Cohen, D., 1985. Association of class II HLA-Dq $\beta$  chain DNA restriction fragments with multiple sclerosis. Immunogenetics 22, 93-96.
- Martin, R., McFarland, H.F., 1995. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Critical Reviews of Clinical Laboratory Science 32, 121-182.
- Massey, E.W., Schoenberg, B.S., 1982. International patterns of mortality from multiple sclerosis. Neuroepidemiology 1, 189-196.
- McCarron, R., McFarlin, D.E., 1988. Adoptively transferred experimental autoimmune encephalomyelitis in SJL/j, PL/j and (SJL/j x PL/j) F1 mice: influence of I-A haplotype on encephalitogenic epitope of myelin basic protein. Journal of Immunology 141, 1143-1149.
- McDonald, W.I., 1984. Multiple sclerosis: epidemiology and HLA associations. Annals of NY Academy of Sciences 436, 109-117.

- McGavern, D.B., Murray, P.D., Rivera-Quinones, C., Schmelzer, J.D., Low, P.A., Rodriguez, M., 2000. Axonal loss results in spinal cord atrophy, electrophysiological abnormalities and neurological deficits following demyelination in a chronic inflammatory model of multiple sclerosis. *Brain* 123, 519-531.
- Mehta, C.L., Tyler, R.J., Cripps, D.J., 1998. Granulomatous dermatitis with focal sarcoidal features associated with recombinant interferon  $\beta$ -1b injections. *Journal of the American Academy of Dermatology* 39, 1024-1028.
- Meyer, A.L., Benson, J.M., Gienapp, I.E., Cox, K.L., Whitacre, C.C., 1996. Suppression of murine chronic relapsing experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. *Journal of Immunology* 157, 4230-4238.
- Millar, J.H.D., Belf, M.D., Vas, C.J., Noronha, M.J., Liversedge, L.A., Rawson, M.D., 1967. Long-term treatment of multiple sclerosis with corticotrophin. *Lancet* 2, 429-431.
- Miller, S.D., Gerety, S.J., 1990. Immunologic aspects of Theiler's murine encephalomyelitis virus (TMEV)-induced demyelination. *Semin. Virol.* 1, 263-272.
- Miller, S.D., Rivera-Quinones, C., Njenga, M.K., Leibowitz, J., Rodriguez, M., 1995. Spontaneous CNS remyelination in  $\beta_2$  microglobulin-deficient mice following virus-induced demyelination. *Journal of Neuroscience* 15, 8345-8352.
- Miller, S.D., Vanderlugt, C.L., Begolka, W.S., Pao, W., Yauch, R.L., Neville, K.L., Katz-Levy, Y., Carrizosa, A., Kim B.S., 1997. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. *Nature Medicine* 3, 1133-1136.
- Milligan, N.M., Newcombe, R., Compston, D.A.S., 1987. A double-blind

- controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. *Journal of Neurology Neurosurgery and Psychiatry* 50, 511-516.
- Mohr, D.C., Goodkin, D.E., Gatto, N., Van Der Wende, J., 1997. Depression, coping, and level of neurological impairment in multiple sclerosis. *Multiple Sclerosis* 3, 254-258.
- Mohr, D.C., Goodkin, D.E., Likosky, W., Gatto, N., Neilley, L.K., Griffin, C., Stiebling, B., 1996. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment. *Multiple Sclerosis* 2, 222-226.
- Mohr, D.C., Likosky, W., Dwyer, P., Van Der Wende, Boudewyn, A.C., Goodkin, D.E., 1999. Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis. *Archives of Neurology* 56, 1263-1265.
- Mosmann, T.R., Coffman, R.L., 1989. Th1 and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties. *Annual Review of Immunology* 7, 145-173.
- Mujtaba, M.G., Soos, J.M., Johnson, H.M., 1997. CD4 T suppressor cells mediate interferon tau protection against experimental allergic encephalomyelitis. *Journal of Neuroimmunology* 75, 35-42.
- Mujtaba, M.G., Streit, W.J., Johnson, H.M., 1998. IFN- $\tau$  suppresses both the autoreactive humoral and cellular immune responses and induces stable remission in mice with chronic experimental allergic encephalomyelitis. *Cellular Immunology* 186, 94-102.
- Murray, P.D., McGavern, D.B., Lin, X., Njenga, M.K., Leibowitz, J., Pease, L.R., Rodriguez, M., 1998. Perforin-dependent neurologic injury in a viral model of multiple sclerosis. *Journal of Neuroscience* 18, 7306-7314.

- Murray, P.D., Pavelko, K.D., Leibowitz, J., Lin, X., Rodriguez, M., 1998. CD4+ and CD8+ T cells make discrete contributions to demyelination and neurologic disease in a viral model of multiple sclerosis. *Journal of Virology* 72, 7320-7329.
- Nair, M.P.N., Schwartz, S.A., 1984. Immunomodulatory effects of corticosteroids on natural killer and antibody-dependent cellular cytotoxic activities of human lymphocytes. *Journal of Immunology* 132, 2876-2882.
- Newman, P.K., Saunders, M., Tilley, P.J.B., 1983. Methylprednisolone therapy in multiple sclerosis. *Journal of Neurology Neurosurgery and Psychiatry* 46, 941-942.
- Newton, G.R., Vallet, J.L., Hansen, P.J., Bazer, F.W., 1989. Inhibition of lymphocyte proliferation by ovine trophoblast protein-1 and a high molecular weight glycoprotein produced by the peri-implantation sheep conceptus. *American Journal of Reproductive Immunology* 19, 99-107.
- Nicholoson, S.M., Peterson, J.D., Miller, S.D., Dal Canto, Melvold, R.W., 1994. BALB/c substrain differences in susceptibility to Theiler's murine encephalomyelitis virus-induced demyelinating disease. *Journal of Neuroimmunology* 52, 19-24.
- Nicholoson, S.M., Wang, K., Dal Canto, M.C., Miller, S.D., Melvold, R.W., 1996. Adoptively transferred CD8+ T lymphocytes provide protection against TMEV-induced demyelinating disease in BALB/c mice. *Journal of Immunology* 156, 1276-1283.
- Niwano, Y., Hansen, T.R., Kazemi, M., Malathy, P.V., Johnson, H.D., Roberts, R.M., Imakawa, K., 1989. Suppression of T-lymphocyte blastogenesis by ovine trophoblast protein-1 and human interferon-alpha may be independent of interleukin-2 production. *American Journal of Reproductive Immunology* 20, 21-26.

- Njenga, M.K., Coenen, M.J., DeCuir, N., Yeh, H., Rodriguez, M., 2000. Short-term treatment with interferon- $\alpha/\beta$  promotes remyelination, whereas long-term treatment aggravates demyelination in a murine model of multiple sclerosis. *Journal of Neuroscience Research* 59, 661-670.
- Njenga, M.K., Pease, L.R., Wettstein, P., Mak, T., Rodriguez, M., 1997. Interferon  $\alpha/\beta$  mediates early virus-induced expression of H-2D and H2-K in the central nervous system. *Laboratory Investigation* 77, 71-84.
- Noronha, A., Toscas, A., Jensen, M.A., 1993. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. *Journal of Neuroimmunology* 46, 145-154.
- Norrby, E., Oxman, M.N., 1990. Measles virus. In: Fields, B.N., Knipe, D.M. (Eds.), *Fields virology*, Raven Press, New York, pp. 1013-1044.
- Okuda, Y., Nakatsuji, Y., Fujimura, H., Esumi, H., Ogura, T., Yanagihara, T., Sakoda, S., 1995. Expression of the inducible isoform of nitric oxide synthase in the central nervous system of mice correlates with the severity of actively induced experimental allergic encephalomyelitis. *Journal of Neuroimmunology* 62, 103-112.
- Olsson, T., 1994. Cerebrospinal fluid. *Annuals of Neurology* 36, s100-s102.
- Olsson, T., 1995. Critical influences of cytokine orchestration on the outcome of myelin antigen-specific T-cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis. *Immunological Reviews* 144, 245-268.
- Olsson, T., Zhi, W.W., Hojeberg, B., Kostulas, V., Yu-Ping, J., Anderson,

- G., Ekre, H.P., Link, H., 1990. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon- $\gamma$ . *Journal of Clinical Investigation* 86, 981-985.
- Ott, T.L., Fleming, J.G., Spencer, T.E., Joyce, M.M., Chen, P., Green, C.N., Zhu, D., Welsh, T.H. Jr, Harms, P.G., Bazer, F.W., 1997. Effects of exogenous recombinant ovine interferon tau on circulating concentrations of progesterone, cortisol, luteinizing hormone, and antiviral activity; interestrous interval; rectal temperature; and uterine response to oxytocin in cyclic ewes. *Biology of Reproduction* 57, 621-629.
- Ott, T.L., Van Heeke, G., Johnson, H.M., Bazer, F.W., 1991. Cloning and expression in *Saccharomyces cerevisiae* of a synthetic gene for the type-1 trophoblast interferon ovine trophoblast protein-1: purification and antiviral activity. *Journal of Interferon Research* 11, 357-364.
- Panitch, H.S., Hirsch, R.L., Schindler, J., Johnson, K.P., 1987. Treatment of multiple sclerosis with  $\gamma$  interferon: exacerbations associated with activation of the immune system. *Neurology* 37, 1097-1102.
- Pasick, J.M., Dales, S., 1991. Infection by coronavirus JHM of rat neurons and oligodendrocyte-type-2 astrocyte lineage cells during distinct developmental stages. *Journal of Virology* 65, 5013-5028.
- Patick, A.K., Pease, L.R., David, C.S., Rodriguez, M., 1990. Major histocompatibility complex-conferred resistance to Theiler's virus-induced demyelinating disease is inherited as a dominant trait in B10 congenic mice. *Journal of Virology* 64, 5570-5576.
- Paty, D.W., Li, D.K.B., the UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group., 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis

- results of a multicenter, randomized, double-blind, placebo-controlled trial. *Neurology* 43, 662-667.
- Pavelko, K.D., Drescher, K.M., McGavern, D.B., David, C.S., Rodriguez, M., 2000. HLA-DQ polymorphism influences progression of demyelination and neurologic deficits in a viral model of multiple sclerosis. *Molecular and Cellular Neuroscience* 15, 495-509.
- Pavelko, K.D., van Engelen, B.G.M., Rodriguez, M., 1998. Acceleration in the rate of CNS remyelination in lysolecithin-induced demyelination. *Journal of Neuroscience* 18, 2498-2505.
- Pettinelli, C.B., McFarlin, D.E., 1981. Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: Requirement for Lyt 1<sup>+</sup> 2<sup>-</sup> T lymphocytes. *Journal of Immunology* 127, 1420-1423.
- Petursson, G., Nathanson, N., Georgsson, G., Panitch, H., Palsson, P.A. 1976. Pathogenesis of visna I. Sequential virologic, serologic, and pathologic studies. *Laboratory Investigations* 35, 402-412.
- Pevear, D.C., Calenoff, M., Rozhon, E., Lipton, H.L., 1987. Analysis of the complete nucleotide sequence of the picornavirus Theiler's murine encephalomyelitis virus indicates that it is closely related to cardioviruses. *Journal of Virology* 61, 1507-1516.
- Pontzer, C.H., Yamamoto, J.K., Bazer, F.B., Ott, T.L., Johnson, H.M., 1997. Potent anti-feline immunodeficiency virus and anti-human immunodeficiency virus effect of interferon-tau. *Journal of Immunology* 158, 4351-4357.
- Poser, S., Poser, W., 1983. Multiple sclerosis and gestation. *Neurology* 33, 1422-1427.
- Prineas, J.W., Raine, C.S., 1976. Electron microscopy and immunoperoxidase studies of early multiple sclerosis lesions. *Neurology* 26, 29-32.

- Prineas, J.W., Wright, R.G., 1978. Macrophages, lymphocytes and plasma cells in the perivascular compartment in chronic multiple sclerosis. *Laboratory Investigation* 38, 409-421.
- PRISMS (Prevention of Relapses and Disability by Interferon  $\beta$ -1a Subcutaneously in Multiple Sclerosis) Study Group, 1998. Randomised double-blind placebo-controlled study of interferon  $\beta$ -1a in relapsing/remitting multiple sclerosis. *Lancet* 352, 1498-1504.
- Pritchard, A.E., Jensen, K., Lipton, H.L., 1993. Assembly of Theiler's virus recombinants used in mapping determinants of neurovirulence. *Journal of Virology* 67, 3901-3907.
- Pullen, L.C., Kim, B.S., 1991. Identification of a suitable target cell line for Theiler's murine encephalomyelitis virus specific CTL. *FASEB Journal* 75, 150.
- Pullen, L.C., Miller, S.D., Dal Canto, M.C., Van der Meide, P.H., Kim, B.S., 1994. Alteration in the level of interferon- $\gamma$  results in acceleration of Theiler's virus-induced demyelinating disease. *Journal of Neuroimmunology* 55, 143-152.
- Pyper, J.M., Clements, J.E., Molineaux, S.M., Narayan O., 1984. Genetic variation among lentiviruses: homology between visna virus and caprine arthritis-encephalitis virus is confined to the 5' gag-pol region and a small portion of the env gene. *Journal of Virology* 51, 713-721.
- Raghupathy, R., 1997. Th1-type immunity is incompatible with successful pregnancy. *Immunology Today* 18, 478-482.
- Renno, T., Lin, J., Piccirillo, C., Antel, J., Owens, T., 1994. Cytokine production by cells in cerebrospinal fluid during experimental allergic encephalomyelitis in SJL/J mice. *Journal of Neuroimmunology* 49, 1-7.

- Rhodes, J., Ivanyi, J., Cozens, P., 1986. Antigen presentation by human monocytes: effects of modifying major histocompatibility complex class II antigen expression and interleukin I production by using recombinant interferons and corticosteroids. European Journal of Immunology 16, 370-375.
- Rinehart, J.J., Wuest, D., Ackerman, G.A., 1982. Corticosteroid alteration of human monocyte to macrophage differentiation. Journal of Immunology 129, 1436-1440.
- Rivera-Quinones, C., McGavern, D., Schmelzer, J.D., Hunter, S.F., Low, P.A., Rodriguez, M., 1998. Absence of neurological deficits following extensive demyelination in a class I-deficient murine model of multiple sclerosis. Nature Medicine 4, 187-193.
- Roberts, R.M., Cross, J.C., Leaman, D.W., 1992. Interferons as hormones of pregnancy. Endocrine Reviews 13, 432-452.
- Rodriguez, M., David, C.S., 1985. Demyelination induced by Theiler's virus: influence of the H-2 haplotype. Journal of Immunology 135, 2145-2148.
- Rodriguez, M.A., De Sanctis, J.B., Blasini, A.M., Leon-Ponte, M., Abadi, I., 1990. Human IFN-gamma up-regulates IL-2 receptors in mitogen-activated T lymphocytes. Immunology 69, 554-557
- Rodriguez, M., Lafuse, W.P., Leibowitz, J., David, C.S., 1986. Partial suppression of Theiler's virus-induced demyelination in vivo by administration of monoclonal antibodies to immune-response gene products (Ia antigens). Neurology 36, 964-970.
- Rodriguez, M., Leibowitz, J., Lampert, P.W., 1983. Persistent infection of oligodendrocytes in Theiler's virus-induced encephalomyelitis. Annals of Neurology 13, 426-433.
- Rodriguez, M., Leibowitz, J., Powell, H.C., Lampert, P.W., 1983. Neonatal

- infection with the Daniels strain of Theiler's murine encephalomyelitis virus. *Laboratory Investigation* 49, 672-679.
- Rodriguez, M., Lindsley, M.D., 1992. Immunosuppression promotes CNS remyelination in chronic virus-induced demyelinating disease. *Neurology* 42, 348-357.
- Rodriguez, M., Lindsley, M.D., Pierce, M.L., 1991. Role of T cells in resistance to Theiler's virus infection. *Microbial Pathogenesis* 11, 269-281.
- Rodriguez, M., Pavelko, K., Coffman, R.L., 1995. Gamma interferon is critical for resistance to Theiler's virus-induced demyelination. *Journal of Virology* 69, 7286-7290.
- Roos, R.P., Firestone, S., Wollmann, R., Variakojis, D., Arnason, B.G., 1982. The effect of short-term and chronic immunosuppression on Theiler's virus demyelination. *Journal of Neuroimmunology* 2, 223-234.
- Rose, J., 1994. Pathogenesis of viral immune-mediated syndromes. In: McK Kendall, R.R., Stroop, W.G. (Eds.), *Handbook of Neurovirology*, Marcell Dekker, New York, pp. 95-102.
- Rosenthal, A., Fujinami, R.S., Lampert, P.W., 1986. Mechanism of Theiler's virus-induced demyelination in nude mice. *Laboratory Investigation* 54, 515-522.
- Rossi, C.P., Delcroix, M., Huitinga, I., McAllister, A., van Rooijen, N., Claassen, E., Brahic, M., 1997. Role of macrophages during Theiler's virus infection. *Journal of Virology* 71, 3336-3340.
- Roulet, E., Verdier-Taillefer, M-H., Amarenco, P., Gharbi, G., Alperovitch, A., Marteau, R., 1993. Pregnancy and multiple sclerosis: a longitudinal study of 125 remittent patients. *Journal of Neurology, Neurosurgery, and Psychiatry* 56, 1062-1065.
- Rueckert, R.R. Pallansch, M.A., 1981. Preparation and characterization

- of encephalomyocarditis (EMC) virus. *Methods in Enzymology* 78, 315-325.
- Sambrook, P.N., Eisman, J.A., Champion, G.D., Pocock, N.A., 1988. Sex hormone status and osteoporosis in postmenopausal women with rheumatoid arthritis. *Arthritis and Rheumatism* 31, 973-978.
- Sapatin, B.V., Petrescu, A.D., Rosenbaum, B.A., Smith, R. 3<sup>rd</sup>, Piedrahita, J.A., Welsh C.J.R., 1995. Characteristics of cloned cerebrovascular endothelial cells following infection with Theiler's virus. II. Persistent infection. *Journal of Neuroimmunology*, 62, 127-135.
- Sato, S., Reiner, S.L., Jensen, M.A., Roos, R.P., 1997. Central nervous system cytokine mRNA expression following Theiler's murine encephalomyelitis virus infection. *Journal of Neuroimmunology* 76, 213-223.
- Satoh, J., Koike, F., Tabira, T., 1988. Experimental allergic encephalomyelitis mediated by murine encephalitogenic T-cell lines specific for myelin proteolipid apoprotein. *Annals New York Academy of Sciences* 540, 343-344.
- Sawcer, S., Jones, H.B., Feakes, R., Gray, J., Smaldon, N., Chataway, J., Robertson, N., Clayton, D., Goodfellow, P.N., Compston, A., 1996. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. *Nature Genetics* 13, 464-469.
- Seder, R.A., Le Gros, G.G., 1995. The functional role of CD8+ T helper type 2 cells. *Journal of Experimental Medicine* 181, 5-7.
- Shoenfeld, Y., Schwartz, R.S., 1984. Immunologic and genetic factors in autoimmune diseases. *New England Journal of Medicine* 311, 1019-1029.
- Siiteri, P.K., Febres, F., Clemens, L.E., Chang, R.J., Gondos, B., Stites,

- D., 1977. Progesterone and maintenance of pregnancy: Is progesterone nature's immunosuppressant? *Annals New York Academy of Sciences* 286, 384-396.
- Skopets, B., Li, J., Thatcher, W.W., Roberts, R.M., Hansen, P.J., 1992. Inhibition of lymphocyte proliferation by bovine trophoblast protein-1(Type I trophoblast interferon) and bovine interferon- $\alpha_1$  (or alpha<sub>1</sub>). *Veterinary Immunology and Immunopathology* 34, 81-96.
- Slavin, A., Ewing, C., Liu, J., Ichikawa, M., Slavin, J., Bernard, C.C., 1998. Induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein. *Autoimmunity* 28, 109-120.
- Smyth, J.M.B., Sheahan, B.J., Atkins, G.J., 1990. Multiplication of virulent and demyelinating Semliki Forest virus in the mouse central nervous system: consequences in BALB/c and SJL mice. *Journal of General Virology* 71, 2575-2583.
- Soos, J.M., Johnson, H.M., 1995. Type I interferon inhibition of superantigen stimulation: implications for treatment of superantigen-associated disease. *Journal of Interferon and Cytokine Research* 15, 39-45.
- Soos, J.M., Subramaniam, P.S., Hobeika, A.C., Schiffenbauer, A., Johnson, H.M., 1995. The IFN pregnancy recognition hormone INF-tau blocks both development and superantigen reactivation of experimental allergic encephalomyelitis without associated toxicity. *Journal of Immunology* 155, 2747-2753.
- Soos, J.M., Mujtaba, M.G., Subramaniam, P.S., Streit, W.J., Johnson, H.M., 1997. Oral feeding of interferon  $\tau$  can prevent the acute and chronic relapsing forms of experimental allergic encephalomyelitis. *Journal of Neuroimmunology* 75, 43-50.

- Spencer, T.E., Bazer, F.W., 1996. Ovine interferon tau suppresses transcription of the estrogen receptor and oxytocin receptor genes in the ovine endometrium. *Endocrinology* 137, 1144-1147.
- Sriram, S., Stewart, G.J., Buhler, M., Grumet, C., Engleman, E., 1985. HLA-DR antigens in multiple sclerosis: two-dimensional gel electrophoresis. *Neurology* 35, 248-251.
- Stewart, H.J., McCann, S.H.E., Northrop, A.J., Lamming, G.E., Flint, A.P.F., 1989. Sheep antiluteolytic interferon: cDNA sequence and analysis of mRNA levels. *Journal of Molecular Endocrinology* 2, 65-70.
- Stuve, O., Dooley, N.P., Uhm, J.H., Antel, J.P., Francis, G.S., Williams, G. and Yong, V.W., 1996. Interferon  $\beta$ -1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase. *Annals of Neurology* 40, 853-863.
- Subak-Sharpe, I., Dyson, H., Fazakerley, J.K., 1993. In vivo depletion of CD8+ T cells prevents lesions of demyelination in Semliki Forest virus infection. *Journal of Virology* 67, 7629-7633.
- Summers, B.A., Appel, M.J., 1987. Demyelination in canine distemper encephalomyelitis: an ultrastructural analysis. *Journal of Neurocytology* 16, 871-881.
- Tafuri, A., Alferink, J., Moller, P., Hammerling, G.J., Arnold, B., 1995. T cell awareness of paternal alloantigens during pregnancy. *Science* 270, 630-633.
- Taguchi, F., Goto, Y., Aiuchi, M., Hayashi, T., Fujiwara, K., 1979. Pathogenesis of mouse hepatitis virus infection. The role of nasal epithelial cells as a primary target of low-virulence virus. MHV-S. *Microbiology and Immunology* 23, 249-262.
- Tennakoon, D.K., Smith, R., Stewart, M.D., Spencer, T.E., Nayak, M.,

- Welsh, C.J.R., 2001. Ovine IFN-tau modulates the expression of MHC antigens on murine cerebrovascular endothelial cells and inhibits replication of Theiler's virus. *Journal of Interferon and Cytokine research* (in press).
- Theil, D.J., Tsundoa, I., Libbey, J.E., Derfuss, T.J., Fujinami, R.S., 2000. Alterations in cytokine but not chemokine mRNA expression during three distinct Theiler's virus infections. *Journal of Neuroimmunology* 104, 22-30.
- Thompson, A.J., Kennard, C., Swash, N., Summers, B., Yuill, G.M., Shepard, D.I., Roche, S., Perkin, G.D., Loizou, L.A., Ferner, R., Hughes, R.A.C., Thompson, M., Hand, J., 1989. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. *Neurology* 39, 969-971.
- Thompson, D.S., Nelson, L.M., Burns, A., Burks, J.S., Franklin, G.M., 1986. The effects of pregnancy in multiple sclerosis: a retrospective study. *Neurology* 36, 1097-1099.
- Tourbah, A., Linnington, C., Bachelin, C., Avellana-Adalid, V., Wekerle, H., Baron-Van Evercooren, A., 1997. Inflammation promotes the survival and migration of the CG4 oligodendrocyte progenitors transplanted in the spinal cord of both inflammatory and demyelinated EAE rats. *Journal of Neuroscience Research* 50, 1-9.
- Tourtellottee, W.W., Haerer, A.F., 1965. Use of oral corticosteroid in the treatment of multiple sclerosis. A double-blind study. *Archives of Neurology* 12, 536-545.
- Trapp, B.D., Peterson, J., Ransohoff, R.M., Rudick, R., Mork, S., Bo, L., 1998. Axonal transection in the lesions of multiple sclerosis. *The New England Journal of Medicine* 338, 278-85.
- Trotter, J.L., Clark, H.B., Collins, K.G., Wegeschiede, C.L., Scarpellini,

- J.D., 1987. Myelin proteolipid protein induces demyelinating disease in mice. *Journal of the Neurological Sciences* 79, 173-188.
- Trowsdale, J., 1995. Both man and bird and beast: comparative organization of MHC genes. *Immunogenetics* 41, 1-17.
- Tsunoda, I., Fujinami, R.S., 1996. Two models for multiple sclerosis: experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis virus. *Journal of Neuropathology and Experimental Neurology* 55, 673-686.
- Tuo, W., Ott, T.L., Bazer, F.W., 1993. Natural killer cell activity of lymphocytes exposed to ovine, type I, trophoblast interferon. *American Journal of Reproductive Immunology* 29, 26-34.
- Vallet, J.L., Lamming, G.E., 1991. Ovine conceptus secretory proteins and bovine recombinant interferon  $\alpha_1$ -1 decrease endometrial oxytocin receptor concentrations in cyclic and progesterone-treated ovariectomized ewes. *Journal of Endocrinology* 131, 475-482.
- Van den Broek, M.F., Müller, U., Huang, S., Zinkernagel, R.M., Aguet, M., 1995. Immune defence in mice lacking type I and/or type II interferon receptors. *Immunological Reviews* 148, 5-18.
- Van der Veen, R.C., Stohlman, S.A., 1993. Encephalitogenic Th1 cells are inhibited by Th2 cells with related peptide specificity: Relative roles of interleukin(IL)-4 and IL-10. *Journal of Neuroimmunology* 48, 213-220.
- Vanguri, P., Shin, M.L., 1988. Hydrolysis of myelin basic protein in human myelin by terminal complement complexes. *Journal of Biological Chemistry* 263, 7228-7234.
- Van Lambalgen, R., Sanders, E.A.C.M., D'Amaro, J., 1986. Sex distribution, age of onset and HLA profiles in two types of multiple sclerosis. A role for sex hormones and microbial infections in the

- development of autoimmunity? *Journal of Neurological Sciences* 76, 13-21.
- Vial, T., Descotes, J., 1994. Clinical toxicity of the interferons. *Drug Safety* 10, 115-150.
- Vigne, R., Neuveut, C., Sire, J., Philippon, V., Filippi, P., 1994. Involvement of viral regulatory gene products in the pathogenesis of lentivirus infections. *Annals New York Academy of Sciences* 724, 107-124.
- Voskuhl, R.R., Martin, R., Bergman, C., Dalal, M., Ruddle, N.H., McFarland, H.F., 1993. T helper 1 (Th1) functional phenotype of human myelin basic protein-specific T lymphocytes. *Autoimmunity* 15(2), 137-143.
- Voskuhl, R.R., Pitchekian-Halabi, H., MacKenzie-Graham, A., McFarland, H.F., Raine, C.S., 1996. Gender differences in autoimmune demyelination in the mouse: Implications for multiple sclerosis. *Annals of Neurology* 39, 724-733.
- Wang, L.Y., Theil, D.J., Whitton, J.L., Fujinami, R.S., 1999. Infection with a recombinant vaccinia virus encoding myelin proteolipid protein causes suppression of chronic relapsing-remitting experimental allergic encephalomyelitis. *Journal of Neuroimmunology* 96, 148-157.
- Warren, K.G., Catz, I., 1993. Autoantibodies to myelin basic protein within multiple sclerosis central nervous system tissue. *Journal of the Neurological Sciences* 115, 169-176.
- Warren, K.G., Catz, I., 1994. Relative frequency of autoantibodies to myelin basic protein and proteolipid protein in optic neuritis and multiple sclerosis cerebrospinal fluid. *Journal of the Neurological Sciences* 121, 66-73.
- Wegmann, T.G., Lin, H., Guilbert, L., Mosmann, T.R., 1993. Bi-

- directional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a Th2 phenomenon? *Immunology Today* 14, 353-6.
- Weinshenker, B.G., Hader, W., Carriere, W., Baskerville, J., Ebers, G.C., 1989. The influence of pregnancy on disability from multiple sclerosis: a population-based study in Middlesex County, Ontario. *Neurology* 39, 1438-1440.
- Weissmann, G., Smolen, J.E., Korchak, H.M., 1980. Release of inflammatory mediators from stimulated neutrophils. *New England Journal of Medicine* 303, 27-34.
- Welsh, C.J.R., Sapatino, B., Rosenbaum, B., Smith, R., Linthicum, D.S., 1993. Correlation between susceptibility to demyelination and interferon gamma induction of major histocompatibility complex class II antigens on murine cerebrovascular endothelial cells. *Journal of Neuroimmunology* 48, 91-98.
- Welsh, C.J.R., Tonks, P., Nash, A.A., Blakemore, W.F., 1987. The effect of L3T4 T cell depletion on the pathogenesis of Theiler's murine encephalomyelitis virus infection in CBA mice. *Journal of General Virology* 68, 1659-1667.
- Whishaw, I.Q., Kolb, B., Sutherland, R.J., 1983. The analysis of behavior in the laboratory rat. In: Robinson, T.E. (Ed), *Behavioral approaches to brain research*, Oxford University Press, New York, pp. 141-221.
- Williams, A.F., 1984. The immunoglobulin superfamily takes shape. *Nature* 308, 12-13.
- Yamada, M., Zurbriggen, A., Fujinami, R.S., 1991. Pathogenesis of Theiler's murine encephalomyelitis virus. *Advances in Virus Research* 39, 291-320.
- Yasuda, C.L., Al-Sabbagh, A., Oliveira, E.C., Diaz-Bardales, B.M.,

- Garcia, C.A.A., Santos, L.M.B., 1999. Interferon  $\beta$  modulates experimental autoimmune encephalomyelitis by altering the pattern of cytokine secretion. *Immunological Investigations* 28, 115-126.
- Yauch, R.L., Kim, B.S., 1994. A predominant viral epitope recognized by T cells from the periphery and demyelinating lesions of SJL/J mice infected with Theiler's virus is located within VP1(233-244). *Journal of Immunology* 153, 4508-4519.
- Yauch, R.L., Palma, J.P., Yahikozawa, H., Koh, C.-S., Kim, B.S., 1998. Role of individual T-cell epitopes of Theiler's virus in the pathogenesis of demyelination correlates with the ability to induce a Th1 response. *Journal of Virology* 72, 6169-6174.
- Yu, M., Nishiyama, A., Trapp, B.D., Tuohy, V.K., 1996. Interferon- $\beta$  inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. *Journal of Neuroimmunology* 64, 91-100.
- Zamvil, S.S., Steinman, L., 1990. The T lymphocyte in experimental allergic encephalomyelitis. *Annual Reviews in Immunology* 8, 579-621.

## APPENDIX

### PREPARING VIRUS FOR MOUSE INTRACRANIAL INJECTION

#### *Materials*

1. BeAnT<sub>1</sub>P<sub>1</sub> concentration  $7.5 \times 10^6$  plaque forming units
2. Sterile 2mL centrifuge tubes
3. Sterile 1X PBS
4. Metofane<sup>®</sup>, Schering-Plough Animal Health Corp., Union, NJ, cat# NDC0061-5038-01 or  
Isoflurane<sup>®</sup>, Abbott Labs, North Chicago, IL, cat# 5260-04-03
5. 1mL syringes
6. 27 gauge  $\frac{1}{2}$ " needles
7. Glass jar with lid
8. Cooler with ice
9. Cotton
10. String

#### *Methods*

1. Keep the virus on ice constantly until time of injection.
2. Remove 1mL BeAnT<sub>1</sub>P<sub>1</sub> concentration  $7.5 \times 10^6$ pfu/mL from the 80°C freezer.
3. Place 0.5mL of virus into a sterile, 2mL centrifuge tube. Repeat.
4. Centrifuge the tubes for 5 min at 7000RPM to remove cellular debris.

5. Add 1mL sterile PBS to each tube.
6. Take the virus, glass jar with lid and anesthetic to LARR. The virus should be in a cooler with wet ice.
7. Add a small amount of Metofane® to a cotton ball and suspend in the glass jar with lid closed. For Isoflurane®, use 5mL.
8. Place one mouse in the jar.
9. Wait for the mouse to go to sleep in the jar, time varies with Metofane®, 30 seconds for Isoflurane®.
10. Remove the mouse and inject 20uL of the PBS/virus solution intracranially into the right cerebrum.
11. Repeat for each mouse.
12. Place a sign on the animal cage that says, "Anesthetized with Metofane® or Isoflurane® today" and include the date.

**Caution!**

Only use the Metofane® or Isoflurane® in the fume hood. Always keep the lids on the bottles and the lid on the glass jar when possible. Both chemicals are powerful anesthetics and will affect humans as well.

## MOUSE TAIL BLEEDING PROCEDURE

### *Materials*

1. 1 Eppendorf tube/ mouse
2. 1 surgical blade/ 5 mice
3. Heat lamp
4. 1 clean cage
5. Restrainer or 1X 50mL centrifuge tube with breathing and tail holes
6. 50mL 70% ethanol  
(100% ETOH, Sigma, St. Louis, MO, cat#E7148 diluted in MilliQ water)
7. Cotton balls
8. Vaseline
9. Rack for Eppendorf tubes

### *Methods*

1. Attach heat lamp to the side of the clean cage.
2. Place one mouse under the heat lamp until the mouse begins wiping it's nose. (approx. 5 min.) The heat will increase the blood flow.
3. Place the mouse in the restraint tube, keeping the tail accessible.
4. Wipe side of tail with ethanol.
5. Make one small nick on the edge of the tail along the vein.

6. Drip the blood into the Eppendorf tube, squeezing the tail if necessary.
  7. Collect approx. 0.5mL.
  8. Wipe off tail with cotton. Hold until bleeding stops.
  9. Apply Vaseline to aid in clotting.
  10. Return mouse to cage.
  11. Add a petri dish of water to each cage that contains mice that have been bled.
- Warnings!**  
Do not keep the mouse under the heat lamp longer than necessary. Too much heat can kill them!!! Watch the mice for about 5 minutes after all the bleeding is completed. If too much blood is removed, the mice will die within that time frame. Assume total blood volume per mouse equals 6% of the mouse body weight. Do not remove more than 10% of blood volume during bleeding or the mouse will go into shock.

## EXTRACTING SERUM FROM BLOOD SAMPLES

### *Materials*

1. Two 0.65mL tubes for each blood sample.
2. One 2mL tube for each blood sample
3. Unplugged, long Pasteur pipettes
4. Pipette bulb

### *Methods*

1. Place blood samples at 4°C for at least 2 hours to cause clot contraction.
2. Transfer all liquid that has not clotted into 0.65mL tubes using a pasture pipette.
3. Cut the lids off of the new 2mL tubes.
4. Place each 0.65mL tube into a topless 2mL tube so they will fit in the centrifuge.
5. Centrifuge for 5 min at 5000 RPM to spin down red blood cells
6. Pipette yellow serum into fresh 0.65mL tubes.
7. Store serum samples at -20°C or -80°C until needed.

**Warnings!**

Storing the whole blood samples at freezing temperatures will result in the rupture of the red blood cell walls. The serum will be pink and not yellow.

## CORTICOSTERONE ANALYSIS OF MOUSE SERUM VIA RADIOIMMUNOASSAY

### *Materials*

1. ImmuChem™ Double Antibody Corticosterone RIA kit, ICN Biomedicals Inc., Costa Mesa, CA, cat#07-120102
2. Gamma counter
3. Test tube rack
4. 10 x 75 mm tubes for RIA
5. Blotting paper
6. Mouse serum, 10 $\mu$ L per mouse

### *Methods*

1. Bring reagents to room temperature.
2. Consecutively number 10 x 75 mm tubes, tubes 1-20 will be used for controls.
3. Dilute mouse serum samples 1:200 with steroid diluent in the kit. Take 10 $\mu$ L of sample and put it in 2.0mL steroid diluent.
4. Add 0.3mL of steroid diluent to tubes 1 and 2.
5. Add 0.1mL steroid diluent to tubes 3 and 4.
6. Add 0.1mL Corticosterone calibrators found in the kit in tubes 5 thru 16 as follows:

tubes 5 and 6 = 0.25ng/mL  
tubes 7 and 8 = 50ng/mL  
tubes 9 and 10 = 100ng/mL  
tubes 11 and 12 = 250ng/mL  
tubes 13 and 14 = 500ng/mL  
tubes 15 and 16 = 1000ng/mL

7. Add 0.1mL diluted (1:200) controls to tubes 17 thru 20 as follows:

tubes 17 and 18 = control I  
tubes 19 and 20 = control II

8. Add 0.1mL diluted mouse serum to tubes beginning with tube 21.

9. Add 0.2mL Corticosterone-<sup>125</sup>I from kit to all tubes.

10. Add 0.2mL anti-corticosterone from kit to all tubes except tubes 1 and 2.

11. Vortex mix all assay tubes and incubate at room temperature of 2 hours.

12. Add 0.5mL precipitant solution for kit to all tubes.

13. Vortex for approximately 1 minute.

14. Centrifuge all assay tubes at 1000 x g for 15 minutes.

15. Pour off the supernatant.

16. Invert tubes and blot the rim of the tubes on absorbent paper.

17. Count the precipitate in a gamma counter.

## ELISA FOR THE DETECTION OF INTERFERON-TAU ANTIBODIES IN MOUSE SERUM

### *Materials*

1. Carbonate coating buffer
2. Serum conjugate
3. 1% BSA in carbonate coating buffer
4. PBS Tween 20
5. ABTS tablets and buffer, Roche, Indianapolis, IN, cat#1204521,  
cat#1204530
6. Interferon-tau
7. Rabbit anti-mouse IgG horseradish peroxidase conjugated antibody  
(H+L) diluted in 1X PBS, Sigma, St. Louis, MO, cat#A9044
8. Immulon I flat bottomed 96 well microtiter plate, Costar Corp.,  
Cambridge, MA, cat#3590
9. ELISA plate reader
10. Cloth towel
11. Serum samples

### *Methods*

1. Add 50µl per well of 20µg/mL peptide antigen (interferon-tau diluted in carbonate coating buffer) to columns 1-11 of an Immulon I flat bottomed 96 well microtiter plate. Add 50µl per well of carbonate coating buffer to column 12. Column 1 = negative controls (blanks).

2. Incubate overnight at 4° C (refrigerate)
3. Wash plate 4 times with PBS-Tween 20, then once with distilled-deionized water. Each wash consists of rapidly squirting liquid into each well (with a squirt bottle, this is not quantitative), then aggressively shaking the liquid out of the plate 10 times, and then pounding the plate on a cloth towel 10 times to remove the remaining liquid.
4. Add 100 $\mu$ L per well of 1% BSA (diluted in carbonate coating buffer) to all wells.
5. Incubate overnight at 4° C (refrigerate).
6. Wash plate as above.

#### Setting up plate

7. Dispense 50 $\mu$ L of serum conjugate to all wells, excluding those wells in columns 2 and 12.
8. Dispense 100 $\mu$ L of a 1:20 dilution of the sample to be tested to the wells in column 2 (sample is diluted in serum conjugate). Positive control is in well 2H 1:20 dilution.
9. Dispense 50 $\mu$ L of the sample to be tested to the wells in column 12.
10. Transfer 50 $\mu$ L from the column 2 wells to column 3. Mix and transfer 50 $\mu$ L from column 3 to column 4. Repeat transfers through column 11, discarding 50 $\mu$ L from column 11 (doubling solutions).

11. Incubate for 40 minutes at 37° C (in a CO<sub>2</sub> incubator).
12. Wash plate as above.
13. Add 50µL/well of Horseradish Peroxidase Conjugated Rabbit Anti-Mouse IgG (H&L) antibody at 1:10,000 dilution (conjugate is diluted in serum conjugate).
14. Incubate for 60 minutes at 37° C.
15. Wash plate as above.
16. Add 50µL per well of substrate, and let develop for 50 minutes at room temperature with ABTS tablets & buffer.
17. Read the absorbence of the wells on an ELISA plate reader at 450nm.

Carbonate Coating Buffer pH 9.6

NaHCO <sub>3</sub>	0.293g, EM Scientific, Gibbstown, NJ, cat#SX0320-1
Na <sub>2</sub> CO <sub>3</sub>	0.159g, EM Scientific, Gibbstown, NJ, cat#SX0445-1
D.D. H <sub>2</sub> O	100mL

Serum Conjugate

NaCl	0.435g, Sigma, St. Louis, MO, cat#S-3014
EDTA	0.018g, Sigma, St. Louis, MO, cat#E-5134
Tris	0.303g, EM Scientific, Gibbstown, NJ, cat#AX0945-3
Tween 20	0.2mL, USB Corp., Cleveland, OH, cat#20605
D.D. H <sub>2</sub> O	100mL

1% BSA in Carbonate Coating Buffer

BSA	0.2g, Roche, Indianapolis, IN, cat#100 360
Carbonate Coating Buffer	20mL

PBS Tween 20 pH 7.4 9 L solution

NaCl	72g	Sigma, cat#S-3014
KH <sub>2</sub> PO <sub>4</sub>	1.8g	EM Scientific, cat#PX1570-1
NaH <sub>2</sub> PO <sub>4</sub> – 12 H <sub>2</sub> O	26.1g	
Or NaH <sub>2</sub> PO <sub>4</sub> – 7 H <sub>2</sub> O	19.535g	EM Scientific, cat#SX0715-1
KCl	1.8g	Sigma, cat#P-5405
Tween 20	4.5mL	USB, cat#20605
D.D. H <sub>2</sub> O	9L	

Preparation of ABTS Solution:

ABTS	1 Tablet	Roche, Indianapolis, IN, cat#1204521
Buffer	5mL	Roche, Indianapolis, IN, cat #1204530

Mix shortly before addition to plate, keep bottle wrapped in foil until use

IFN-Tau (from Bazer Lab, Kleberg Bldg.) 1:20 dilution per well

IFN-Tau Sample	6 $\mu$ L
Serum Conjugate	114 $\mu$ L

Anti-mouse IgG Peroxidase Conjugate 1:10,000

IgG	0.5 $\mu$ L	Sigma, cat#A9044
Serum Conjugate	4999.5 $\mu$ L	

## MEASURING DELAYED TYPE HYPERSENSITIVITY REACTIONS TO CNS MYELIN IN TMEV INFECTED MICE

### *Materials*

1. Metofane<sup>®</sup>, Schering-Plough Animal Health Corp., Union, NJ, cat# NDC0061-5038-01
2. Glass jar with lid and cotton ball on string
3. Engineer's micrometer, Swiss Precision Instruments, Los Angeles, CA
4. Mouse myelin in PBS
5. 1X PBS
6. 1mL syringes and 26 ½" needles

### *Methods*

1. Anesthetize mouse with Metofane<sup>®</sup> in the glass jar with the lid on in a fume hood.
2. Measure the ear thickness of each ear with the micrometer.
3. Inject one mouse ear with 20µL of PBS and the other ear with 10µg of mouse myelin in 20µL PBS.
4. 24 hours later, measure both ears again.
5. 48 hours later, measure the ears for the final reading.

## NEUROLOGICAL EXAMINATION SCORE SHEET FOR MICE

Mouse\_\_\_\_\_

Date\_\_\_\_\_

Rater\_\_\_\_\_

## Posture in cage

## Behavior during removal

Flattened	F	Sits quietly	0
On side	L	Vocal/not resistant	1
Curled	S	Rears/looks ahead	
Sitting/head low	H	Runs around	3
Sitting normal	O	Freezes	4
Alert/looks ahead	A	Aggressive/attacks	5
Rearing	R		
Vertical jump	J		
Circling	C	Piloerection (Ruffled Fur)	
Pacing	P	Y/N	
Writhing	W		

## Hair Coat

## Mucus membranes/eye/skin color

Clean	0	Pink	Pale
Slightly soiled	1	Dark, cyanotic	Dark, brown
Moderate soiled	2	Bright, deep red	
Very soiled	3		

## Respiratory Rate

## Respiratory Character

Normal		Normal	Shallow	Deep
Increased	Decreased	Labored	Rales	Gasping
Eye Prominence		Eyelid Closure		
Normal		Wide open	Closed	
Exophthalmos		Slightly drooped		
Enophthalmos		Drooping halfway		
Seizure Onset		Type of Seizure		
Spontaneous		Chewing	CH	
Induced by stimuli		Jacksonian/chewing	J	
		Jacksonian/initial site	I	
Length of Seizure		Mild clonic/limbs	M	
Time in minutes_____		Clonic/body	C	
		Tonic seizure	T	
Length of Post-ictal Period		Tonic-clonic seizure	TC	
Time in minutes_____		Opisthotonus	OP	
		Emprosthotonus	EP	
		Spasmodic jumping	SJ	
		Agonal/asphyxial	AS	
		Status epilepticus	SE	
Mental Status		Handling Behavior		

Alert	Disoriented	Very easy, totally limp
Depressed	Stupor	Easy, alert, limbs close to body
Coma		Moderately easy, vocal
		Freezes, rigid in hand
		Difficult, squirming, tries to bite

Stereotypic Behavior		Limb Muscle Tone
Head flick	Head search	Muscle is firm not hard
Hallucinatory	Catalepsy	Muscle is soft, may be atrophied
Compulsive lick	Prancing	Muscle is tense and hard
Circling	Waltzing	
Retropulsion	Spatial disorientation	
Rocking	Excessive grooming	
		Abdominal Tone
Passive Manipulation		
-Place on back and flex each limb		Slight resistance
		Completely flaccid
Moderate resistance		Slightly flaccid
No resistance		Pain, struggling
Slight resistance		Extreme resistance
Some resistance, easy rotation		
Increased resistance, difficult rotation		

#### Rearing Activity

Eye Position	O	Did not rear
	D	Falls backward while rearing
	V	Rears on hind limbs with tail
	M	Rears on hind limbs without tail
	L	Falls to side while rearing
Head Position		
Normal	O	
Deviated dorsally	D	
Deviated ventrally	V	
Deviated medially	M	
Deviated laterally	L	No tilt O    Tilt left L    Tilt right R

Resting Nystagmus			Static Limb Position		
None	O	Left L	Right R	Normal	O
				Crossover medially	C
				Deviated medially	M
				Deviated laterally	L
Positional Nystagmus			Tail Elevation		
Eyes return to center quickly			O		
Nystagmus on movement, left	L		Lifted while walking	0	
Nystagmus on movement, right	R		Occasionally lifted	1	
			Drags end of tail	2	

Pinna Touch Response		Tail held vertically	3
		Tail held 45 degrees	4
No response	0		
One twitch	1	Abnormal Gait	
More than one twitch	2		
Whole body withdraws	3	None	Knuckling over
		Steppage	Crossing over
		Spastic	Drags hind limbs
		Waddling	Thorax not lifted

#### Startle Response

No reaction	0		
Flinch or flicks ear	1	Ataxic Gait	
Jumps or violent	2		
		None	0
Visual Orientation		Slight but definite	1
		Considerable, no falling	2
Orients toward object as it enters	O	Considerable, some fall	3
Orients after well in visual field	S	Considerable,frequent	4
Orients and responds aggressively	A	Always falls	5
Does not orient at all	N		

Locomotor Activity		Approach Response	
Reduced activity	0	Rodent approaches and sniffs	O
Resting, slow spatial orient.	1	No reaction	N
Vigorous scratching	2	Rodent freezes	F
Vigorous movement	3	Pulls away slightly	P
Sharp, rapid darting	4	Jumps to avoid object	T
		Jumps at object, attacks	J
Paresis		Righting Reflex	
None	0	Rights when turned, either side	O
Weak but ambulatory	1	Rights but impaired, either side	I
Non ambulatory	2	Attempts to right but cannot	A
Some voluntary movement	3	Does not right from right side	R
No voluntary movement	4	Does not right from left side	L
		Does not right from either side	E
Proprioceptive Positioning		Extensor Postural Thrust	
R TL 0    1    2		Prior to contact, extends the PL to bear weight	O
L TL 0    1    2		Hindlimbs extended, stumbling on contact	S
R PL 0    1    2		On contact hindlimbs not extended	N
R PL 0    1    2			

Visual Placing		Tail Pinch	
Early vigorous TL extension	0	Walks forward	O
Extension prior to vibrissae contact	1	Sluggishly turns to look	T
After vibrissae contact	2	No response	N
After marked vibrissae contact	3	Freezes with or without vocalization	F
After nose contact	4	Immediately bites	A
Bizarre behavior hampers placing	5	Jumps forward with or without vocals	J
No extension after nose contact	6	Exaggerated response, rapid turning	E

## MOUSE PERFUSION

### *Materials*

1. 70% Ethanol (100% Ethanol, Sigma, St. Louis, MO, cat#E7148 diluted in MilliQ water)
2. 10% Formalin, Sigma, St. Louis, MO, cat#HT50-1-2
3. 1X PBS
4. Rompun, Bayer Corp., Shawnee Mission, KS: Sedative and Analgesic, dilute 1:100 in PBS 5uL/10g mouse
5. Ketaset, Fort Dodge Animal Health, Fort Dodge, IA: Anaesthetic 10uL/10g mouse
6. Two way syringe w/ 10mL syringes, 3 way tap, IV tubing, 271/2 gauge needle on end
7. 1cc syringes and 271/2 gauge needles for sedative injection
8. Plastic bags, 1/mouse or 50ml centrifuge tubes.
9. Medical tape for securing mouse
10. Sharp dissecting scissors, forceps, and small scissors for heart
11. Package of paper towels
12. Cage lid

### *Methods*

1. Fill both 10cc syringes, one with PBS, the other with formalin.
2. Fill 1cc syringe with Ketaset and another with diluted Rompun.

3. Inject 100uL of Ketaset and Rompun into mouse i.p.
4. Wait until mouse is immobile and begins "deep breathing" or gasping.
5. Secure mouse on it's back to wire grid with medical tape.
6. Place paper towels under cage to catch blood.
7. Pull on one foot and pinch to check reflex.  
If there is no movement, pour ethanol on belly fur.
8. Cut up through the rib cage beginning at the midsection, be careful not to cut the heart with small scissors.
9. Stab the left ventricle with the IV needle, careful not to punch through the heart. Cut the right atrium of the heart.
10. Slowly pump in about 5mL saline to flush out the blood.
11. Slowly switch the 3 way valve to formalin and pump through about 5mL. This will fix the brain tissue.
12. Remove the mouse from the wire rack.
13. Place the mouse right side up and cut between the spinal cord and the brain stem.

14. Place the mouse in a plastic bag or centrifuge tube marked with mouse number.
15. Cover the mouse with 10% Formalin.
16. Refill the syringes. Flush out the IV tubing with PBS to clean out residual formalin.
17. Replace paper towels after each mouse. Keep the towels under the hood until the entire procedure is over.
18. When the dissections are complete, all mouse tissue and paper towels should be placed in biohazard bags and disposed of at LARR.

## SAMPLE COLLECTION FOR HISTOLOGICAL ANALYSIS

### *Materials*

1. 70% Ethanol (100% Ethanol, Sigma, St. Louis, MO, cat#E7148 diluted in MilliQ water)
2. 10% Formalin, Sigma, St. Louis, MO, cat#HT50-1-2 or 4% Paraformaldehyde/4% gluteraldehyde,  
Paraformaldehyde, EM Scientific, Ft. Washington, PA, cat# PX0055  
Gluteraldehyde, EM Scientific, Ft. Washington, PA, cat# GX015305
3. 1X Phosphate buffered saline, PBS
4. Labeled cassette
5. Plastic container (wide opening)
6. Razor blade
7. Surgical instruments
8. Sodium cacodylate-trihydrate, 0.2M, EM Scientific, Ft. Washington, PA, cat#12300

### *Methods*

1. Spleen: if possible, leave in one piece only.
2. Small samples like adrenals and lymph nodes: cut small square piece of lens paper, fold into 4, place inside small funnel, then inside small beaker, wet with PBS, add your sample, fold lens paper so the sample won't get out, place inside labeled cassette, then add 70% ethanol.
3. Spinal cord and brain tissue: if possible try to cut each piece the same size, that way you can have all type of tissue section on each slide. For Brain, remember to keep in formalin and take the same day as perfusion to the histology lab for processing. Leaving the tissue in

70% ethanol overnight can cause artificial spongiform changes. For CNS tissues, it is best to leave the brain in the skull overnight in formalin before removing it for histology. This will prevent artifact in the form of dark staining neurons.

4. Intestine or stomach: flush with sterile PBS before placing sample inside the cassette or it will harden during processing.

**DO NOT OVERFIX YOUR TISSUE:**

If you need your slides for immunohistochemistry, over fixation will minimize your reaction and decrease antigen retrieval. If the immunohistochemistry is for the spinal cord samples, request formic acid for the decalcification method.

5. If you are collecting tissue for electron microscopy, perfuse with the 4%paraformaldehyde/4% gluteraldehyde instead of formalin. Place the tissue in the same solution in a 50mL tube for 12-16 hours at 4°C. After fixation, dissect out the tissue for EM and place in sodium cacodylate buffer. Process immediately if possible. Store at 4°C.

## HISTOLOGY SCORING SHEETS FOR SPINAL CORD SECTIONS

Mouse\_\_\_\_\_

Rater\_\_\_\_\_

Date\_\_\_\_\_

**Inflammation**

- A. Meninges
- B. White Matter
- C. Grey Matter

**Status Spongiosus**

- A. Meninges
- B. White Matter
- C. Grey Matter

**Demyelination**

- A. Meninges
- B. White Matter
- C. Grey Matter

**Notes and Comments****Location of Lesion****A. White Matter**

1. Dorsal funiculi
2. Lateral funiculi
3. Ventral funiculi

**B. Grey Matter**

1. Dorsal Horn
2. Intermediate
3. Ventral Horn
4. Medial Grey

**Rating System**

0.0 No lesion

0.5 Very mild: marginally identifiable lesion

1.0 Mild: definitive lesion, focal to multifocal, limited in severity

2.0 Moderate: definitive lesion, multifocal to regional distribution, extensive severity

3.0 Prominent: definitive lesion, multifocal to diffused distribution, extensive severity

4.0 Very prominent: definitive lesion, multifocal to diffused distribution, very prominently extensive in severity

**TRIPURE™ RNA EXTRACTION FROM WHOLE TISSUE**

*Materials*

1. 200mL beaker with wet ice
2. Round bottom Nalgene tubes, two for each tissue sample, Fisher, Pittsburgh, PA, cat#05-562-106
3. TriPure Isolation reagent, 1mL for each 50-100 mg of tissue, Roche, Indianapolis, IN, cat#1667165
4. RNA Zap decontamination spray, Ambion, Austin, TX, cat#9782
5. 95% ETOH, 250mL
6. 75% ETOH, 1mL for each mL of TriPure used
7. DEPC-treated water, 500mL, Ambion, Austin, TX, cat#9915G
8. RNase free tips and microcentrifuge tubes (NEVER USED AUTOCLAVED SUPPLIES – THE CONTAMINATION IS VERY HIGH)
9. 7X soap, ICN, Aurora, OH, cat#76-670-94
10. Kimwipe
11. Nanopure water (Bazer lab has water filter system)
12. Chloroform, 0.2mL per 1mL of TriPure used, Sigma, St. Louis, MO, cat#C2432
13. Parafilm
14. Isopropanol, 0.5mL per 1mL TriPure used, Sigma, St. Louis, MO, cat#I9516
15. Ambion™ Ultrapure water, 100uL per sample, Ambion, Austin, TX, cat#9930
16. Spectrophotometer
17. Power homogenizer
18. 4°C microcentrifuge

**CAUTION!**

When working with RNA, RNA proteases are constantly in your surroundings. Make sure to spray all pipettes, hands, and surfaces with RNA zap periodically while working. If you touch something that is not sprayed with RNA zap, spray it and your hands again.

***Methods***

1. Wash the Nalgene tubes in 7X soap. Rinse with distilled water 6X. Squirt RNA zap into each tube and scrub with tube brush. Rinse each tube 6X with Nanopure water. Spray again with RNA zap and dry with Kimwipe.
2. Using the cleaned, round bottom, Nalgene tubes, add 1mL TriPure to every 50-100mg of tissue at room temp. The capacity of the tube should be twice the volume of the tissue plus the TriPure. Record the amount of TriPure used per sample. For samples less than 10mg, use 0.8mL TriPure.
3. Add tissue to the tubes with the TriPure using a sterile pipette tip to remove the tissue from the cryovial.
4. Homogenize the tissue for about 30 seconds. Keep the bottom of the tube in a beaker filled with ice. Make sure to wash the homogenizer with 95% ethanol and DEPC-treated water between each sample. Dry the homogenizer with a Kimwipe.

**FOR BRAIN AND SPLEEN SAMPLES:** Clarify the homogenate by spinning at 12,000 x g for 10 minutes at 4°C. Transfer the supernatant below the fatty film on top to a fresh round bottom tube.

5. Incubate each sample at room temp for 5 minutes.
6. Add 0.2mL chloroform to each sample for each 1mL TriPure used.
7. Cover with parafilm and vortex each sample for approx. 50 seconds.
8. Incubate at room temp for 15 minutes.
9. Centrifuge at 12,000 x g for 15 minutes at 4°C. The upper colorless phase contains the RNA. The interphase contains the DNA, and the red organic phase is the protein.
10. Transfer the colorless phase into Eppendorf tubes. Each tube will need to hold 0.5mL isopropanol for each 1mL TriPure used. Split into separate tubes if necessary.
11. Add 0.5mL isoproponal for each 1mL TriPure used.
12. Invert the tubes to mix thoroughly.
13. Incubate for 10 min at room temperature.
14. Centrifuge at 12,000 x g for 10 min at 4°C.
15. Discard the supernatant.

16. Add 1mL 75% ethanol to each sample per 1mL TriPure. The RNA pellet can be stored in ETOH for at least a week at 4°C and at least a year at -20°C. Stop here if necessary.
17. Wash the RNA pellet in the ethanol by vortexing.
18. Centrifuge the sample at 7500 x g for 5 min at 4°C. Pour off the supernatant.
19. Remove the excess ETOH by inverting on the bench top and wicking the extra ETOH off the sides with a Kimwipe. Be careful not to totally dry the pellet or touch it with a Kimwipe.
20. Resuspend the pellet by adding 30uL per tube of Ambion Ultrapure water. Combine the like tubes and keep the samples on ice after resuspending. Record final volume of samples.
21. Make a 1:60 dilution of each sample. 2uL sample into 118uL DEPC-treated water.
22. Place stock RNA into -80°C.
23. Take diluted samples to Bazer lab and read on the spectrophotometer nucleic acid program setting. Load 100uL of each dilution into the cuvette. Be careful to rinse the cuvette with DEPC-treated water in between each reading.

24. Record the 260nm absorbence and the 260nm/280nm ratio. RNA samples should have a 260nm/280nm reading between 1.6 and 2.0.

To calculate total RNA:

$$260\text{nm reading} \times \text{dilution factor} \times 40 / 1000 = \mu\text{g}/\mu\text{L}$$

Dilution factor = 60

RNA constant = 40

## EXTRACTING RNA FROM DNA CONTAMINATED SAMPLES

### *Materials*

1. Rq1 RNase free DNase, Sigma, St. Louis, MO, cat#D7291
2. DEPC water, Ambion, Austin, TX, cat#9915G
3. Phenol:chloroform:isoamyl alcohol 25:24:1, Sigma, St. Louis, MO, cat#P3803
4. RNase free 200uL tips and 2 mL tubes, Ambion, Austin, TX, cat#12650, cat#12425
5. Chloroform, Sigma, St. Louis, MO, cat#C2432
6. 3M Sodium acetate, Sigma, St. Louis, MO, cat#S2889
7. 100% Ethanol, Sigma, St. Louis, MO, cat#E7148
8. 70% Ethanol (100% Ethanol diluted in MilliQ water)
9. Ambion Ultra-pure water, Ambion, Austin, TX, cat#9930

### *Methods*

#### Day 1

1. Spin samples quickly to bring all liquid to the bottom of the tube.
2. Add 1uL Rq1 RNase free DNase to each 14uL of sample.
3. Incubate at 37°C for 15 minutes in a heat block or water bath.
4. Add 185uL DEPC water per 1uL Rq1 to each sample.
5. Add equal volume phenol:choloroform:isoamyl alcohol (200uL for 1uL Rq1).

6. Vortex 20 seconds and centrifuge at full speed for 2 minutes.
7. Remove the top layer in the tube and place in a separate tube.
8. Add equal volume of chloroform to the new tube.
9. Vortex 20 seconds and centrifuge at full speed for 2 minutes.
10. Remove the top layer in the tube and place in a separate tube.
11. Add 1:10 volume 3M sodium acetate pH 7.4 (20uL into 200uL)
12. Add 2.5X 100% ethanol and store at -20°C for 4-24 hours.

#### Day 2

13. Spin at 4°C at 20,000 x g for 30 minutes.
14. Carefully pour off ethanol.
15. Add 1mL 70% ethanol to each sample and spin at 4°C at 20,000 x g for 15 minutes.
16. Pour off ethanol and invert tubes on bench to dry.
17. Use a Kimwipe to absorb excess ethanol but do not touch the pellet.
18. Reconstitute in 35uL Ambion Ultra-pure water and keep the samples on ice.

19. Make a 1:60 dilution (2 $\mu$ L/118 $\mu$ L) of sample into DEPC water.
20. Place undiluted samples into the -80°C.
21. Read diluted samples on the spectrophotometer nucleic acid setting.

## IMMUNOSTAINING FOR CNS MYELIN

### *Materials*

1. 1 Coplin jar per 10 slides
2. 10mM Sodium citrate pH 6.0 (Sigma, St. Louis, MO, cat#S4641 diluted in MilliQ water)
3. Xylene, Sigma, St. Louis, MO, cat#X2377)
4. 100% Ethanol, Sigma, St. Louis, MO, cat#E7148
5. 95% Ethanol (100% Ethanol diluted in MilliQ water)
6. 70% Ethanol (100% Ethanol diluted in MilliQ water)
7. 30% Hydrogen peroxide, EM Scientific, Gibbstown, NJ, cat#HX0635-2
8. Methanol, Sigma, St. Louis, MO, cat#17-5
9. 1X PBS
10. PBS/BSA 2%
11. PBS/BSA 2% with 1% triton
12. Myelin/oligodendrocyte Ab-1 (Clone CE1) NeoMarkers, Inc., Fremont, CA, cat#MS-245-P
13. Rabbit anti-mouse IgG horseradish peroxidase conjugated, Sigma, St. Louis, MO, cat#A9044
14. 0.05M Tris-HCl pH 6.8 (Sigma, St. Louis, MO, cat#T2413 diluted in MilliQ water)
15. 3,3'Diaminobenzidine tetrahydrochloride (DAB) tablets, ICN, Aurora, OH, cat#980681
16. Normal rabbit serum for blocking, Sigma, St. Louis, MO, cat#R-9133
17. Mouse IgM antibody, Sigma, St. Louis, MO, cat#M1520

18. Mayer's hematoxylin solution, Sigma, St. Louis, MO, cat#MHS-16
19. 250mL glass cuvette
20. Aluminum foil
21. Kimwipe
22. Pap pen, The Binding Site Inc, San Diego, CA, cat#AD100.5
23. Humidified chamber made of plastic container with wet paper towels inside
24. Glass 50mL beaker for DAB solution
25. MilliQ water
26. DAB waste bottle and dry waste bag
27. Q-tips
28. Glycerol gelatin for slide mounting, Sigma, St. Louis, MO, cat#GG-1
29. 3mL syringe
30. 40mm-50mm cover slips, 1 per slide
31. Parafilm

*Methods*

Day 1

1. Turn on 80°C water bath with Coplin jar containing 50mL 10mM Sodium Citrate 1 hour before deparaffinizing slides
2. Deparaffinize slides through xylene and graded alcohol  
Xylene ..... 5 min  
Xylene ..... 5 min

100% Ethanol.....3 min

100% Ethanol.....3 min

95% Ethanol.....3 min

70% Ethanol.....3 min

**Mix Quenching Solution**

3. Quench sections for 30 minutes in 0.3% H<sub>2</sub>O<sub>2</sub> in methanol.

\* Light sensitive, cover with foil.

(0.5mL 30% H<sub>2</sub>O<sub>2</sub> in 49.5mL methanol in Coplin jar)

(2.0mL 30% H<sub>2</sub>O<sub>2</sub> in 198mL methanol in glass cuvette)

4. Antigen retrieval

30 min @ 80°C in 10mM (0.01M) Sodium Citrate, pH 6.0 in a separate Coplin jar (six slides per jar).

5. Rinse slowly 2X in dH<sub>2</sub>O in Coplin jar after cooled to Room Temperature (45 min). Fill Coplin jar with distilled water.

Wick off dH<sub>2</sub>O around tissue with Kimwipe and draw circle with pap pen.

6. Rinse 3X with PBS and then rinse fourth time and leave the sections in PBS for 5 minutes.

7. Rinse with PBS/BSA(2%) as per step 5.

8. Rinse again with PBS/BSA(2%), dry around sections and put on 160µL 10% Normal Rabbit Serum, RT, 20 minutes in humidified chamber w/ lid on top.(120 NRS from -80°C + 1080PBS/BSA(2%), good for 6 slides).

9. Prepare primary Ab and IgM control. Ab and IgM diluted in PBS/BSA(2%).

Stock oligodendrocyte ab = 200 $\mu$ g/mL IgM

For 6 slides = 1036.8 $\mu$ L PBS/BSA + 43.2 $\mu$ L primary antibody  
(Vortex and then centrifuge @ 12,800g for 3 minutes)

IgM (made in mouse) stock = 1000  $\mu$ g/mL

(Vortex and then centrifuge @ 12,800g for 3 minutes)

10. Remove Rabbit serum and dry around sections. Add 160 $\mu$ L ab, PBS, or IgM to slides. INCUBATE slides for 14-15 hrs, 4°C (one section with Ab, the other with IgG, and the third section with PBS/BSA) in humidified chamber.

## DAY 2

11. Remove DAB bottle from the -20°C freezer

12. Rinse slides with PBS/BSA(2%) containing 1% triton. (as per step 5, cuts down on background)

13. Rinse with PBS (as per step 5); 2X

14. Rinse with PBS/BSA(2%) containing 1% triton. (as per step 5)

15. Rinse with PBS/BSA(2%) containing 1% triton, dry around sections.

16. Prepare 2°AB (HP conjugated rabbit anti-mouse)  
diluted in 5% NRS and PBS/BSA(2%)  
(1:200 dilution stock at 1:10 dilution) located in -20°C  
(60µL antibody + 1140µL PBS/BSA(2%)/NRS for 6 slides)  
Vortex and spin similar to 1° antibody
17. Dry around sections and add 160µL 2° antibody to all slides.  
INCUBATE for 1 hour at room temp in humidified chamber w/ lid on top.
18. Add DAB tablet to 8.33mL Tris-HCl in DAB beaker –  
WRAP BEAKER IN FOIL.
19. Rinse with PBS/BSA(2%) containing 1% triton, (as per step 5).
20. Rinse with PBS (as per step 5). 2X
21. Rinse with PBS, then with Tris-HCl (0.05M concentration).
22. Dry around sections and apply 160uL peroxidase solution per slide  
(Add H<sub>2</sub>O<sub>2</sub> just before use; in beaker with foil, dab tablet and Tris-HCl),  
wait till color develops (10 min) grind tablet with pipette tip before use  
PEROXIDASE SOL'N = 5mg DAB + 8.33mL Tris – HCl(0.05M) + 83.33µL  
H<sub>2</sub>O<sub>2</sub>(3%) DAB: 3,3- diaminobenzidine-HCl.

PLACE DAB WASTE AND TRIPLE RINSES OF DAB BEAKER IN WASTE BOTTLE IN THE FUME HOOD.

23. Rinse in d H<sub>2</sub>O, 2 changes, 5 minutes. Place all rinses in DAB waste bottle.
24. Counter stain with filtered Hematoxylin (10 seconds).
25. Rinse with ddH<sub>2</sub>O, 4 changes, 3 minutes.
26. Rinse with PBS, then ddH<sub>2</sub>O.
27. Let slides air dry in fume hood.
28. Place DAB gloves and pipette tips in DAB dry waste in fume hood.
29. Cover all solutions with parafilm and store at 4°C.
30. Remove pap pen from dry sections with xylene in fume hood using a Q-tip. Be careful not to touch the tissue with the xylene.
31. All approx. 0.5mL per slide of mounting media on the bottom edge of the slide in a line using 3mL syringe w/o needle. Also add mounting media to the underside of a cover slip (40mm-50 mm) in the same manner.
32. Slowly lower cover slip onto the slide starting at the bottom and slowly lowering slide. Mounting media will wick up the slide from the bottom. Avoid bubbles. Push out and bubble by gently rolling a Q-tip across the cover slip.
33. Let the slides dry for 1 hour before viewing.